KOL | Harry Roger BüllerDepartment of Medicine, Amsterdam University Medical Center, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands | From KU Leuven Department of Cardiovascular ... |
Kol melanjutkan untuk Harry Roger Büller
| Year | |
|---|---|
| 2022 | Department of Medicine, Amsterdam University Medical Center, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands |
| 2021 | From KU Leuven Department of Cardiovascular Sciences, Vascular Medicine and Hemostasis, Leuven, Belgium (P.V.); Anthos Therapeutics, Cambridge, MA (B.A.Y., J.S., D.B.); International Trial Expertise Advisory and Services (A.S.) and the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam (H.R.B.) - both in Amsterdam; Hudson College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City (G.E.R.); and the Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, ON, Canada (J.I.W.). Amsterdam University Medical Center, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands (H.R.B.). |
| 2020 | From the Faculty of Medical Sciences, State University of Groningen, Groningen, the Netherlands (M.O.); Department of Vascular Medicine, Amsterdam University Medical Centre, Amsterdam, the Netherlands (H.R.B., N.V.Es.); Department of Radiology, Haaglanden Medical Centre, The Hague, the Netherlands (D.K.); Department of Radiology, Nederlands Kanker Instituut, Amsterdam, the Netherlands (S.F.O.); Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, U.S.A. (T.M.); Department of Intensive Care Medicine, Erasmus Medical Centre, Rotterdam, the Netherlands (D.G.); 7. National Institute of Public Health, Ministry of Health, Bilthoven, the Netherlands (J.V.D.); Department of Vascular Medicine, Maastricht University, Maastricht, the Netherlands (H.T.C.); Edinburgh Imaging, Queens Medical Research Institute, University of Edinburgh, Edinburgh, U.K.(E.J.R.V.B.) Department of Vascular Medicine, Amsterdam University Medical Center, Amsterdam, The Netherlands |
| 2019 | Department of Vascular Medicine, Academic Medical Center, Universiteit van Amsterdam, Amsterdam, The Netherlands. Dept of Vascular Medicine, Amsterdam Cardiovascular Science, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands |
| 2018 | Department of Vascular Medicine, Academic Medical Centre Amsterdam, University of Amsterdam, Amsterdam, Netherlands |
| 2017 | Department of Vascular Medicine, Academic Medical Center, Meibergdreef 9, AZ, Amsterdam, The Netherlands. From Academic Medical Center and Slotervaartziekenhuis, Amsterdam, the Netherlands; Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Université de Bretagne Occidentale, Brest, France; Hospital of Padua, Padua, Italy; Clinica Universidad de Navarra, Pamplona, Spain; Virgen del Rocio Hospital, Seville, Spain; Karolinska Institutet, Stockholm, Sweden; Warsaw Medical University, Warsaw, Poland; Centre Hospitalo-Universitaire Estaing, Clermont-Ferrand, France; University of Utah, Salt Lake City, Utah; University Hospital Leuven, Leuven, Belgium; and University G. D'Annunzio, Chieti-Pescara, Italy. |
| 2016 | Center for Experimental and Molecular Medicine, Amsterdam Medical Center, Amsterdam, The Netherlands |
| 2015 | Academic Medical Center University of Amsterdam Department of Vascular Medicine Amsterdam the Netherlands |
| 2014 | From the College of Public Health, University of Oklahoma Health Sciences Center (G.E.R., M.M., A.W.); Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand (P.A.); División Hemostasia, Academia Nacional de Medicina, Buenos Aires, Argentina (A.N.B.); Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands (H.B.); SA Pathology–Department of Hematology, Flinders Medical Center, Adelaide, South Australia, Australia (A.G.); Thrombosis and Thrombophilia Centre, Guy’s & St Thomas’ NHS Foundation Trust, London, United Kingdom (B.J.H.); Boston University School of Medicine, MA (E.M.H.); Thrombosis Research Institute, London, United Kingdom (A.K.); Center for Thrombosis and Hemostasis, Johannes Gutenberg University, Mainz, Germany (S.V.K.); Department of Laboratory Medicine, University of Yamanashi, Tamaho, Yamanashi, Japan (Y.O.); and McMaster University and Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada (J.I.W.). Department of General Practice, Academic Medical Centre, University of Amsterdam, Amsterdam and |
| 2013 | Department of Vascular Medicine, F4-140, Academic Medical Centre, Meibergdreef 9, Amsterdam 1105 AZ, The Netherlands Academic Medical Center, Amsterdam (H.R.B.) |
| 2012 | Academic Medical Center, Department of Vascular Medicine, Amsterdam (H.R.B.) Vascular Medicine, AMC, Amsterdam, the Netherlands |
| 2011 | Internal Medicine, Academic Medical Center, Amsterdam, Netherlands, From the Academic Medical Center and Slotervaart Hospital, Amsterdam |
Harry Roger Büller: Statistik pengaruh
Jalankan laporan
| Concept | World rank |
|---|---|
| standalone ddimer testing | #1 |
| levels procoagulant factors | #1 |
| matisse clinical trials | #1 |
| baseline pvo | #1 |
| patients protein deficiencies | #1 |
| ddimer levels cdr | #1 |
| ufh grade | #1 |
| 7268 patients suspected | #1 |
| pvo qscan | #1 |
| dose response apixaban | #1 |
| sgs pretest probability | #1 |
| safety idraparinux | #1 |
| treat thrombosis | #1 |
| heparin acenocoumarol | #1 |
| apc resistance factor | #1 |
| treatment experimental thrombosis | #1 |
| patients deep | #1 |
| anticoagulant fondaparinux | #1 |
| fondaparinux rfviia injection | #1 |
| lmwh plasma levels | #1 |
| aged nadroparin | #1 |
| compression ultrasonography patients | #1 |
| laalleles platelets | #1 |
| ultrasound compression ultrasound | #1 |
| enoxaparin heparin treatment | #1 |
| acenocoumarol initial treatment | #1 |
| prophylaxis idraparinux | #1 |
| protein resistance control | #1 |
| 5 avidin infusion | #1 |
| clinical decision rule | #1 |
| heparin vitamin antagonist | #1 |
| diagnostic strategies strategies | #1 |
| dalteparin major bleeding | #1 |
| reduceddose noacs stroke | #1 |
| women elevated levels | #1 |
| carriers recurrence | #1 |
| category fxainhibitors | #1 |
| practiceassistants | #1 |
| survival lmwh | #1 |
| timeperiod | #1 |
| embolism sensitivity | #1 |
| rnapc2 united states | #1 |
| cancer cdr | #1 |
| dvt 3 | #1 |
| 0·2 edoxabantreated | #1 |
| idraparinux patients | #1 |
| treated vka | #1 |
| pulmonary embolism fondaparinux | #1 |
| pyridines recurrence | #1 |
| tests prevalence abi | #1 |
| enoxaparin tb402 | #1 |
| uesvt | #1 |
| ipe expert radiologists | #1 |
| avidin idrabiotaparinux | #1 |
| bleeding risk treatment | #1 |
| relatives normal levels | #1 |
| simplified wells rule | #1 |
| uesvt median | #1 |
| efficacy heparin therapy | #1 |
| scenarioanalysis | #1 |
| 3 idraparinux | #1 |
| apixaban conventional therapy | #1 |
| feasibility venography | #1 |
| united states rnapc2 | #1 |
| patients idraparinux | #1 |
| patients malignancy | #1 |
| probability normal | #1 |
| d‐dimer level | #1 |
| patients advanced prostate | #1 |
| 5mg apixaban | #1 |
| submassive elevated ctni | #1 |
| oral rivaroxaban treatment | #1 |
| tb402 enoxaparin | #1 |
| 2630 pilots | #1 |
| safety outcome | #1 |
| warfarin cstatistic | #1 |
| venous thrombosis pregnancy | #1 |
| rule dimer | #1 |
| venous thromboembolism episode | #1 |
| oral apixaban treatment | #1 |
| ifngamma pselectin | #1 |
| apixaban extended treatment | #1 |
| constans score | #1 |
| fxainhibitors vka recipients | #1 |
| subsequent diagnosis malignancy | #1 |
| incidental symptomatic vte | #1 |
| randomized studies efficacy | #1 |
| risk pulmonary embolism | #1 |
| impedance thrombophlebitis | #1 |
| carriers thrombophilic defects | #1 |
| venous thromboembolism idraparinux | #1 |
| cancer edoxaban | #1 |
| pulmonary embolism tests | #1 |
| anticoagulants probability | #1 |
| rivaroxaban standard therapy | #1 |
| oral anticoagulants phase | #1 |
| sustained antithrombotic effects | #1 |
| venous thrombosis recurrence | #1 |
| increasing levels ft4 | #1 |
| rivaroxaban lmwh vka | #1 |
| doacs cirrhosis patients | #1 |
| intestinal microbiota coagulation | #1 |
| embolism suspected | #1 |
| intrinsic coagulation vivo | #1 |
| travel‐related venous thrombosis | #1 |
| idraparinux | #1 |
| ventricular dysfunction edoxaban | #1 |
| rfviia idraparinux | #1 |
| cancer patients patients | #1 |
| venous thrombosis vwf | #1 |
| vte risk day | #1 |
| controlledstudy | #1 |
| lmwh replacement | #1 |
| 7268 patients | #1 |
| normal lung scan | #1 |
| cancer patients cvcs | #1 |
| rabinovpaulin | #1 |
| amplify trial apixaban | #1 |
| relatives normal fviii | #1 |
| netherlands 5 years | #1 |
| lmwh users incidence | #1 |
| vte trial | #1 |
| studies doac treatment | #1 |
| treatment idraparinux | #1 |
| prospective management study | #1 |
| extensive screening cancer | #1 |
| 2479 relatives | #1 |
| ctscan qscan | #1 |
| prolactin venous thrombosis | #1 |
| doacs factor | #1 |
| clinical probability exclusion | #1 |
| relatives antithrombin | #1 |
| anticoagulant treatment patients | #1 |
| non‐invasive diagnostic work‐up | #1 |
| coagulation clinical | #1 |
| 123362 | #1 |
| standardintensity vkas doacs | #1 |
| deficiency proteins | #1 |
| inherited thrombophilia patients | #1 |
| wound haematoma | #1 |
| death category | #1 |
| single dose tb402 | #1 |
| anticoagulant treatment vte | #1 |
| xainhibitors | #1 |
| compression ultrasonography | #1 |
| fviii normal levels | #1 |
| dvt costs | #1 |
| netherlands vka | #1 |
| selective beta‐blocker treatment | #1 |
| studies ttr | #1 |
| simplified geneva score | #1 |
| p0424 | #1 |
| bmi fondaparinux | #1 |
| cdr ddimer test | #1 |
| longhaul flight | #1 |
| rnapc2 inhibition | #1 |
| probability cdr | #1 |
| clinical probability patients | #1 |
| reduceddose noacs | #1 |
| nadroparin patients | #1 |
| aged venous | #1 |
| standard treatment idraparinux | #1 |
| 50 rivaroxaban | #1 |
| association protein levels | #1 |
| normotensive patients studies | #1 |
| efficacy vte | #1 |
| netherlands lmwh | #1 |
| orthopedic thromboprophylaxis | #1 |
| recommendations dvt | #1 |
| carriers pulmonary embolism | #1 |
| venous thrombosis hyperglycemia | #1 |
| placebo rnapc2 | #1 |
| qscan | #1 |
| venography feasibility | #1 |
| tests venography | #1 |
| vte fatal | #1 |
| predefined outcomes | #1 |
| orthopedic surgery netherlands | #1 |
| idraparinux recurrent thromboembolism | #1 |
| administration lmwh | #1 |
| presentation 1 week | #1 |
| members symptomatic carriers | #1 |
| 3633 patients edoxaban | #1 |
| atherosclerosis hemophilia patients | #1 |
| cancer patients uedvt | #1 |
| timerequirement | #1 |
| idraparinux versus | #1 |
| excluding pulmonary | #1 |
| vka share | #1 |
| flebography | #1 |
| quantitative ddimer tests | #1 |
| tomography angiography vte | #1 |
| somittrial | #1 |
| protein levels mortality | #1 |
| clinical probability risk | #1 |
| ddimer test combination | #1 |
| suspected cdr | #1 |
| threemonth incidence | #1 |
| 20210a mutation | #1 |
| vivo coagulation factor | #1 |
| ddimer result | #1 |
| extended anticoagulation apixaban | #1 |
| elderly outpatients combination | #1 |
| followup overt cancer | #1 |
| venous thrombus growth | #1 |
| alternative diagnoses patients | #1 |
| vka recipients | #1 |
| respondents 60 | #1 |
| 95ci tb402 | #1 |
| efficacy outcome | #1 |
| prescriptionbased | #1 |
| rivaroxaban replacement | #1 |
| vte occurred | #1 |
| influenza case patients | #1 |
| vte arterial | #1 |
| patients artificial graft | #1 |
| fondaparinux unfractionated | #1 |
| recurrent vte immobilization | #1 |
| diagnostic management patients | #1 |
| outcome recurrent | #1 |
| time recombinant | #1 |
| s1p1activation | #1 |
| prothrombin 20210a mutation | #1 |
| 560 pharmacies | #1 |
| recurrent vte statin | #1 |
| individuals air travel | #1 |
| abelacimab | #1 |
| factual hemorrhage heparin | #1 |
| silent dvt | #1 |
| crp test patients | #1 |
| recurrent vte doacs | #1 |
| ili score | #1 |
| abdominal pelvic strategies | #1 |
| safety clinical utility | #1 |
| idraparinux 6 months | #1 |
| heparin vitamin | #1 |
| combination cdrscore | #1 |
| heparin org 10172 | #1 |
| proximal extent ipe | #1 |
| elevated cardiac troponins | #1 |
| pregnancyrelated complications relatives | #1 |
| clinically suspected dvt | #1 |
| idraparinux standard therapy | #1 |
| relevant bleeding | #1 |
| loss subsequent pregnancy | #1 |
| vte difference | #1 |
| org aptt | #1 |
| uedvt clinical | #1 |
| compression ultrasonography presentation | #1 |
| realtime bmode ultrasonography | #1 |
| severe presentation patients | #1 |
| easier monitoring | #1 |
| gogh dvt trial | #1 |
| acenocoumarol efficacy | #1 |
| patients laalleles | #1 |
| 8h flight | #1 |
| asymptomatic extension | #1 |
| rivaroxaban dvt treatment | #1 |
| questionnaires thrombosis | #1 |
| suspected symptomatic | #1 |
| early time recurrence | #1 |
| early discharge strategies | #1 |
| cip diagnostic management | #1 |
| rnapc2 groups | #1 |
| equinox study | #1 |
| unexplained dvt patients | #1 |
| pvoq | #1 |
| axa activity 5 | #1 |
| dvt 56 | #1 |
| lmwh edoxaban | #1 |
| prevalence coagulation | #1 |
| scan pulmonary embolism | #1 |
| idraparinux 25 | #1 |
| protein mortality | #1 |
| leg ultrasonography patients | #1 |
| bleeding clinically | #1 |
| dose daily edoxaban | #1 |
| ddimer test patients | #1 |
| graft patency patency | #1 |
| cancer patients ufh | #1 |
| enoxaparin vkas | #1 |
| anticoagulation period | #1 |
| patients ivte | #1 |
| pvo ctscan | #1 |
| 750 μg l1 | #1 |
| thiazoles venous | #1 |
| sensitivity 100 percent | #1 |
| withheld | #1 |
| dalteparin 6 months | #1 |
| subcutaneous nadroparin placebo | #1 |
| obese controls difference | #1 |
| 3633 patients edoxabantreated | #1 |
| pulmonary embolism cdr | #1 |
| proportion pulmonary embolism | #1 |
| deep vein thrombosis | #1 |
| 12 months edoxaban | #1 |
| absolute annual incidences | #1 |
| ddimer test | #1 |
| dimer result | #1 |
| lmwhs 95 | #1 |
| symptomatic pts | #1 |
| cstatistic major bleeding | #1 |
| initial treatment patients | #1 |
| patients examiner | #1 |
| strategies ultrasonography | #1 |
| edoxaban dalteparin | #1 |
| 12 kg1 enoxaparin | #1 |
| adjusted dose ufh | #1 |
| doses 75 microg | #1 |
| plateletactivating antibodies risk | #1 |
| heparins inhibition | #1 |
| current comprehensions | #1 |
| older patients cdr | #1 |
| treatment cumulative incidence | #1 |
| plasma concentration fviii | #1 |
| adjunct thrombolysis | #1 |
| fetal loss stillbirth | #1 |
| synthetic selective factor | #1 |
| hokusaivte trial | #1 |
| preferred oral anticoagulant | #1 |
| screening carriers | #1 |
| ldfr symptomatic legs | #1 |
| dimer clinical | #1 |
| departments orthopedic surgery | #1 |
| khorana | #1 |
| 9 incidence | #1 |
| embolism radionuclide | #1 |
| patients acute recurrent | #1 |
| standardintensity vkas | #1 |
| hellp syndrome mutations | #1 |
| lmwh immobilization | #1 |
| ivte | #1 |
| deepvein thrombosis incidence | #1 |
| vkas efficacy | #1 |
| normal venogram | #1 |
| molecular weight fondaparinux | #1 |
| lowmolecularweight heparin category | #1 |
| tb402 12 kg1 | #1 |
| standard therapy rivaroxaban | #1 |
| control anticardiolipin antibodies | #1 |
| tsh antitpo | #1 |
| annual incidence patients | #1 |
| leg veins patients | #1 |
| survival fondaparinux | #1 |
| study centre duration | #1 |
| dose rnapc2 | #1 |
| cdr dimer | #1 |
| prediction models recurrence | #1 |
| ddimer test result | #1 |
| clinical presentation category | #1 |
| ultrasound strategies patients | #1 |
| avidin vte | #1 |
| noacs prevention | #1 |
| cdrscore | #1 |
| casedescription | #1 |
| major bleeds vka | #1 |
| venous thromboembolism edoxaban | #1 |
| heparins data | #1 |
| patients antithrombotic prescriptions | #1 |
| intensity vkas doacs | #1 |
| patients wells rule | #1 |
| standard therapy months | #1 |
| category perelated death | #1 |
| wells cdr | #1 |
| departments pharmacological prophylaxis | #1 |
| cancer patients cdr | #1 |
| ivte clinical practice | #1 |
| preference doacs | #1 |
| extra hospital visits | #1 |
| successful attenuation | #1 |
| presenting location women | #1 |
| pulmonary embolism studies | #1 |
| chest perfusion scan | #1 |
| thromboembolism relatives | #1 |
| cdr normal | #1 |
| coagulation fibrinolytic proteins | #1 |
| acquired atiii deficiency | #1 |
| principal safety | #1 |
| advanced malignancy | #1 |
| vitamin antagonists treatment | #1 |
| upper extremity uedvt | #1 |
| double heterozygous carriers | #1 |
| dalteparin vte treatment | #1 |
| heparin initial | #1 |
| neoplasms heparin | #1 |
| einsteinextension | #1 |
| rfviia 3 | #1 |
| elevated ctni patients | #1 |
| pulmonary embolism | #1 |
| lmwh delivery | #1 |
| fviii vte | #1 |
| 5395 patients | #1 |
| study ecq | #1 |
| oral administration bsf | #1 |
| previous surveys netherlands | #1 |
| quantitative dimer | #1 |
| amplify trial | #1 |
| tb402 prevention | #1 |
| phase doacs | #1 |
| superficial thrombophlebitis incidence | #1 |
| placebo 25mg apixaban | #1 |
| months standard therapy | #1 |
| patients khorana | #1 |
| hokusai‐vte trial | #1 |
| mutation relatives | #1 |
| presenting location vte | #1 |
| thrombo‐embolic events | #1 |
| apc resistance tests | #1 |
| vkas lmwh | #1 |
| vte day | #1 |
| relevant major | #1 |
| travel venous thromboembolism | #1 |
| calfvein thrombi | #1 |
| patency smokers | #1 |
| calf dvt ultrasound | #1 |
| bleeding risk lmwh | #1 |
| elderly patients dvt | #1 |
| desogestrelcontaining coagulation factors | #1 |
| endotoxemia tests | #1 |
| variable d‐dimer thresholds | #1 |
| evaluable patients 95 | #1 |
| cancer patients cancer | #1 |
| clinically suspected cancer | #1 |
| mdct expert radiologist | #1 |
| crt cvc | #1 |
| elevated fviii age | #1 |
| local radiologist experts | #1 |
| normohomocysteinemic relatives hyperhomocysteinaemia | #1 |
| vitamin anticoagulants | #1 |
| strategies diagnostic management | #1 |
| low levels ft4 | #1 |
| 208791 | #1 |
| safety 60 dose | #1 |
| 0·620·74 | #1 |
| 5‐snp scores | #1 |
| death venous thromboembolism | #1 |
| uesvt uedvt | #1 |
| tinaquant assay comparison | #1 |
| 500 org | #1 |
| original wells | #1 |
| pulmonary embolism metaanalysis | #1 |
| 023 relatives | #1 |
| 97 compression ultrasonography | #1 |
| travellers thrombosis | #1 |
| proximal location ipe | #1 |
| selective ddimer thresholds | #1 |
| uesvt patients | #1 |
| botticelli dvt dose‐ranging | #1 |
| symptomatic venous | #1 |
| embolism randomized | #1 |
| probabilityscan | #1 |
| poc test patients | #1 |
| reduceddose noacs warfarin | #1 |
| cstatistic model discrimination | #1 |
| dimer test | #1 |
| intravenous unfractionated | #1 |
| rfviia fondaparinux | #1 |
| patients enoxaparin vkas | #1 |
| suspected perfusion scan | #1 |
| evaluable patients apixaban | #1 |
| antithrombotic prescriptions adherence | #1 |
| limited screening 95 | #1 |
| wells clinical | #1 |
| ambulatory computers | #1 |
| dvt anticoagulants | #1 |
| heparin initial treatment | #1 |
| aptt org | #1 |
| management study | #1 |
| test venography | #1 |
| recurrence major bleeding | #1 |
| 378 patients edoxaban | #1 |
| diagnosis deepvein thrombosis | #1 |
| fviii women | #1 |
| failure diagnostic management | #1 |
| local radiologist | #1 |
| postthrombotic symptoms patients | #1 |
| rate recurrent | #1 |
| antidote vitamin | #1 |
| comparison vidas assay | #1 |
| daily dalteparin treatment | #1 |
| monoclonal antibodies apc | #1 |
| ecq ankle brachial | #1 |
| intravenous injections lmwh | #1 |
| normal levels fviii | #1 |
| symptomatic recurrent | #1 |
| diagnostic strategies patients | #1 |
| embolism wells | #1 |
| treatment venous | #1 |
| year prophylaxis | #1 |
| 95 3633 patients | #1 |
| heparins cancer patients | #1 |
| cart lower levels | #1 |
| risk homozygous women | #1 |
| respondents lmwh | #1 |
| nadroparin therapeutic dose | #1 |
| obese hemophilic patients | #1 |
| puerperium diagnostic suspicion | #1 |
| ufh grade 1a | #1 |
| presence venous thrombosis | #1 |
| wells rule primary | #1 |
| lmwh departments | #1 |
| fetal loss miscarriage | #1 |
| lmwh venous thrombosis | #1 |
| outcome clinically | #1 |
| acenocoumarol therapy acenocoumarol | #1 |
| absolute thrombotic risk | #1 |
| enoxaparin initial treatment | #1 |
| subcutaneous length life | #1 |
| activecontrol placebo | #1 |
| cancer 145 patients | #1 |
| chest perfusion scintigraphy | #1 |
| strategy abdominal pelvic | #1 |
| inr studies | #1 |
| pulmonary embolism life | #1 |
| einsteindvt | #1 |
| 69 conclusions | #1 |
| 547253 | #1 |
| xageneration | #1 |
| perelated death category | #1 |
| oral edoxaban dose | #1 |
| svt lmwh | #1 |
| pulmonary angiography study | #1 |
| lmwh rtap | #1 |
| 6 months avidin | #1 |
| suspected deep | #1 |
| exclusion pulmonary | #1 |
| d‐dimer test | #1 |
| laalleles | #1 |
| normal ddimer concentration | #1 |
| studies 3 months | #1 |
| current practise | #1 |
| malignancy achieved inr | #1 |
| tb402 50 | #1 |
| nadroparin aspirin | #1 |
| lmwh acute treatment | #1 |
| fxainhibitors | #1 |
| 65±9years | #1 |
| patients mismatched scan | #1 |
| thromboembolism 3 | #1 |
| outpatients symptomatic dvt | #1 |
| conventional therapy enoxaparin | #1 |
| uedvt recurrent vte | #1 |
| 393 patients warfarin | #1 |
| vte location | #1 |
| topic thrombophlebitis | #1 |
| animal female heparin | #1 |
| presentation major | #1 |
| single‐detector row | #1 |
| pharmacological methods prophylaxis | #1 |
| referral basis | #1 |
| combination cdrs | #1 |
| nondiagnostic lung scan | #1 |
| qscan 3 weeks | #1 |
| p0001 saline | #1 |
| elevated fviii patients | #1 |
| acute treatment lmwh | #1 |
| cancer clinical presentation | #1 |
| 15 lmwh | #1 |
| mortality postthrombotic symptoms | #1 |
| protecht shr | #1 |
| vte risk coc | #1 |
| level loss patency | #1 |
| quantitative ddimer test | #1 |
| frequency venous thromboembolism | #1 |
| ml1 ctpa | #1 |
| models development studies | #1 |
| patients reduceddose noacs | #1 |
| hokusai vte cancer | #1 |
| heparin survival | #1 |
| thrice daily gentamicin | #1 |
| ventilation lung scanning | #1 |
| vte procoagulant activity | #1 |
| inr range ttr | #1 |
| venography tests | #1 |
| venous thrombosis mutations | #1 |
| relative risks carriers | #1 |
| patients uedvt uesvt | #1 |
| excluded pulmonary | #1 |
| edoxabantreated | #1 |
| quantitative ddimer testing | #1 |
| clinically suspected uedvt | #1 |
| einstein dvt patients | #1 |
| revascularisation procedures patients | #1 |
| polyethylenglycolhirudin | #1 |
| reported incidence vte | #1 |
| fibrinolysis levels | #1 |
| initial heparin patients | #1 |
| ldf cus | #1 |
| cdrscore combination | #1 |
| smoking patency | #1 |
| 0·2 3633 patients | #1 |
| rule exclusion | #1 |
| factor viii homocysteine | #1 |
| decisions duration | #1 |
| riskstroponin | #1 |
| edoxaban warfarin groups | #1 |
| edoxaban east asian | #1 |
| women edoxaban | #1 |
| wells rules | #1 |
| iii plg | #1 |
| scores riete score | #1 |
| factor viii relatives | #1 |
| elevated levels fviii | #1 |
| incidence ctni | #1 |
| vitamin antagonist patients | #1 |
| simplified rule proportion | #1 |
| clinical uedvt | #1 |
| dvt impedance plethysmography | #1 |
| wellscdr | #1 |
| uedvt terms | #1 |
| predefined outcomes vte | #1 |
| bleeding einstein | #1 |
| vte airline pilots | #1 |
| 250 patients cancer | #1 |
| double reports | #1 |
| role exclusion | #1 |
| rhir lmwh | #1 |
| rnapc2 patients | #1 |
| probability categories | #1 |
| messages justification | #1 |
| 00515 | #1 |
| hokusaivte study | #1 |
| patients treatment duration | #1 |
| infections gentamicin | #1 |
| patients normal tests | #1 |
| pulmonary angiography ultrasonography | #1 |
| unexplained dvt | #1 |
| idraparinux vitamin antagonist | #1 |
| false normal | #1 |
| hemorrhage heparin | #1 |
| patients advanced malignancy | #1 |
| heparinoid | #1 |
| normal ddimer result | #1 |
| lmprovement | #1 |
| 2 diagnostic management | #1 |
| cus strategies | #1 |
| probability ventilation | #1 |
| rivaroxaban acute dvt | #1 |
| method factor | #1 |
| wellsrule | #1 |
| relatives mutation | #1 |
| chromogenic endotoxin | #1 |
| recurrent thrombosis pts | #1 |
| dvt 69 | #1 |
| ankle brachial prevalence | #1 |
| normal dimer | #1 |
| reocclusion antithrombotic drug | #1 |
| prophylaxis crt | #1 |
| distal clots | #1 |
| death vte studies | #1 |
| 53 amputations | #1 |
| patients inherited thrombophilia | #1 |
| idrabiotaparinux idraparinux | #1 |
| apixaban randomized patients | #1 |
| doacs initial heparin | #1 |
| ccus 4 | #1 |
| edoxaban risk factors | #1 |
| dvt symptomatic | #1 |
| fetal loss carriers | #1 |
| abnormal ipg | #1 |
| matisse trials | #1 |
| extended treatment edoxaban | #1 |
| vka treatment treatment | #1 |
| isolated deficiencies proteins | #1 |
| bleeding rates quality | #1 |
| avidin placebo | #1 |
| heparins cancer spread | #1 |
| perelated death classification | #1 |
| acenocoumarol heparin | #1 |
| pulmonary embolism carriers | #1 |
| risk percentage points | #1 |
| fviii hyperhomocysteinemia | #1 |
| extended anticoagulation doacs | #1 |
| segmental subsegmental | #1 |
| fviii concentration | #1 |
| pulmonary embolism role | #1 |
| symptomatic recurrent vte | #1 |
| 36 papers | #1 |
| noncarriers annual incidence | #1 |
| wells simplified | #1 |
| doacs anatomical extent | #1 |
| therapeutic doses lmwh | #1 |
| age∗10μg | #1 |
| enoxaparin vkas treatment | #1 |
| doac recipients | #1 |
| pioped study study | #1 |
| lowmolecularweight heparin treatment | #1 |
| proportion 75 years | #1 |
| coagulationinhibiting | #1 |
| carriers relative risks | #1 |
| milliliter enoxaparin | #1 |
| subcutaneous idraparinux | #1 |
| progression svt | #1 |
| severity clinical presentation | #1 |
| scores occult cancer | #1 |
| cdr physicians | #1 |
| doubleheterozygotes | #1 |
| patients tests prevalence | #1 |
| sspe proximal | #1 |
| diagnostic strategy primary | #1 |
| perfusion scan | #1 |
| 3 rfviia | #1 |
| presentation category | #1 |
| beneficial lmwh | #1 |
| ultrasonography dvt | #1 |
| baseline characteristics duration | #1 |
| consensus strategy strategy | #1 |
| thrombophlebitis tomography | #1 |
| anticoagulants double | #1 |
| association travel | #1 |
| initial treatment dvt | #1 |
| incidence venous | #1 |
| thrombosis vitamin | #1 |
| clinically relevant disease | #1 |
| vka netherlands | #1 |
| total vte patients | #1 |
| long haul flights | #1 |
| systematic search cteph | #1 |
| rabinov | #1 |
| replacement vka | #1 |
| fxiaso enoxaparin | #1 |
| ultrasonography diagnostic | #1 |
| symptomatic legs dvt | #1 |
| falsenormal | #1 |
| simple diagnostic strategy | #1 |
| residual thrombotic mass | #1 |
| —brachial | #1 |
| thromboembolism treated | #1 |
| weight heparinoid | #1 |
| ldf diagnosis | #1 |
| idraparinux months | #1 |
| recurrent dvt dvt | #1 |
| positive vte | #1 |
| included patients study | #1 |
| hokusai‐vte cancer study | #1 |
| abnormal vaginal bleeding | #1 |
| lowmolecularweight heparin 95 | #1 |
| org heparin | #1 |
| pulmonary angiography strategies | #1 |
| combination nonhigh cdr | #1 |
| wellscdrscore | #1 |
| thrombophilia patients doacs | #1 |
| guidelines abi | #1 |
| heparins vitamin antagonists | #1 |
| combination cdr | #1 |
| echocardiography normotensive patients | #1 |
| relatives elevated levels | #1 |
| pulmonary embolism basis | #1 |
| procoagulant factors levels | #1 |
| obstetric complications relatives | #1 |
| types major bleeding | #1 |
| vitamin antagonists time | #1 |
| anticoagulants chemotherapy | #1 |
| idraparinux placebo | #1 |
| combined training gps | #1 |
| specificity pulmonary embolism | #1 |
| lmwhmediated | #1 |
| guideline adherence justification | #1 |
| strategies abdominal pelvic | #1 |
| ft4 level patients | #1 |
| patients clinical probability | #1 |
| tests pulmonary embolism | #1 |
| achieved inr patients | #1 |
| thrombosis vte | #1 |
| prothrombin individuals | #1 |
| category death | #1 |
| thrombophilia late loss | #1 |
| enoxaparin warfarin antiplatelet | #1 |
| rnapc2 groups placebo | #1 |
| elevated fviii | #1 |
| hyperhomocysteinemia relatives | #1 |
| mutation arg506 | #1 |
| 95 elevated ctni | #1 |
| international thrombosis experts | #1 |
| patients unexplained dvt | #1 |
| warfarin cancer patients | #1 |
| 50 years combination | #1 |
| efficacy conventional treatment | #1 |
| levonorgestrel desogestrelcontaining | #1 |
| presenting vte location | #1 |
| hokusaivte trial patients | #1 |
| smoking graft patency | #1 |
| beta thromboglobulin org | #1 |
| cdrs patients | #1 |
| duration heparin treatment | #1 |
| patients initial heparin | #1 |
| age recurrent vte | #1 |
| 5 years lmwh | #1 |
| compression ultrasonography detection | #1 |
| fviii venous thromboembolism | #1 |
| relatives tafi levels | #1 |
| acute recurrent patients | #1 |
| fviii homocysteine | #1 |
| patients tb402 | #1 |
| ctscanreading | #1 |
| patients compression ultrasonography | #1 |
| initial heparin edoxaban | #1 |
| intracranial clinical presentation | #1 |
| nonhigh cdr | #1 |
| submassive incidence | #1 |
| analysis hokusai | #1 |
| enoxaparin primary efficacy | #1 |
| combination ddimer testing | #1 |
| crptest | #1 |
| gastrointestinal cancer edoxaban | #1 |
| vte addition | #1 |
| uesvt mortality | #1 |
| compression ultrasound dvt | #1 |
| recurrence bleeding risk | #1 |
| pulmonary embolism idraparinux | #1 |
| age multiple comorbidities | #1 |
| failure rate efficiency | #1 |
| vte study | #1 |
| cvc crt | #1 |
| recurrent thromboembolism enoxaparin | #1 |
| coagulation factors markers | #1 |
| efficiency subgroups | #1 |
| popliteal veins sensitivity | #1 |
| individualized duration | #1 |
| undvt | #1 |
| women factor leiden | #1 |
| cdr ddimer levels | #1 |
| 25mg apixaban | #1 |
| rtap lmwh | #1 |
| avws prevalence | #1 |
| failure cip | #1 |
| controlled trials thrombophilia | #1 |
| wells rule exclusion | #1 |
| ultrasonography leg veins | #1 |
| 95 intracranial | #1 |
| probability lung scan | #1 |
| elevated biomarkers hospital | #1 |
| gentamicin patients netilmicin | #1 |
| subsequent symptomatic cancer | #1 |
| matisse dvt | #1 |
| platelets iqr | #1 |
| major bleeding cancer | #1 |
| rule cdr | #1 |
| uesvt recurrent vte | #1 |
| edoxaban cancer patients | #1 |
| idraparinux vte | #1 |
| ventilation scan chest | #1 |
| progression vte | #1 |
| prevention topic guidelines | #1 |
| patients retropubic prostatectomy | #1 |
| aptt org 10172 | #1 |
| tinaquant vidas | #2 |
| normohomocysteinemic relatives | #2 |
| rnapc2 | #2 |
| exclude pulmonary | #2 |
| major bleeding recurrent | #2 |
| primary healthcare secondary | #2 |
| amadeus study | #2 |
| alife study | #2 |
| gauge plethysmography | #2 |
| bleeding complications treatment | #2 |
| mdct reference standard | #2 |
| mutations propeptide | #2 |
| hospitalbased strategies | #2 |
| influenza prothrombotic state | #2 |
| incidental vte | #2 |
| mutation 35 | #2 |
| subsegmental emboli | #2 |
| fibrinolysis pentoxifylline | #2 |
| safety pravastatin therapy | #2 |
| risk deep | #2 |
| thromboembolism thrombophilia | #2 |
| computerized impedance | #2 |
| referred patients secondary | #2 |
| relation coagulation factors | #2 |
| n1423 | #2 |
| coagulation fibrinolytic | #2 |
| pravastatin therapy children | #2 |
| concomitant thrombophilic | #2 |
| interleukin‐10 response | #2 |
| women therapeutic doses | #2 |
| treatment ttr | #2 |
| graft occlusion patients | #2 |
| rule combined | #2 |
| bleeding occurred | #2 |
| clinical prediction model | #2 |
| embolism primary | #2 |
| factor iia | #2 |
| suspected pulmonary embolism | #2 |
| fvl carriers carriers | #2 |
| khorana protecht | #2 |
| death vte | #2 |
| clinically suspected | #2 |
| apixaban lmwh vka | #2 |
| venographically | #2 |
| uedvt cancer patients | #2 |
| vitamin antagonists quality | #2 |
| cha2ds2vasc nri | #2 |
| primary efficacy outcome | #2 |
| blood coagulation inhibition | #2 |
| major clinically | #2 |
| exposure flights | #2 |
| rnapc2 doses | #2 |
| antagonists vka | #2 |
| 8 wk risk | #2 |
| 95 cancer patients | #2 |
| 20210a mutations | #2 |
| pulmonary embolism purpose | #2 |
| embolism safely | #2 |
| wells cdr patients | #2 |
| pregnancy venous thrombosis | #2 |
| raskob | #2 |
| resource utilisation treatment | #2 |
| hmb primary outcome | #2 |
| patients prior vte | #2 |
| regression pravastatin | #2 |
| 3306 patients | #2 |
| warfarintreated | #2 |
| enoxaparin warfarin | #2 |
| 95 dvt | #2 |
| major bleeding intermediate | #2 |
| anticoagulated patients permanent | #2 |
| venous | #2 |
| lmwh users | #2 |
| ageadjusted ddimer testing | #2 |
| years 36 | #2 |
| model cancer patients | #2 |
| standardised time intervals | #2 |
| biomarkers casecontrol studies | #2 |
| lmwh efficacy | #2 |
| recombinant hirudin cgp | #2 |
| efficiency diagnostic strategies | #2 |
| pulmonary embolism efficacy | #2 |
| ddimer determination | #2 |
| thrombosis normal | #2 |
| heparin administered | #2 |
| rule proportion | #2 |
| vidas assay | #2 |
| wells cdr cdr | #2 |
| major bleeding cindexes | #2 |
| pentasaccharide fondaparinux | #2 |
| intrinsic cascade | #2 |
| limits cancer | #2 |
| relevant patient subgroups | #2 |
| patients hemorr2hages | #2 |
| coumarin sensitivity | #2 |
| plasma d‐dimer concentration | #2 |
| statins recurrent vte | #2 |
| venous thromboembolism enoxaparin | #2 |
| decision rule | #2 |
| crd42017056309 | #2 |
| venous thrombophlebitis | #2 |
| levels coagulation factors | #2 |
| performance constans rule | #2 |
| impedance plethysmography diagnosis | #2 |
| treated edoxaban | #2 |
| surgical casts | #2 |
| lowmolecularweight heparin women | #2 |
| negative ageadjusted ddimer | #2 |
| vte elevated fviii | #2 |
| current clinical challenges | #2 |
| life treatment duration | #2 |
| diagnostic lung | #2 |
| adapted ddimer thresholds | #2 |
| sustained antithrombotic | #2 |
| protein rnapc2 | #2 |
| ufh 6 months | #2 |
| risk khorana | #2 |
| patients peripheral graft | #2 |
| score dimer | #2 |
| endogenous activated protein | #2 |
| coagulation factors prolactin | #2 |
| clinical probability estimate | #2 |
| sspe patients patients | #2 |
| rivaroxaban thiazoles | #2 |
| duration anticoagulant | #2 |
| c1173t dimorphism | #2 |
| recurrence thromboembolism | #2 |
| nct00633893 | #2 |
| analysis venous | #2 |
| serum tnf activity | #2 |
| prothrombin pulmonary embolism | #2 |
| amuse strategy | #2 |
| treated anticoagulants | #2 |
| hellp syndrome prevalence | #2 |
| thromboinflammation cardiovascular disease | #2 |
| thyroid hormone coagulation | #2 |
| inflammation neutrophils thrombosis | #2 |
| uedvt efficiency | #2 |
| thrombophilic disorders | #2 |
| vein compressibility | #2 |
| exclusion pulmonary embolism | #2 |
| secondary efficiency | #2 |
| patients khorana score | #2 |
| undiagnosed malignancy | #2 |
| hokusai vtecancer study | #2 |
| euro138 | #2 |
| heparin nadroparin | #2 |
| 95 0·2 | #2 |
| months 25 | #2 |
| f5 r506q | #2 |
| hasbled score hemorr2hages | #2 |
| normal ddimer test | #2 |
| global public awareness | #2 |
| vitamin antagonist rivaroxaban | #2 |
| simplired test | #2 |
| clinical pretest probability | #2 |
| plasmin activity inhibition | #2 |
| extended constans score | #2 |
| n832 | #2 |
| heparin treatment influenza | #2 |
| fibrinolysis influenza | #2 |
| deficiencies proteins | #2 |
| duration anticoagulant treatment | #2 |
| fibrinolytic proteins | #2 |
| absolute incidence | #2 |
| nematode anticoagulant | #2 |
| hokusai vte | #2 |
| administration rviia | #2 |
| cdr wells cdr | #2 |
| heparin effective | #2 |
| subcutaneous length | #2 |
| crnm bleeds | #2 |
| employees longhaul flight | #2 |
| influenza coagulation | #2 |
| composite scores area | #2 |
| 8292 patients | #2 |
| symptomatic outpatients | #2 |
| ventilation scanning | #2 |
| impedance plethysmography patients | #2 |
| major bleeding edoxaban | #2 |
| single administration tb402 | #2 |
| vte 1000 personyears | #2 |
| blood coagulation rnapc2 | #2 |
| 95 comparator individuals | #2 |
| patients abi measurement | #2 |
| recurrent vte risk | #2 |
| comparator individuals 95 | #2 |
| efficiency original score | #2 |
| dimer thresholds | #2 |
| patients low probability | #2 |
| test cancer | #2 |
| compression doppler | #2 |
| bleeding rate patients | #2 |
| measurement ankle brachial | #2 |
| mild risk factor | #2 |
| events severe | #2 |
| outcome symptomatic | #2 |
| heparin compounds | #2 |
| cancer recurrent vte | #2 |
| endotoxininduced activation coagulation | #2 |
| uedvt performance | #2 |
| angioplasty clopidogrel | #2 |
| sr34006 | #2 |
| recurrent deep | #2 |
| bleeding edoxaban | #2 |
| pharmacological strategies | #2 |
| acquired antithrombin | #2 |
| recombinant nematode | #2 |
| treatment deep | #2 |
| common alternative diagnoses | #2 |
| incidental venous | #2 |
| vte svt | #2 |
| failure rate strategy | #2 |
| ufh survival | #2 |
| ultrasonography patients | #2 |
| simplified wells | #2 |
| idraparinux vitamin | #2 |
| efficiency strategy | #2 |
| oral direct inhibitors | #2 |
| beta‐receptor blockade | #2 |
| gcpg | #2 |
| fviii increased risk | #2 |
| vte 12 | #2 |
| prolactin relation | #2 |
| principal safety outcome | #2 |
| lower clinical utility | #2 |
| intermediate phenotype vte | #2 |
| scan normal | #2 |
| secondary strategies | #2 |
| low‐molecular‐weight heparin | #2 |
| 6 months scores | #2 |
| central localization | #2 |
| incidence recurrent | #2 |
| hyperglycemia diagnosis | #2 |
| patients oral factor | #2 |
| levothyroxine exposure | #2 |
| hemorr2hages atria scores | #2 |
| pulmonary embolism asthma | #2 |
| medscape | #2 |
| thrombophilic defects risk | #2 |
| embolism deep | #2 |
| screening fvl | #2 |
| ddimer assay | #2 |
| risk anticoagulation therapy | #2 |
| ate cancer patients | #2 |
| arterial thrombotic disease | #2 |
| rfviia injection rfviia | #2 |
| suspected upper | #2 |
| primary hospitalbased strategies | #2 |
| received edoxaban | #2 |
| rivaroxaban 30 bid | #2 |
| cdr variables cdr | #2 |
| 17 apixaban | #2 |
| suspected pulmonary | #2 |
| plasma concentrations endotoxin | #2 |
| annual incidences | #2 |
| travel venous | #2 |
| pregnancy coc | #2 |
| apixaban enoxaparin warfarin | #2 |
| cancer addition | #2 |
| computed venous | #2 |
| quality warfarin treatment | #2 |
| mutations cleavage sites | #2 |
| healthcare settings findings | #2 |
| uptake noacs | #2 |
| enoxaparin difference | #2 |
| nonpermanent heart failure | #2 |
| vte orthopedic surgery | #2 |
| brain metastases doacs | #2 |
| presentation dvt | #2 |
| age‐adjusted d‐dimer testing | #2 |
| favour lmwh | #3 |
| patients 6575 years | #3 |
| patients venous | #3 |
| 3633 patients | #3 |
| heparin heparin | #3 |
| probability dimer | #3 |
| baseline values placebo | #3 |
| pad smokers | #3 |
| cancer active cancer | #3 |
| tb‐402 | #3 |
| clinical models patients | #3 |
| lowmolecularweight humans length | #3 |
| ddimer assays | #3 |
| monoclonal replacement | #3 |
| 3month incidence | #3 |
| patients gastrointestinal cancer | #3 |
| ddimer threshold | #3 |
| mutation venous | #3 |
| diagnosis deep | #3 |
| wells rule dvt | #3 |
| cardiac troponine | #3 |
| administration rnapc2 | #3 |
| negative predictive proportion | #3 |
| hf severity risk | #3 |
| fxiaso | #3 |
| venous thromboembolism apixaban | #3 |
| female hemorrhage humans | #3 |
| thromboembolism low | #3 |
| death clinical studies | #3 |
| tinaquant assay | #3 |
| adult patients vte | #3 |
| vte major burden | #3 |
| capillary blood sample | #3 |
| safely exclude | #3 |
| thrombophlebitis treatment | #3 |
| presenting location | #3 |
| primary rule | #3 |
| multiple comorbidities polypharmacy | #3 |
| introduction mdct | #3 |
| dalteparin difference | #3 |
| platelet agents | #3 |
| svt vte | #3 |
| dip placebo | #3 |
| pulmonary embolism gestalt | #3 |
| patients proximalvein thrombosis | #3 |
| 6575 years | #3 |
| prolactin controls | #3 |
| ft4 risk | #3 |
| atria hemorr2hages | #3 |
| treatment vka | #3 |
| thiophenes venous | #3 |
| warfarin subgroup | #3 |
| nct00643201 | #3 |
| endogenous apc | #3 |
| prevalence hemostatic abnormalities | #3 |
| cdr combination | #3 |
| 20210ga | #3 |
| travel venous thrombosis | #3 |
| single diagnostic | #3 |
| dvt primary | #3 |
| gestalt 95 | #3 |
| knee factor | #3 |
| prevalence avws | #3 |
| gestalt probability | #3 |
| activecontrol | #3 |
| desogestrelcontaining | #3 |
| studies cus strategies | #3 |
| recurrent thromboembolic | #3 |
| patients ft4 level | #3 |
| dvt hip | #3 |
| 95 wells rule | #3 |
| dimer blood | #3 |
| inhibition blood coagulation | #3 |
| influence heparins | #3 |
| embolism‐related | #3 |
| placebo n4 | #3 |
| therapy venous | #3 |
| normal result | #3 |
| impedance predictive | #3 |
| nadroparin placebo | #3 |
| rnapc2 fviia | #3 |
| combination wells score | #3 |
| einstein patients | #3 |
| ipe cancer patients | #3 |
| safely excluded | #3 |
| coagulation influence | #3 |
| vte denmark | #3 |
| 3month vte incidence | #3 |
| composite stroke | #3 |
| patients venography | #3 |
| sensitivity compression | #3 |
| dose reduction edoxaban | #3 |
| treatment vitamin antagonists | #3 |
| bleeding major | #3 |
| dvt major | #3 |
| coagulation air travel | #3 |
| venous thrombosis cancer | #3 |
| proximalvein thrombosis | #3 |
| age annual incidence | #3 |
| dvt einstein | #3 |
| thombosis | #3 |
| crt cancer patients | #3 |
| 100 years year | #3 |
| studies hemorrhage | #3 |
| tfindependent | #3 |
| protein thrombophilia | #3 |
| older children vte | #3 |
| ctnt risk stratification | #3 |
| detection dvt | #3 |
| approaches primary | #3 |
| vein thrombosis | #3 |
| dvt systematic differences | #3 |
| pulmonary embolism models | #3 |
| treatment low | #3 |
| failurerate | #3 |
| standard therapy treatment | #3 |
| extensive screening | #3 |
| antithrombin iii concentrate | #3 |
| patients wells | #3 |
| wells rule gestalt | #3 |
| mechanisms heparin | #3 |
| heparin edoxaban | #3 |
| intravenous loading dose | #3 |
| vte performance | #3 |
| cancer randomised trials | #3 |
| alternative diagnoses | #3 |
| outcome venous | #3 |
| incidence enoxaparin | #3 |
| time venous thrombosis | #3 |
| 12month study period | #3 |
| vte low | #3 |
| safety acenocoumarol | #3 |
| products follow | #3 |
| venous thrombosis positive | #3 |
| definition perelated death | #3 |
| subcutaneous lmwh | #3 |
| safely | #3 |
| diagnosis pulmonary embolism | #3 |
| revised geneva efficiency | #3 |
| deep vein | #3 |
| incidental pulmonary embolism | #3 |
| “gestalt | #3 |
| idrabiotaparinux | #3 |
| simplified wells specificity | #3 |
| outpatients dvt | #3 |
| cohort study employees | #3 |
| compensated dic | #3 |
| heparins cancer | #3 |
| hasbled | #3 |
| lmwh | #3 |
| idrabiotaparinux warfarin | #3 |
| iii deficiency | #3 |
| factor viiic | #3 |
| idiopathic venous | #3 |
| thrombophilic defect | #3 |
| low probability models | #3 |
| 02011 | #3 |
| bleeding 3 | #3 |
| thromboembolism background | #3 |
| patients 6 months | #3 |
| plethysmography impedance | #3 |
| pulmonary embolism primary | #3 |
| lmwh pph | #3 |
| hokusai‐vte | #3 |
| subcutaneous fondaparinux | #3 |
| incidence total vte | #3 |
| selectine | #3 |
| outpatient treatment dvt | #3 |
| treatment vte recurrence | #3 |
| recurrence thrombophlebitis | #3 |
| chemotherapy prophylaxis | #3 |
| ventilation scan | #3 |
| pulmonary embolism‐related death | #3 |
| discontinuation ufh | #3 |
| axa activity | #3 |
| lowmolecularweight heparin placebo | #3 |
| oral hormonal cross | #3 |
| recombinant hirudin rhir | #3 |
| apc protective | #3 |
| users incidence | #3 |
| stable acute | #3 |
| pph lmwh | #3 |
| efficacy heparin | #3 |
| einstein studies | #3 |
| vte venous thrombosis | #3 |
| ultrasonography strategies | #3 |
| cancer patients ipe | #3 |
| venous thromboembolism thrombophilia | #3 |
| normal ctnt presentation | #3 |
| female humans inhibitors | #3 |
| venous arterial | #3 |
| treatment lowmolecularweight heparin | #3 |
| vte 3 | #3 |
| healthy donor fmt | #3 |
| factors prothrombin | #3 |
| einstein dvt | #3 |
| predictable pharmacokinetics | #3 |
| patients ultrasonography | #3 |
| diagnosis pulmonary | #3 |
| enoxaparin follow | #3 |
| topic heparin heparin | #3 |
| strategies efficiency | #3 |
| venous thrombosis travel | #3 |
| primary wells rule | #3 |
| venous thromboembolism | #3 |
| cancer patients ate | #3 |
| patients incidental vte | #3 |
| daily netilmicin | #4 |
| serial impedance plethysmography | #4 |
| hemostatic profile | #4 |
| diagnostic prediction models | #4 |
| enoxaparin day | #4 |
| levels ft4 | #4 |
| thromboembolism occurred | #4 |
| diagnostic management | #4 |
| women normal levels | #4 |
| lowmolecularweight heparin | #4 |
| oral rivaroxaban | #4 |
| proximal patients | #4 |
| pregnancies carriers | #4 |
| venous thromboembolism patients | #4 |
| sankyo | #4 |
| 150 microg desogestrel | #4 |
| patient education treatment | #4 |
| 10172 | #4 |
| venous thrombosis levels | #4 |
| patient category | #4 |
| 35±4 | #4 |
| patients fondaparinux | #4 |
| life duration | #4 |
| rule pulmonary | #4 |
| doac studies | #4 |
| risk occult cancer | #4 |
| impedance plethysmography | #4 |
| thromboembolism treatment | #4 |
| thrombophilia 95 | #4 |
| amadeus trial | #4 |
| received warfarin | #4 |
| vte netherlands | #4 |
| vka treatment | #4 |
| fibrin generation test | #4 |
| embolism tomography | #4 |
| patients alternative diagnosis | #4 |
| series venograms | #4 |
| arterial thrombotic | #4 |
| chinese korean ethnicity | #4 |
| preexisting heparin | #4 |
| rfviia injection | #4 |
| bleeding anticoagulants | #4 |
| negative point | #4 |
| vitamin antagonists | #4 |
| coagulation factors risk | #4 |
| diagnosis uedvt | #4 |
| hyperhomocysteinemic relatives | #4 |
| 6 months prophylaxis | #4 |
| estrogen therapy patients | #4 |
| postthrombotic symptoms | #4 |
| vte global burden | #4 |
| protecht | #4 |
| contraindications treatment | #4 |
| predilution postdilution | #4 |
| thrombosis deep | #4 |
| symptomatic deep | #4 |
| ageadjusted cutoff patients | #4 |
| enoxaparin female humans | #4 |
| chads2 p0001 | #4 |
| clot lysis patients | #4 |
| chemotherapy vte prophylaxis | #4 |
| “reversal | #4 |
| criteria dose reduction | #4 |
| recurrent vte months | #4 |
| lmwhs standard heparin | #4 |
| global burden vte | #4 |
| venography patients | #4 |
| gramnegative bacteria humans | #4 |
| abdomen relationship | #4 |
| refuted | #4 |
| population rivaroxaban | #4 |
| activation fibrinolytic | #4 |
| tinaquant | #4 |
| primary pulmonary embolism | #4 |
| dimer assays | #4 |
| 0651 | #4 |
| patients primary healthcare | #4 |
| thromboembolism vitamin | #4 |
| rivaroxaban 20 | #4 |
| embolism roc | #4 |
| vte highincome countries | #4 |
| rviia thrombin generation | #4 |
| thrombophilic families | #4 |
| global disease burden | #4 |
| cancer vwf | #4 |
| dose noacs | #4 |
| primary failure rate | #4 |
| thrombosis uedvt | #4 |
| measurement abi | #4 |
| extended treatment | #4 |
| women apc resistance | #4 |
| risk vkas | #4 |
| vte total | #4 |
| treatment unfractionated heparin | #4 |
| idiopathic venous thrombosis | #4 |
| thromboembolism systematic | #4 |
| patients edoxaban | #4 |
| noacs netherlands | #4 |
| thromboembolism arterial | #4 |
| 150 microg levonorgestrel | #4 |
| warfarin 3 months | #4 |
| embolism dimer | #4 |
| total vte | #4 |
| control anticoagulation | #4 |
| clinically relevant bleeding | #4 |
| chemotherapy shr | #4 |
| thrombosis ischemic stroke | #4 |
| hemorr2hages | #4 |
| mbe patients | #4 |
| disease vte | #4 |
| patients dimer | #4 |
| point dimer | #4 |
| serial impedance | #4 |
| questionnaires venous | #4 |
| ultrasonography venous | #4 |
| lmwh cancer patients | #4 |
| vte treatment patients | #4 |
| thromboembolism factor | #4 |
| episode venous | #4 |
| lmwh female heparin | #4 |
| apixaban efficacy | #4 |
| procoagulant factors | #4 |
| leiden carriers | #4 |
| nct00571649 | #4 |
| prophylaxis lmwh | #4 |
| dutch orthopedic | #4 |
| edoxaban patients | #4 |
| thromboembolism study | #4 |
| patients venous thromboembolism | #4 |
| patients crcl 60 | #4 |
| chromogenic compounds | #4 |
| noacs cancer patients | #4 |
| vitamin antagonist treatment | #4 |
| advanced cancer 95 | #4 |
| patients submassive | #4 |
| cleavage sites apc | #4 |
| patients clinically | #4 |
| travel thrombosis | #4 |
| diagnostic management strategies | #4 |
| clot resolution | #4 |
| coagulation endotoxin | #4 |
| embolism background | #4 |
| safety pravastatin | #4 |
| thrombosis symptomatic | #4 |
| lowmolecular weight heparins | #4 |
| 3587 | #4 |
| probability prospective | #4 |
| patients nonpermanent | #4 |
| netherlands pulmonary | #4 |
| 335 patients | #4 |
| death survey | #4 |
| vte global | #4 |
| ddimer assay patients | #4 |
| thrombosis air | #4 |
| disease burden vte | #4 |
| vitamin antagonists patients | #4 |
| treatment acute dvt | #5 |
| dvt prevalence | #5 |
| thromboembolism idraparinux | #5 |
| thrombophlebitis ultrasonography | #5 |
| thromboembolism thrombosis | #5 |
| low‐molecular‐weight | #5 |
| embolism reproducibility | #5 |
| endogenous activated | #5 |
| day rivaroxaban | #5 |
| lmwh recommended | #5 |
| deepvein thrombosis | #5 |
| repeated ultrasonography | #5 |
| phlebography plethysmography | #5 |
| suspected uedvt | #5 |
| pad smoking | #5 |
| normal ctpa | #5 |
| endotoxin testing | #5 |
| antithrombotic drug treatment | #5 |
| hirudin treatment | #5 |
| clinical probability | #5 |
| recurrent dvt patients | #5 |
| cdr patients | #5 |
| southern latin america | #5 |
| iii plasminogen | #5 |
| 8491 | #5 |
| patients subtherapeutic | #5 |
| thrombosis primary | #5 |
| incidence prognostic significance | #5 |
| exclusion venous thromboembolism | #5 |
| thromboembolism | #5 |
| treatment fondaparinux | #5 |
| coc pregnancy | #5 |
| bleeding cancer | #5 |
| diagnostic strategies | #5 |
| ventricular dysfunction echocardiography | #5 |
| isolated calfvein thrombosis | #5 |
| burden vte | #5 |
| predilution | #5 |
| thrombosis leg | #5 |
| women warfarin | #5 |
| patients pulmonary embolism | #5 |
| low molecularweight humans | #5 |
| molecularweight heparin | #5 |
| 2 rules | #5 |
| specificity thrombophlebitis | #5 |
| ft4 level | #5 |
| secondary dvt | #5 |
| heparin compared | #5 |
| adjusted dimer | #5 |
| preschool contraceptives | #5 |
| patients superficial thrombophlebitis | #5 |
| pulmonary embolism patients | #5 |
| outpatients hospital | #5 |
| sensitivity negative predictive | #5 |
| venous thromboembolism studies | #5 |
| patients wells score | #5 |
| medea study | #5 |
| previous venous thromboembolism | #5 |
| endotoxin chimpanzees | #5 |
| vte 6 | #5 |
| 8292 | #5 |
| factor leiden 95 | #5 |
| coronary angioplasty angioplasty | #5 |
| elevated plasma level | #5 |
| vte factor | #5 |
| panwards | #5 |
| clinical presentation clinical | #5 |
| severe pph women | #5 |
| compression ultrasound | #5 |
| vka patients | #5 |
| fviii families | #5 |
| upper extremity thrombosis | #5 |
| patients recurrent dvt | #5 |
| lmwh incidence | #5 |
| pregnancy pph | #5 |
| thromboembolism studies | #5 |
| cgp 39393 | #5 |
| transfusion blood loss | #5 |
| cancer strategy | #5 |
| asymptomatic carriers mutation | #5 |
| fviia rnapc2 | #5 |
| efficiency patients | #5 |
| risk prediction scores | #5 |
| clinical probability assessment | #5 |
| outcome major | #5 |
| diagnosis questionnaire | #5 |
| rivaroxaban enoxaparin vka | #5 |
| patients parenteral anticoagulants | #5 |
| netilmicin patients | #5 |
| daiichi sankyo | #5 |
| hokusai | #5 |
| vte patients cancer | #5 |
| dimer combination | #5 |
| consensus strategy | #5 |
| thrombosis upper | #5 |
| gestalt | #5 |
| inhibition plasminogen activation | #5 |
| fh patients cvd | #5 |
| secondary venous thrombosis | #5 |
| subcutaneous low | #6 |
| 10±4 | #6 |
| low absolute risk | #6 |
| isolated deficiencies | #6 |
| simplired dimer | #6 |
| risk increasing levels | #6 |
| vte cancer | #6 |
| compression stockings patients | #6 |
| patients pulmonary angiography | #6 |
| factor leiden carriers | #6 |
| symptoms intermittent claudication | #6 |
| subjects vte | #6 |
| 049 95 | #6 |
| anticoagulants hemorrhage | #6 |
| treatment ufh | #6 |
| dabigatran etexilate dabigatran | #6 |
| efficiency proportion | #6 |
| apixaban treatment dose | #6 |
| proportion cancer patients | #6 |
| risk khorana score | #6 |
| warfarin venous thromboembolism | #6 |
| duration rivaroxaban | #6 |
| vte anticoagulant treatment | #6 |
| endotoxin assays | #6 |
| fviia inhibition | #6 |
| combined utility | #6 |
| embolism pulmonary | #6 |
| pembqol questionnaire | #6 |
| patients tests | #6 |
| severe antithrombin | #6 |
| recurrent pulmonary | #6 |
| patients anticoagulation clinic | #6 |
| leiden | #6 |
| effects ufh | #6 |
| stressinduced hyperglycaemia | #6 |
| incidence recurrence | #6 |
| amplify | #6 |
| treatment pulmonary embolism | #6 |
| endotoxininduced activation | #6 |
| elisapositive | #6 |
| prevalence vte | #6 |
| patients iohexol | #6 |
| lmwh cancer | #6 |
| blood coagulation mechanism | #6 |
| svt extension | #6 |
| c1173 | #6 |
| levonorgestrel desogestrel | #6 |
| 393 patients | #6 |
| conventional therapy treatment | #6 |
| subcutaneous nadroparin | #6 |
| probability pulmonary | #6 |
| dalteparin dose | #6 |
| vte controls | #6 |
| clinically relevant subgroups | #6 |
| patients suspected | #6 |
| pulmonary embolism presence | #6 |
| patients lowmolecularweight heparin | #6 |
| repeatedly normal | #6 |
| assay fibrin | #6 |
| enoxaparin incidence | #6 |
| myocardial infarction ctni | #6 |
| venograms | #6 |
| effects levonorgestrel | #6 |
| anticoagulants female | #6 |
| fixeddose regimen | #6 |
| synthetic pentasaccharides | #6 |
| patients proximal | #6 |
| thrombosis guidelines | #6 |
| thromboembolism bleeding | #6 |
| initial heparin treatment | #6 |
| thrombophilic defects | #6 |
| neoplasms pulmonary embolism | #6 |
| patients factor mutation | #6 |
| d‐dimer testing | #6 |
| ultrasonography normal | #6 |
| treatment intermittent claudication | #6 |
| 12month cumulative incidence | #6 |
| ft4 patients | #6 |
| embolism ventricular | #6 |
| selective beta | #6 |
| lmwh users users | #6 |
| standardized morbidity ratio | #6 |
| women hyperhomocysteinemia | #6 |
| vka | #6 |
| 39393 | #6 |
| anticoagulant treatment | #6 |
| outcome occurred | #6 |
| antagonists treatment | #6 |
| grade 1a ufh | #6 |
| wells rule | #6 |
| daily gentamicin | #6 |
| perioperative blood loss | #6 |
| oral anticoagulants dabigatran | #6 |
| dimer cut | #6 |
| patients uedvt | #6 |
| arterial cardiovascular | #6 |
| edoxaban efficacy | #6 |
| rate major bleeding | #6 |
| severe dic | #6 |
| symptomatic legs | #6 |
| oral edoxaban | #6 |
| patients diagnostic | #6 |
| cancer primary patients | #6 |
| funding bayer | #6 |
| dvt trial | #6 |
| diagnostic workup | #6 |
| treatment svt | #6 |
| recurrent dvt | #7 |
| factor female humans | #7 |
| thromboembolism adult | #7 |
| levels factor viii | #7 |
| negative predictive npv | #7 |
| relation levels | #7 |
| thromboembolism total | #7 |
| thrombophlebitis adolescent | #7 |
| patients standard heparin | #7 |
| silent pulmonary embolism | #7 |
| carriers venous thromboembolism | #7 |
| dvt ipg | #7 |
| thromboembolism vte | #7 |
| specific antidotes | #7 |
| unselected women | #7 |
| treatment doac | #7 |
| nondiagnostic lung scans | #7 |
| vka therapy | #7 |
| thrombophilia pregnancy loss | #7 |
| placebo rivaroxaban | #7 |
| 597939 | #7 |
| plasma levels ifngamma | #7 |
| vitamin antagonists vka | #7 |
| prothrombin risk | #7 |
| diagnostic suspicion | #7 |
| tb402 | #7 |
| major bleeding rate | #7 |
| neoplasms pulmonary | #7 |
| major bleeding | #7 |
| carriers defects | #7 |
| perelated death | #7 |
| diagnosis venous thrombosis | #7 |
| blood coagulation humans | #7 |
| doppler skin | #7 |
| tnf injection | #7 |
| statin treatment risk | #7 |
| rates edoxaban | #7 |
| lung scan | #7 |
| protein protein deficiencies | #7 |
| heparin org | #7 |
| 680 | #7 |
| combination ipg | #7 |
| ottawa score | #7 |
| spiral sensitivity | #7 |
| presence cteph | #7 |
| inhibitor apixaban | #7 |
| pulmonary embolism sensitivity | #7 |
| major bleeding vkas | #7 |
| noncompressibility | #7 |
| relation prolactin levels | #7 |
| arterial cardiovascular disease | #7 |
| antithrombin protein | #7 |
| deepvein thrombosis patients | #7 |
| venous thrombosis treatment | #7 |
| day initial treatment | #7 |
| embolism prospective | #7 |
| leg ultrasonography | #7 |
| rivaroxaban 10 | #7 |
| general practitioners guideline | #7 |
| administration bsf | #7 |
| negative ddimer test | #7 |
| mpc1609 | #7 |
| ufh treatment | #7 |
| coagulation humans | #7 |
| etexilate oral | #7 |
| anticoagulant parameters | #7 |
| stockings control | #7 |
| primary dvt | #7 |
| 220 dabigatran | #7 |
| phenprocoumon polymorphism | #7 |
| vte cancer diagnosis | #7 |
| mutations factor viii | #7 |
| primary efficacy | #7 |
| incidence recurrent vte | #7 |
| proportion older patients | #7 |
| aspirin combined | #7 |
| vka lmwh | #8 |
| patients extended anticoagulation | #8 |
| discontinuation anticoagulant treatment | #8 |
| anticoagulation unprovoked vte | #8 |
| compression surveys | #8 |
| occult cancer patients | #8 |
| lmwh grade 1a | #8 |
| wells scores | #8 |
| patients symptomatic vte | #8 |
| 1599 patients | #8 |
| euro55 | #8 |
| prospective management | #8 |
| xii deficient | #8 |
| ageadjusted ddimer cutoff | #8 |
| testing rule | #8 |
| current approach | #8 |
| levonorgestrelcontaining | #8 |
| venous thrombosis hyperhomocysteinaemia | #8 |
| arg506 factor | #8 |
| heparin vitamin antagonists | #8 |
| pvoct | #8 |
| nondiagnostic scan | #8 |
| overt cancer | #8 |
| optimal intensity | #8 |
| 150 enoxaparin | #8 |
| thrombosis prophylaxis | #8 |
| inr determination | #8 |
| leiden prothrombin | #8 |
| structured algorithm | #8 |
| prevention vte | #8 |
| symptomatic deepvein thrombosis | #8 |
| cancer pulmonary embolism | #8 |
| funding daiichi | #8 |
| administration low | #8 |
| fxi aso | #8 |
| treatment venous thrombosis | #8 |
| risk employees | #8 |
| 0·2 | #8 |
| inherited thrombophilic | #8 |
| nafronyl | #8 |
| dimer tests | #8 |
| 97 95 | #8 |
| dimer concentration | #8 |
| proximal deep | #8 |
| chemotherapy low risk | #8 |
| duration treatment | #8 |
| comorbidity polypharmacy | #8 |
| acute symptomatic vte | #8 |
| recurrent vte mb | #8 |
| enoxaparin vka | #8 |
| international organisations | #8 |
| proximal deepvein thrombosis | #8 |
| normal computed | #8 |
| thrombosis adolescent | #8 |
| patients excluded | #8 |
| vitamin antagonists vkas | #8 |
| consecutive outpatients | #8 |
| low clinical probability | #8 |
| products humans | #8 |
| ufh initial treatment | #8 |
| physicians stockings | #8 |
| recurrent vte bleeding | #8 |
| oral apixaban | #8 |
| severe preeclampsia patients | #8 |
| persistent risk factors | #8 |
| objectively confirmed | #8 |
| vascular endothelial barrier | #8 |
| v617f jak2 | #8 |
| oral glucocorticoids risk | #8 |
| bnp ctnt | #8 |
| aged phlebography | #8 |
| carriers fvl | #8 |
| vte score | #8 |
| contrast venography | #8 |
| tests pulmonary | #8 |
| increased fibrinolytic | #8 |
| probability lung | #8 |
| deficiency antithrombin | #8 |
| point ultrasonography | #8 |
| agnelli | #8 |
| anticoagulants antineoplastic | #8 |
| oac adherence | #8 |
| analysis apixaban | #8 |
| unprovoked vte patients | #8 |
| p0001 hasbled score | #8 |
| years cumulative incidence | #8 |
| initial heparin | #8 |
| warfarin hazard ratio | #8 |
| homocysteine markers | #8 |
| inr values patients | #8 |
| apixaban enoxaparin | #8 |
| risks dvt | #8 |
| therapeutic dose patients | #9 |
| generation pill | #9 |
| serotonin platelet | #9 |
| vte rcts | #9 |
| atiii concentrates | #9 |
| strategies dimer | #9 |
| months efficacy | #9 |
| combination stroke | #9 |
| anticoagulant pathways | #9 |
| hemorr2hages atria | #9 |
| homocysteine women | #9 |
| discontinuing anticoagulation | #9 |
| apixaban oral factor | #9 |
| thrombosis venous thromboembolism | #9 |
| lipoproteina women | #9 |
| büller | #9 |
| concomitant cancer | #9 |
| lmwh mortality | #9 |
| iii concentrate | #9 |
| compression stockings prevention | #9 |
| enoxaparin factor | #9 |
| thrombosis compared | #9 |
| fxa inhibitor | #9 |
| oral contraceptive pregnancy | #9 |
| incidental pulmonary | #9 |
| normal ddimer | #9 |
| nonpermanent | #9 |
| cofact | #9 |
| cancer cell extravasation | #9 |
| treatment edoxaban | #9 |
| acute medical illnesses | #9 |
| fondaparinux cancer patients | #9 |
| method enoxaparin | #9 |
| characteristics severity | #9 |
| longterm treatment vte | #9 |
| bled bleeding | #9 |
| incidence postthrombotic syndrome | #9 |
| treatment prophylaxis | #9 |
| cancer factor | #9 |
| patients active cancer | #9 |
| diagnosis mdct | #9 |
| independent committee | #9 |
| weight heparin | #9 |
| heparin therapy patients | #9 |
| ultrasonogram | #9 |
| diagnostic prediction model | #9 |
| cancer episode | #9 |
| daiichisankyo | #9 |
| vte relatives | #9 |
| placebo plasma levels | #9 |
| thromboembolism cancer | #9 |
| abnormal vaginal | #9 |
| male oligosaccharides | #9 |
| edoxaban major bleeding | #9 |
| patients fxa inhibitors | #9 |
| comorbidities polypharmacy | #9 |
| factors thrombophlebitis | #9 |
| major bleeding treatment | #9 |
| prothrombin 20210a | #9 |
| embolism venous | #9 |
| postdilution | #9 |
| crcl 60 | #9 |
| tafi levels | #9 |
| oral antithrombins | #9 |
| carriers factor leiden | #9 |
| thrombosis thromboinflammation | #9 |
| dvt lower extremity | #10 |
| leg veins | #10 |
| magellan study | #10 |
| vnv | #10 |
| inr cases | #10 |
| snp scores | #10 |
| venous thromboembolic event | #10 |
| normohomocysteinemic | #10 |
| treatment aprotinin | #10 |
| treatment vitamin | #10 |
| aged antithrombin | #10 |
| severity clinical | #10 |
| rfviia blood loss | #10 |
| year years | #10 |
| fondaparinux risk | #10 |
| major bleeding crnmb | #10 |
| 4470 | #10 |
| anticoagulants | #10 |
| retrospective study efficacy | #10 |
| embolism patients | #10 |
| intimamedia thickness imt | #10 |
| rabbits administration | #10 |
| inherited thrombophilic factors | #10 |
| rates recurrent vte | #10 |
| factor levels patients | #10 |
| wells | #10 |
| thrombosis background | #10 |
| vte efficacy | #10 |
| 100 years discontinuation | #10 |
| thr incidence | #10 |
| cancer patients vte | #10 |
| cancer patients lmwh | #10 |
| protein dic | #10 |
| oral thrombin inhibitor | #10 |
| incidence 1000 personyears | #10 |
| patients endotoxemia | #10 |
| fii mutation | #10 |
| injection avidin | #10 |
| embolism clinical | #10 |
| subcutaneous metaanalysis | #10 |
| venous thrombosis | #10 |
| crp test | #10 |
| bled scores | #10 |
| asymptomatic pulmonary embolism | #10 |
| induced coagulation | #10 |
| oral administration dabigatran | #10 |
| patients venous thrombosis | #10 |
| deficiencies antithrombin | #10 |
| ageadjusted cutoff | #10 |
| incidence major bleeding | #10 |
| lmwh studies | #10 |
| gramnegative septicemia | #10 |
| pregnancy carriers | #10 |
| cvd fh patients | #10 |
| ddimer concentration | #10 |
| probability pulmonary embolism | #10 |
| simplified geneva | #10 |
| factor prevention | #10 |
| heparin nomogram | #10 |
| cus diagnosis | #10 |
| magellan trial | #10 |
| thrombophlebitis adult | #10 |
| extremity deep | #10 |
| treatment uedvt | #10 |
| single loss | #10 |
| hypocoagulable state | #10 |
| nadroparine | #10 |
| 598 patients | #10 |
| 1215 patients | #10 |
| animal heparin | #10 |
| schedule heparin | #10 |
| d‐dimer levels | #11 |
| patients cancer vte | #11 |
| hospital lmwh | #11 |
| org 10172 | #11 |
| air travel | #11 |
| cancer patients dvt | #11 |
| inhibitors hemorrhage | #11 |
| cancer patients evidence | #11 |
| thromboembolism major | #11 |
| dvt | #11 |
| intensity anticoagulation | #11 |
| ldfr | #11 |
| gps training | #11 |
| screening cancer | #11 |
| 880 patients | #11 |
| pcc dabigatran | #11 |
| pyridines thiazoles | #11 |
| 750 μg | #11 |
| fondaparinux hemorrhage | #11 |
| previous venous | #11 |
| haemophilia vwd | #11 |
| factor venous | #11 |
| carriers factor | #11 |
| sulfates dermatan | #11 |
| 30 microg ethinylestradiol | #11 |
| lmwh pregnancies | #11 |
| weight humans | #11 |
| mutations prevalence | #11 |
| crnmb 95 | #11 |
| pulmonary embolism incidence | #11 |
| variation inr | #11 |
| patients anticoagulant treatment | #11 |
| patients probability | #11 |
| adult anticoagulants | #11 |
| gentamicin treatment patients | #11 |
| medical conferences | #11 |
| edoxaban | #11 |
| dabigatran enoxaparin | #11 |
| knee clinical trials | #11 |
| pregnancyrelated complications | #11 |
| endotoxin assay | #11 |
| endotoxin pentoxifylline | #11 |
| pulmonary angiography venography | #11 |
| embolism recurrence | #11 |
| embolism prevalence | #11 |
| ufh studies | #11 |
| clinical pretest | #11 |
| combination dimer | #11 |
| heparinoid org | #11 |
| incidence major | #11 |
| lmwh pregnancy | #11 |
| patients cvcs | #11 |
| oral dabigatran | #11 |
| reference testing | #11 |
| vte vwf | #11 |
| levels prolactin | #11 |
| recombinant human tnf | #11 |
| subsegmental pulmonary emboli | #12 |
| factor leiden prothrombin | #12 |
| warfarin treated | #12 |
| risk venous | #12 |
| women factor | #12 |
| event recurrence | #12 |
| patients incidental | #12 |
| stopping anticoagulation | #12 |
| female heparin humans | #12 |
| geneva score | #12 |
| topic venous | #12 |
| anticoagulation unprovoked | #12 |
| 9295 | #12 |
| thrombosis dvt | #12 |
| observation risk | #12 |
| treatment crt | #12 |
| prevention venous thrombosis | #12 |
| outcomes venous thromboembolism | #12 |
| vka noacs | #12 |
| paulin | #12 |
| patients lmwhs | #12 |
| patients lupus anticoagulant | #12 |
| humanized arthroplasty | #12 |
| 72 children | #12 |
| control metaanalysis | #12 |
| recurrent vte | #12 |
| recurrent vte anticoagulation | #12 |
| anticoagulant factor | #12 |
| bnp cardiac troponin | #12 |
| perelated | #12 |
| peghirudin | #12 |
| bayer schering pharma | #12 |
| proximal veins | #12 |
| proximal vein | #12 |
| venous thromboembolism incidence | #12 |
| 9702 | #12 |
| outpatient management patients | #12 |
| nephro | #12 |
| vte recurrence risk | #12 |
| warfarin therapy inr | #12 |
| thrombophilic | #12 |
| hirulog1 | #12 |
| warfarin recurrent vte | #12 |
| noacs vka | #12 |
| pioped study | #12 |
| dvt treatment | #12 |
| deficient women | #12 |
| thrombin generation fibrinolysis | #12 |
| months primary | #12 |
| annual incidence vte | #12 |
| concomitant disorders | #12 |
| livebirth rate | #12 |
| hemodynamically stable | #12 |
| fondaparinux unfractionated heparin | #12 |
| safety efficiency | #12 |
| ageadjusted ddimer | #12 |
| crd42013003526 | #12 |
| doseadjustment | #12 |
| spiral computed tomography | #13 |
| superficial thrombophlebitis | #13 |
| 95 carriers | #13 |
| nct00986154 | #13 |
| conventional anticoagulants | #13 |
| dabigatran 220 | #13 |
| ufh dalteparin | #13 |
| dimer threshold | #13 |
| treatment venous thromboembolism | #13 |
| thrombosis young | #13 |
| safety doacs | #13 |
| vte | #13 |
| concomitant antiplatelet therapy | #13 |
| thrombosis acute | #13 |
| vte recurrence 95 | #13 |
| plethysmography | #13 |
| levels factor | #13 |
| 86 percent | #13 |
| patients anticoagulant | #13 |
| dvt lower | #13 |
| indication anticoagulation | #13 |
| bleeding events edoxaban | #13 |
| daily subcutaneous | #13 |
| vte groups | #13 |
| strain gauge plethysmography | #13 |
| major hip | #13 |
| clinical decision rules | #13 |
| association venous thrombosis | #13 |
| selective testing | #13 |
| obesity haemophilia patients | #13 |
| patients thrombophilia | #13 |
| hematologic pregnancy trimester | #13 |
| vte 64 | #13 |
| pselectin patients | #13 |
| dimer testing | #13 |
| groups inr | #13 |
| arterial thromboembolism ate | #13 |
| heparin low | #13 |
| antithrombin iii activity | #13 |
| rivaroxaban thiophenes | #13 |
| occult cancer | #13 |
| bayer healthcare | #13 |
| marder score | #13 |
| inhibition tnf | #13 |
| safety oral | #13 |
| vte major | #13 |
| plethysmograms | #13 |
| randomized cross | #13 |
| continuous intravenous heparin | #13 |
| prevention venous thromboembolism | #13 |
| time prothrombin | #13 |
| factor leiden mutation | #13 |
| dabigatran vte | #13 |
| recombinant hirudin rhirudin | #13 |
| arixtra | #13 |
| inferiority efficacy | #13 |
| factor viii apc | #13 |
| deepvein thrombosis dvt | #13 |
| category studies | #13 |
| uedvt | #13 |
| vte female humans | #13 |
| acute deep | #14 |
| treatment duration patients | #14 |
| riete score | #14 |
| limited screening | #14 |
| edoxaban warfarin | #14 |
| patients dvt | #14 |
| patients acute vte | #14 |
| vte statin | #14 |
| aged plethysmography | #14 |
| symptomatic pulmonary | #14 |
| female fibrin | #14 |
| conventionaltherapy | #14 |
| treated lmwh | #14 |
| ultrasound strategies | #14 |
| bolus intravenous injection | #14 |
| revised geneva | #14 |
| edoxaban oral factor | #14 |
| costs dvt | #14 |
| crnm | #14 |
| effects hyperthyroidism | #14 |
| recurrent venous | #14 |
| loss women | #14 |
| obstetric complications women | #14 |
| thrombophilia patients | #14 |
| lmwh vka | #14 |
| aged anticoagulants | #14 |
| gastrointestinal bleeding patients | #14 |
| standard heparin | #14 |
| unprovoked vte vte | #14 |
| higher ddimer levels | #14 |
| cadherins endothelium | #14 |
| placebo rfviia | #14 |
| doseranging study | #14 |
| experimental endotoxaemia | #14 |
| aspirin women | #14 |
| fvl carriers | #14 |
| patients outpatients | #14 |
| factor viii levels | #14 |
| incidence severe pph | #14 |
| thrombosis | #14 |
| recurrent venous thromboembolism | #14 |
| pregnancy venous | #14 |
| vte months | #14 |
| cancer patients anticoagulation | #14 |
| 12 kg1 | #14 |
| dvt lower extremities | #14 |
| anticoagulant rivaroxaban | #14 |
| plasminogen apoa | #14 |
| awareness pad | #14 |
| 17 placebo | #14 |
| atiii deficiency | #14 |
| safety edoxaban | #14 |
| thromboembolism age | #14 |
| patients vka therapy | #14 |
| low molecular | #14 |
| patients ctpa | #15 |
| cardiovascular diseases thrombosis | #15 |
| activation contact | #15 |
| symptomatic events | #15 |
| fondaparinux efficacy | #15 |
| subcutaneous regimen | #15 |
| coc vte | #15 |
| coagulation | #15 |
| probability assessment | #15 |
| diagnosis venous | #15 |
| hyperthyroidism atrial fibrillation | #15 |
| established vte | #15 |
| cteph incidence | #15 |
| lomoparan | #15 |
| prophylaxis venous thromboembolism | #15 |
| anticoagulants patients | #15 |
| inr range | #15 |
| arg562 | #15 |
| vitaminkantagonists | #15 |
| abdominal pelvic | #15 |
| clinically relevant endpoints | #15 |
| recombinant factor viia | #15 |
| prior venous thromboembolism | #15 |
| edoxaban treatment | #15 |
| lmwh ufh | #15 |
| enoxaparin vte | #15 |
| factor leiden | #15 |
| thrombus growth | #15 |
| thyroid hormone excess | #15 |
| 500 pg | #15 |
| subcutaneous enoxaparin | #15 |
| khorana score | #15 |
| antagonist vka | #15 |
| primary safety outcome | #15 |
| studies pulmonary | #15 |
| thrombinography | #15 |
| arg506 | #15 |
| inr patient | #15 |
| doacs aspirin | #15 |
| generation oral | #15 |
| patients vitamin antagonists | #15 |
| oral direct factor | #15 |
| pregnancy outcome pregnancy | #15 |
| thrombosis diagnosis | #15 |
| control subjects prevalence | #15 |
| experimental thrombosis | #15 |
| treatment 12 months | #15 |
| thrombosis low | #16 |
| thrombosis association | #16 |
| women unexplained | #16 |
| major bleeding events | #16 |
| positivity threshold | #16 |
| viia activity | #16 |
| venous thrombosis warfarin | #16 |
| 6 months placebo | #16 |
| cancer screening patients | #16 |
| vterelated death | #16 |
| thrombosis adult | #16 |
| recurrent symptomatic | #16 |
| factor inhibitor | #16 |
| test clinical | #16 |
| major bleeding anticoagulation | #16 |
| thromboembolism time | #16 |
| risk clinically | #16 |
| ddimer levels patients | #16 |
| bleeding aged | #16 |
| 100 95 | #16 |
| arterial vascular events | #16 |
| deep venous thrombosis | #16 |
| avws patients | #16 |
| thrombosis haemostasis | #16 |
| patients acenocoumarol | #16 |
| factors major | #16 |
| combination clinical | #16 |
| vte khorana score | #16 |
| analysis rivaroxaban | #16 |
| netilmicin gentamicin | #16 |
| dvt lmwh | #16 |
| postthrombotic syndrome children | #16 |
| warfarin acenocoumarol | #16 |
| cancer cancer patients | #16 |
| occult cancer detection | #16 |
| impaired fibrinolysis | #16 |
| subsequent pregnancy loss | #16 |
| abdomino | #16 |
| incidence pts | #17 |
| dvt prevention | #17 |
| factor monoclonal | #17 |
| fibrinolysis treatment | #17 |
| topic hemorrhage humans | #17 |
| 516 patients | #17 |
| patients impedance | #17 |
| anticoagulants clinical | #17 |
| women mutation | #17 |
| anticoagulants drug | #17 |
| permanent patients | #17 |
| gentamicin netilmicin | #17 |
| endotoxemia bacteremia | #17 |
| fragment f1 | #17 |
| compared enoxaparin | #17 |
| scan classification | #17 |
| vkorc1 gene | #17 |
| management crt | #17 |
| thrombosis clinical | #17 |
| ctscans | #17 |
| lower specificity | #17 |
| mutation women | #17 |
| diagnosis svt | #17 |
| dimer assay | #17 |
| 12 months patients | #17 |
| 2688 | #17 |
| patients overt hypothyroidism | #17 |
| lmwhs patients | #17 |
| female humans vte | #17 |
| factors venous | #17 |
| excessive blood loss | #17 |
| prohemostatic | #17 |
| hematoma heparin | #17 |
| rivaroxaban oral factor | #17 |
| anticoagulant therapy patients | #17 |
| recurrent vte events | #17 |
| thromboembolism patients | #17 |
| pharmo record linkage | #17 |
| vte edoxaban | #17 |
| warfarin hazard | #18 |
| thromboembolism venous | #18 |
| vka edoxaban | #18 |
| antithrombotic treatment patients | #18 |
| treatment vkas | #18 |
| combined form | #18 |
| sanofi aventis | #18 |
| hivinfected patients cart | #18 |
| 023 | #18 |
| apc thrombin generation | #18 |
| diagnostic strategy | #18 |
| aptt heparin | #18 |
| venous thromboembolism rivaroxaban | #18 |
| cancer vte | #18 |
| weight adjusted | #18 |
| simplired | #18 |
| stable anticoagulation | #18 |
| commercial airline pilots | #18 |
| edoxaban vte | #18 |
| annual incidence | #18 |
| outcome events | #18 |
| patients strategy | #18 |
| relevant nonmajor | #18 |
| thrombosis pulmonary | #18 |
| lmwh doacs | #18 |
| vka vte | #18 |
| proximal vein thrombosis | #18 |
| intravenous heparin therapy | #18 |
| poc test | #18 |
| thrombosis total | #18 |
| 4 clinical | #18 |
| favor lmwh | #18 |
| prothrombin g20210a | #18 |
| women pregnancy loss | #18 |
| flight hours | #18 |
| prognostic echocardiography | #19 |
| patients prevalence | #19 |
| active search | #19 |
| ipdma | #19 |
| adjusted dose | #19 |
| versions version | #19 |
| vitamin antagonist | #19 |
| fondaparinux enoxaparin | #19 |
| ufh lmwh | #19 |
| recurrent venous thrombosis | #19 |
| objective testing | #19 |
| local angiogenesis | #19 |
| acute recurrent | #19 |
| low platelets | #19 |
| subcutaneous dalteparin | #19 |
| coagulation studies | #19 |
| systemic activation coagulation | #19 |
| treatment heparin | #19 |
| dvt rivaroxaban | #19 |
| doubleblinding | #19 |
| abnormal ultrasound | #19 |
| thromboembolism administration | #19 |
| oral dabigatran enoxaparin | #19 |
| patients derivation | #19 |
| patients sspe | #19 |
| lmwh patients | #19 |
| vwf vte | #19 |
| 56 95 | #19 |
| venography sensitivity | #19 |
| antibodynegative | #19 |
| extended oral | #19 |
| recurrence vte | #19 |
| fibrinolytic response | #19 |
| patients major bleeding | #19 |
| symptomatic dvt | #19 |
| venous thromboembolism relatives | #19 |
| patients elevated biomarkers | #19 |
| retropubic prostatectomy | #19 |
| ddimer tests | #19 |
| studies factor | #19 |
| increased risk relatives | #19 |
| endogenous fibrinolysis | #19 |
| increased fibrinolytic activity | #19 |
| 35 women | #19 |
| edoxaban dose | #19 |
| compared ufh | #20 |
| life venous thrombosis | #20 |
| shr 95 | #20 |
| incidences death | #20 |
| antitpo | #20 |
| proteins thrombin | #20 |
| anticoagulation clinic | #20 |
| guidance ssc | #20 |
| single criterion | #20 |
| patients ddimer testing | #20 |
| nadroparin | #20 |
| control situation | #20 |
| impedance plethysmography ipg | #20 |
| thrombosis ultrasonography | #20 |
| established atherosclerosis | #20 |
| versions questionnaire | #20 |
| symptomatic venous thrombosis | #20 |
| dabigatran 150 | #20 |
| risk thrombophilia | #20 |
| subsegmental | #20 |
| absolute risk | #20 |
| ctnt bnp | #20 |
| new agent | #20 |
| recurrence bleeding | #20 |
| pregnancyrelated vte | #20 |
| therapy rivaroxaban | #20 |
| distance treatment | #20 |
| injections subcutaneous | #20 |
| statin vte | #20 |
| intravenous injections | #20 |
| abi risk factors | #20 |
| diagnostic workup patients | #20 |
| excluded patients | #20 |
| cancer severity | #20 |
| thrombophilia vte | #20 |
| antagonists vkas | #20 |
| abi measurement | #20 |
| portola | #20 |
| warfarin edoxaban | #20 |
| residual venous | #20 |
| standardtherapy hazard ratio | #20 |
| prothrombin mutation | #20 |
| calf veins | #20 |
| treatment vte | #20 |
| synthetic cross | #20 |
| malignancy time | #20 |
| blindly | #20 |
| carriers prothrombin | #20 |
| thrombosis anticoagulants | #21 |
| ddimer concentrations | #21 |
| occult malignancy | #21 |
| concomitant anti | #21 |
| outcome incidence | #21 |
| d‐dimer | #21 |
| risk cohort study | #21 |
| thromb | #21 |
| hemodynamically stable patients | #21 |
| hemostatic abnormalities | #21 |
| vte patients | #21 |
| disease ischemic | #21 |
| carriers noncarriers | #21 |
| venogram | #21 |
| current standard treatment | #21 |
| treatment apixaban | #21 |
| fibrinolysis inflammation | #21 |
| treatment acenocoumarol | #21 |
| doacs lmwhs | #21 |
| major bleeding patients | #21 |
| internists cardiologists | #21 |
| discriminatory performance | #21 |
| prothrombin 20210 | #21 |
| patients 3 months | #21 |
| distance quality | #21 |
| deep venous | #21 |
| public awareness | #22 |
| bleeding treatment | #22 |
| anticoagulants humans | #22 |
| hormonal cross | #22 |
| ttr inr | #22 |
| recurrent thromboembolism | #22 |
| lpa plasminogen | #22 |
| dose subcutaneous | #22 |
| riskbenefit ratio | #22 |
| treatment dvt | #22 |
| thrombophilia screening | #22 |
| daily enoxaparin | #22 |
| safety treatment | #22 |
| dimer age | #22 |
| patients immobilization | #22 |
| dichotomously | #22 |
| host defense response | #22 |
| time inr | #22 |
| patients recurrent symptoms | #22 |
| doppler venous thrombosis | #22 |
| cttr | #22 |
| venous thromboembolic | #22 |
| anticoagulants heparin | #22 |
| acute vte | #22 |
| alternative anticoagulation | #22 |
| patientyears | #22 |
| vascular endotoxins | #22 |
| cmax ctrough | #22 |
| patients severe hf | #22 |
| hasbled score | #23 |
| thromboembolism anticoagulants | #23 |
| venous arterial thrombosis | #23 |
| 011 | #23 |
| clotbound thrombin | #23 |
| recurrence venous | #23 |
| standardduration | #23 |
| cancer patients risk | #23 |
| lower extremity amputation | #23 |
| enoxaparin 40 | #23 |
| 2 investigators | #23 |
| time platelet | #23 |
| vte studies | #23 |
| normal angiogram | #23 |
| odis | #23 |
| bidirectional relation | #23 |
| kakkar | #23 |
| life pulmonary embolism | #23 |
| rivaroxaban dosing | #23 |
| gentamicin patients | #23 |
| patients coagulation disorders | #23 |
| prevalence venous thromboembolism | #23 |
| fondaparinux | #23 |
| development dic | #23 |
| percentage increase | #23 |
| elevated ctni | #23 |
| 5392 | #23 |
| n1157 | #23 |
| direct factor inhibitors | #23 |
| ambulatory cancer patients | #23 |
| ufh patients | #24 |
| viiic | #24 |
| patients abnormal perfusion | #24 |
| lowmolecularweight humans | #24 |
| predefined criteria | #24 |
| fondaparinux placebo | #24 |
| years episode | #24 |
| levels fviii | #24 |
| prevalence deficiencies | #24 |
| presence dvt | #24 |
| bleeding complication | #24 |
| specific antidote | #24 |
| patients acute treatment | #24 |
| 049 | #24 |
| independent external validation | #24 |
| patients severe bleeding | #24 |
| followup incidence | #24 |
| therapy heparin | #24 |
| parameters fibrinolysis | #24 |
| rates venous thromboembolism | #24 |
| food drugs | #24 |
| recurrent pulmonary embolism | #24 |
| safety fondaparinux | #24 |
| a21gly | #24 |
| recurrent thromboembolism patients | #24 |
| subtherapeutic | #24 |
| desogestrel levonorgestrel | #24 |
| ddimer testing | #24 |
| overt hyperthyroidism | #24 |
| month incidence | #24 |
| thrombosis carriers | #24 |
| fibrinogen degradation | #25 |
| cha2ds2vasc chads2 | #25 |
| lmwh treatment | #25 |
| studies lmwh | #25 |
| anatomical extent | #25 |
| specificity efficiency | #25 |
| sepsis intravascular coagulation | #25 |
| expert radiologists | #25 |
| patients gastrointestinal bleeding | #25 |
| fatima | #25 |
| influence smoking | #25 |
| vte clinical | #25 |
| willebrand factor adamts13 | #25 |
| xii activity | #25 |
| treatment symptomatic | #25 |
| amadeus | #25 |
| factors anticoagulants | #25 |
| f1 2 levels | #25 |
| suggestions improvement | #25 |
| perfusion lung scan | #25 |
| middeldorp | #25 |
| thromboembolism acute | #25 |
| hormonal manipulation | #26 |
| homozygous carriers | #26 |
| treatment lmwh | #26 |
| dalteparin ufh | #26 |
| patients cdr | #26 |
| unprovoked vte | #26 |
| doacs vitamin antagonists | #26 |
| edoxaban versus | #26 |
| patients essential thrombocythaemia | #26 |
| rate recurrent vte | #26 |
| patients symptomatic dvt | #26 |
| parameters risk | #26 |
| asymptomatic carriers | #26 |
| specificity negative predictive | #26 |
| miscarriage stillbirth | #26 |
| venous thromboemboli | #26 |
| failure rate | #26 |
| rethoracotomy | #26 |
| edoxaban vka | #26 |
| ecq | #26 |
| thromboprophylaxis hospitalized patients | #26 |
| 9715 | #26 |
| viia complex | #26 |
| major bleeding bleeding | #26 |
| events year | #26 |
| combined training | #27 |
| training gps | #27 |
| thrombophlebitis | #27 |
| thrombosis venous | #27 |
| anticoagulants blood | #27 |
| vte doacs | #27 |
| noncarriers 95 | #27 |
| anticoagulants factor | #27 |
| npv patients | #27 |
| unprovoked venous | #27 |
| treating physician | #27 |
| 0·63 | #27 |
| current guidance | #27 |
| lowmolecularweight heparin patients | #27 |
| female heterozygote | #27 |
| enoxaparin female | #27 |
| extremity venous | #27 |
| patients 50 | #27 |
| lmwh prophylaxis | #27 |
| cancer spread | #27 |
| patients major hemorrhage | #27 |
| nonmajor | #27 |
| months studies | #27 |
| low molecularweight heparin | #27 |
| perfusion lung | #27 |
| patients elevated levels | #27 |
| thrombocytopenia antibodies | #27 |
| day 35 | #27 |
| venous thromboembolism carriers | #27 |
| vte thr | #27 |
| airline pilots | #27 |
| objective tests | #28 |
| rfviia placebo | #28 |
| specific reversal agent | #28 |
| patients unprovoked | #28 |
| unexplained | #28 |
| therapeutic doses | #28 |
| tests diagnostic | #28 |
| anticoagulants compared | #28 |
| presentation followup | #28 |
| pph severe pph | #28 |
| receiving rivaroxaban | #28 |
| anticoagulation women | #28 |
| vitamin aged | #28 |
| monitoring therapy | #28 |
| hirudin therapy | #28 |
| 2½ | #28 |
| acutely medical patients | #28 |
| 4650 | #28 |
| pembqol | #28 |
| embolism retrospective | #28 |
| factors recurrent | #28 |
| apc plasma | #28 |
| coagulation tissue factor | #28 |
| vte 6 months | #28 |
| cancer venous thromboembolism | #28 |
| heparin versus | #29 |
| pulmonary embolism recurrence | #29 |
| blind trials | #29 |
| pbac score | #29 |
| dvt pulmonary embolism | #29 |
| g20210a mutation | #29 |
| dabigatran pcc | #29 |
| recurrence svt | #29 |
| aspirin placebo | #29 |
| cindexes | #29 |
| major bleeding rivaroxaban | #29 |
| plateletactivating antibodies | #29 |
| prediction scores | #29 |
| spread cancer | #29 |
| bleeding increased | #29 |
| septicemia | #29 |
| years year | #29 |
| diagnosis dvt | #29 |
| resistance activated protein | #29 |
| current management strategies | #29 |
| patients standard therapy | #29 |
| 1000 individuals | #29 |
| 8240 | #29 |
| authors incidence | #29 |
| pulmonary angiography | #29 |
| direct oral anticoagulants | #29 |
| aged morpholines | #29 |
| aminoglycoside therapy | #29 |
| thrombo | #29 |
| acenocoumarol patients | #29 |
| dutch famine | #29 |
| patients avws | #29 |
| thrombosis treatment | #29 |
| sex‐specific differences | #29 |
| thrombosis 95 | #29 |
| pulmonary embolism death | #29 |
| oral glucocorticoids | #29 |
| xii factor | #30 |
| new anticoagulants | #30 |
| rule patients | #30 |
| cancer venous | #30 |
| markers coagulation activation | #30 |
| prevention venous | #30 |
| administration pentoxifylline | #30 |
| residual thrombosis | #30 |
| vte coc | #30 |
| 1000 personyears incidence | #30 |
| costs diagnosis | #30 |
| patients vte | #30 |
| thromboembolism warfarin | #30 |
| embolism risk | #30 |
| subcutaneous heparin | #30 |
| 95 risk | #30 |
| support techniques | #30 |
| ufh vte | #30 |
| f1 2 | #30 |
| doac vka | #30 |
| direct oral factor | #30 |
| women recurrent miscarriage | #31 |
| dimer cutoff | #31 |
| dvt pulmonary | #31 |
| placebo observation | #31 |
| ventilation scintigraphy | #31 |
| imaging sensitivity specificity | #31 |
| 0206 | #31 |
| rfviia novoseven | #31 |
| recurrent vte patients | #31 |
| inhibitor edoxaban | #31 |
| incidence cteph | #31 |
| 8755 | #31 |
| antithrombotic therapies | #31 |
| apixaban placebo | #31 |
| iii activity | #31 |
| patients deepvein thrombosis | #31 |
| events 95 | #31 |
| activation blood coagulation | #31 |
| thromboprophylaxis risk | #31 |
| ufh fondaparinux | #31 |
| recurrent patients | #31 |
| vte ufh | #31 |
| analysis reviewers | #31 |
| experimental endotoxemia | #31 |
| bled | #31 |
| 2 antiplasmin | #31 |
| rhir | #31 |
| pharmacological prophylaxis | #31 |
| thromboembolism adolescent | #31 |
| prevalence probability | #31 |
| term risk | #31 |
| standardtherapy | #31 |
| extended prophylaxis | #31 |
| incidence pph | #31 |
| recurrent episode | #31 |
| ufh | #32 |
| leiden mutation | #32 |
| low clinical | #32 |
| generation patients | #32 |
| negative dimer | #32 |
| treatment anticoagulants | #32 |
| khorana score patients | #32 |
| parenteral anticoagulants | #32 |
| resistance activated | #32 |
| international society thrombosis | #32 |
| factor female | #32 |
| varicosis | #32 |
| year 95 | #32 |
| suspected patients | #32 |
| netherlands predictive | #32 |
| age adjusted | #32 |
| factors thrombolytic | #32 |
| normal genotype | #32 |
| parenteral anticoagulation | #32 |
| negative septicemia | #32 |
| warfarin vte | #32 |
| data meta | #33 |
| apixaban treatment | #33 |
| low probability | #33 |
| unitage | #33 |
| nephrotoxicity gentamicin | #33 |
| anticoagulant protein | #33 |
| prophylaxis vte | #33 |
| thromboembolism young | #33 |
| active implementation | #33 |
| subcutaneous male | #33 |
| mega study | #33 |
| heparin lmwh | #33 |
| chapter patients | #33 |
| pulmonary angiogram | #33 |
| warfarin risks | #33 |
| factor viii patients | #33 |
| additional tests | #33 |
| activation factors | #33 |
| cancer patients diagnosis | #33 |
| rhirudin | #33 |
| vte compared | #34 |
| 10 95 | #34 |
| lmwh unfractionated heparin | #34 |
| vte thrombophilia | #34 |
| 9241 | #34 |
| apcsr | #34 |
| subsegmental pulmonary embolism | #34 |
| control trials | #34 |
| warfarin adult | #34 |
| phytonadione | #34 |
| 3 months treatment | #34 |
| reocclusion patients | #34 |
| compare efficacy | #34 |
| deficiency protein | #34 |
| anticoagulant | #34 |
| thrombosis lower | #34 |
| plasmin alpha | #34 |
| hemorrhage heparin humans | #34 |
| grade 1a | #34 |
| pregnancy loss women | #34 |
| 590 | #34 |
| bilateral venography | #34 |
| surgery hip | #35 |
| statin association | #35 |
| neoplasms venous | #35 |
| patients efficiency | #35 |
| risk members | #35 |
| weekly subcutaneous | #35 |
| enoxaparin prevention | #35 |
| pph blood loss | #35 |
| activation coagulation | #35 |
| anticoagulants benzimidazoles | #35 |
| 36 95 | #35 |
| rviia | #35 |
| embolism | #35 |
| lung scanning | #35 |
| radiologists diagnosis | #35 |
| prevention model | #35 |
| inherited risk factors | #36 |
| riskbenefit | #36 |
| fibrinogen depletion | #36 |
| 1698 | #36 |
| peripheral endovascular | #36 |
| 4139 | #36 |
| catheterrelated infection | #36 |
| studies echocardiography | #36 |
| hellp patients | #36 |
| venous thromboembolic disease | #36 |
| 287 patients | #36 |
| dose reduction patients | #36 |
| venous thromboembolism dabigatran | #36 |
| thrombophilia venous | #36 |
| treatment acute vte | #36 |
| iii antithrombin | #36 |
| factors travel | #36 |
| viii levels | #36 |
| regular monitoring | #36 |
| fibrinolytic activation | #36 |
| levels coagulation | #36 |
| acute symptomatic | #36 |
| novoseven | #36 |
| prophylactic heparin | #37 |
| rivaroxaban thromboprophylaxis | #37 |
| genotype 95 | #37 |
| anticoagulants prevention | #37 |
| ctpa patients | #37 |
| outcome composite | #37 |
| magellan | #37 |
| suspected venous | #37 |
| pad studies | #37 |
| risk venous thrombosis | #37 |
| factors thrombophilia | #37 |
| tat complexes | #37 |
| excluding | #37 |
| cumulative incidence vte | #37 |
| perelated mortality | #37 |
| bagsvaerd | #37 |
| lwmh | #37 |
| risk factors pts | #37 |
| recombinant hirudin | #37 |
| venography | #37 |
| anticoagulant action | #37 |
| vte increased | #37 |
| warfarin 95 | #37 |
| screening occult | #37 |
| thrombosis humans | #37 |
| ototoxicity nephrotoxicity | #37 |
| vte bleeding | #38 |
| vte cancer patients | #38 |
| 3306 | #38 |
| doac lmwh | #38 |
| 10 total | #38 |
| 2835 | #38 |
| nonmajor bleeding | #38 |
| fetal loss women | #38 |
| age recurrence | #38 |
| sensitivity biomarkers | #38 |
| submassive pulmonary | #38 |
| recurrence day | #38 |
| coagulation protein | #38 |
| congenital deficiencies | #38 |
| rivaroxaban placebo | #38 |
| anticoagulants female humans | #38 |
| catheterrelated thrombosis | #38 |
| restenosis reocclusion | #38 |
| patients ddimer levels | #38 |
| time compression | #39 |
| low molecular weight | #39 |
| superficial vein thrombosis | #39 |
| doacs | #39 |
| compression stocking | #39 |
| fibrin fibrinogen | #39 |
| septic syndrome | #39 |
| enoxaparin placebo | #39 |
| heparins lmwhs | #39 |
| specificity patients | #39 |
| children familial hypercholesterolemia | #39 |
| incidence cancer | #39 |
| systemic inflammatory responses | #39 |
| diagnostic prediction | #39 |
| 277 patients | #39 |
| incidence patients | #39 |
| submassive | #39 |
| subcutaneous intention | #39 |
| continued treatment | #39 |
| embolus | #39 |
| anticoagulation therapy patients | #40 |
| anticoagulant therapy | #40 |
| dalteparin treatment | #40 |
| day 6 months | #40 |
| pemb | #40 |
| international clinical | #40 |
| patients normal | #40 |
| episode venous thromboembolism | #40 |
| thrombinantithrombin complexes | #40 |
| arterial vascular | #40 |
| standardized definition | #40 |
| ambulatory cancer | #40 |
| common femoral vein | #40 |
| therapeutic dosages | #40 |
| activatable fibrinolysis | #40 |
| endotoxininduced | #40 |
| tfmp | #40 |
| bleeding | #40 |
| clotting activation | #40 |
| fviiic | #40 |
| grade 1a patients | #40 |
| submassive pulmonary embolism | #41 |
| anticoagulated patients | #41 |
| lung scintigraphy | #41 |
| lowmolecularweight heparins | #41 |
| 7268 | #41 |
| placebo 6 months | #41 |
| calf vein thrombosis | #41 |
| endotoxin induced | #41 |
| heparin therapy | #41 |
| pentasaccharides | #41 |
| dabigatran etexilate | #41 |
| 95 genotype | #41 |
| risk recurrent vte | #41 |
| cancer lmwh | #41 |
| triage tests | #41 |
| patients silent | #42 |
| thrombosis administration | #42 |
| stroke thrombosis | #42 |
| netilmicin | #42 |
| patients prospective | #42 |
| prophylaxis venous | #42 |
| anticoagulation risk | #42 |
| patients vasopressors | #42 |
| standardization committee | #42 |
| major contributor | #42 |
| type graft | #42 |
| cell extravasation | #42 |
| 8101 | #42 |
| neoplasms thrombosis | #42 |
| patients vte risk | #43 |
| 543 patients | #43 |
| cancer adjusted | #43 |
| post‐thrombotic syndrome | #43 |
| venous thromboembolism vte | #43 |
| heparin risk | #43 |
| initial treatment | #43 |
| ischemic events | #43 |
| vkas patients | #43 |
| draft document | #43 |
| warfarin anticoagulants | #43 |
| fetal loss | #43 |
| rtap | #43 |
| venous thrombosis thrombophilia | #43 |
| probability patients | #43 |
| monthly incidence | #43 |
| 20 30 | #44 |
| efficiency models | #44 |
| recurrent vte 95 | #44 |
| rate venous | #44 |
| role coagulation | #44 |
| restoration euthyroidism | #44 |
| nonvka oral anticoagulants | #44 |
| 95 pulmonary embolism | #44 |
| factors thromboembolism | #44 |
| edoxaban therapy | #44 |
| protein sepsis | #44 |
| 10–14 | #44 |
| uedvt patients | #44 |
| experimental venous thrombosis | #44 |
| enoxaparin risk | #44 |
| expert physicians | #44 |
| indications patients | #44 |
| mild hyperhomocysteinaemia | #44 |
| patients tinzaparin | #44 |
| dvt patients | #45 |
| coagulation activation | #45 |
| wells score | #45 |
| 95 warfarin | #45 |
| oral direct | #45 |
| revascularisation procedures | #45 |
| venous thrombotic | #45 |
| coumarin therapy | #45 |
| fondaparinux patients | #45 |
| patients bnp | #45 |
| years algorithm | #45 |
| dose lmwh | #45 |
| treated warfarin | #45 |
| dose adjusted | #45 |
| patients unprovoked vte | #46 |
| standard therapy | #46 |
| abtpo | #46 |
| pioped | #46 |
| major bleeding placebo | #46 |
| percent confidence | #46 |
| bleeding rivaroxaban | #46 |
| ruling | #46 |
| daily rivaroxaban | #46 |
| treatment model | #46 |
| ssc isth | #46 |
| extended duration | #46 |
| prothrombin fragment f1 | #46 |
| healthcare settings | #46 |
| management venous | #46 |
| stroke risk assessment | #46 |
| hospital outpatients | #46 |
| day levels | #46 |
| central venous lines | #47 |
| outcome vitamin | #47 |
| new oral anticoagulant | #47 |
| mutation pregnancy | #47 |
| male methimazole | #47 |
| iiia receptors | #47 |
| mechanical prophylaxis | #47 |
| bristol myers squibb | #47 |
| episode vte | #47 |
| ambulatory anticoagulants | #47 |
| roccurve | #47 |
| plasma ddimer levels | #47 |
| boehringer ingelheim | #47 |
| fondaparinux heparin | #48 |
| thromboprophylactic | #48 |
| intermediate risk risk | #48 |
| patients pulmonary | #48 |
| recurrence venous thromboembolism | #48 |
| thrombotic burden | #48 |
| diagnosis physicians | #48 |
| rivaroxaban compared | #48 |
| daiichi | #48 |
| elevated plasma levels | #48 |
| risk recurrent | #48 |
| travel risk | #48 |
| factors rivaroxaban | #48 |
| patients acute dvt | #48 |
| small studies | #48 |
| subcommittee | #48 |
| factor viii deficiency | #49 |
| calf vein | #49 |
| women aspirin | #49 |
| vte diagnosis | #49 |
| enoxaparin | #49 |
| lowmolecularweight heparin lmwh | #49 |
| rivaroxaban prevention | #49 |
| levels protein | #49 |
| cardiac surgery mortality | #50 |
| prospective diagnostic | #50 |
| etexilate | #50 |
| transient risk factor | #50 |
| outpatient therapy | #50 |
| thromboembolism aged | #50 |
| treatment threshold | #50 |
| atria patients | #50 |
| intensity treatment | #50 |
| incidence venous thromboembolism | #50 |
| acute respiratory insufficiency | #50 |
| dvt diagnosis | #50 |
| nonselective betablockers | #50 |
| vitamink antagonists | #50 |
| buller | #50 |
| protein deficiencies | #51 |
| 95 apixaban | #51 |
| tomography pulmonary | #51 |
| patients 11 | #51 |
| normal perfusion | #51 |
| discrimination model | #51 |
| strategies treatment | #51 |
| previous survey | #51 |
| global disease | #51 |
| effects coagulation | #51 |
| factor vte | #51 |
| acenocoumarol | #51 |
| free thyroxine ft4 | #52 |
| unnecessarily | #52 |
| 1·12 | #52 |
| vte major bleeding | #52 |
| risk venous thromboembolism | #52 |
| hematologic malignancies patients | #52 |
| doacs vka | #52 |
| pdvt | #52 |
| svt patients | #52 |
| lung scans | #52 |
| inhibitors heparin | #52 |
| patients comorbid conditions | #52 |
| 3 month | #52 |
| apixaban vte | #52 |
| lmwh fondaparinux | #52 |
| suspected venous thromboembolism | #53 |
| 40 daily | #53 |
| versus enoxaparin | #53 |
| thrombophilic factors | #53 |
| cross study | #53 |
| patients initially | #53 |
| warfarintreated patients | #53 |
| postthrombotic syndrome | #53 |
| preference patients | #53 |
| absolute risks | #53 |
| hemostatic balance | #53 |
| reported incidence | #53 |
| 1522 | #53 |
| thromboembolism prevention | #53 |
| 479 patients | #53 |
| 378 patients | #54 |
| vte mortality | #54 |
| antithrombotic drug | #54 |
| familial thrombophilia | #54 |
| male pulmonary embolism | #54 |
| pai1 levels patients | #54 |
| patients obese | #54 |
| acquired risk factors | #54 |
| 034 | #54 |
| chads2 cha2ds2vasc | #54 |
| thromboembolism death | #54 |
| bled score | #54 |
| major bleeds | #54 |
| 2537 | #54 |
| patients incidence | #54 |
| prethrombotic | #54 |
| endocrine disorders | #54 |
| treatment thresholds | #55 |
| long term risk | #55 |
| anticoagulants arthroplasty replacement | #55 |
| legs patients | #55 |
| dosereduction | #55 |
| biological pan | #55 |
| unfractionated heparin ufh | #55 |
| insurances | #55 |
| nondeficient | #55 |
| compared lmwh | #55 |
| proximal extent | #55 |
| unfractionated heparin | #55 |
| methods randomized | #55 |
| rivaroxaban | #55 |
| deficiency prevalence | #56 |
| 20210a | #56 |
| tromboembólica | #56 |
| risk major bleeding | #56 |
| vte death | #56 |
| weight heparins | #56 |
| enoxaparin patients | #56 |
| vasopressors | #56 |
| inr values | #56 |
| preeclampsia hellp syndrome | #56 |
| vitamin warfarin | #56 |
| level mortality | #56 |
| reduced capacity | #56 |
| major bleeding apixaban | #56 |
| physicians guidelines | #56 |
| enoxaparin rivaroxaban | #56 |
| venous outflow obstruction | #56 |
| seventh accp conference | #56 |
| time event | #56 |
| inhibitors female humans | #57 |
| subsegmental pulmonary | #57 |
| risk factors vte | #57 |
| clinical models | #57 |
| ctscan | #57 |
| levels survival | #57 |
| antithrombin iii heparin | #57 |
| calf dvt | #57 |
| pharmo | #58 |
| unfractionated heparin patients | #58 |
| spiral computed | #58 |
| doacs patients | #58 |
| fibrinolysis humans | #58 |
| lowmolecular weight heparin | #58 |
| inhibitors female | #58 |
| malignancy mortality | #58 |
| thrombin activatable | #58 |
| ruled | #58 |
| risk periods | #59 |
| acute venous thromboembolism | #59 |
| direct oral | #59 |
| incidence symptomatic | #59 |
| warfarin treatment | #59 |
| clot lysis time | #59 |
| factor generation | #59 |
| heterozygous factor | #59 |
| mutation prothrombin | #59 |
| risk factors sensitivity | #59 |
| aventis | #59 |
| bias trial | #59 |
| thrombosis aged | #59 |
| risk vte | #59 |
| safety warfarin | #59 |
| women difference | #60 |
| atrial fibrillation metaanalysis | #60 |
| target inr | #60 |
| hemorrhage humans | #60 |
| pulmonary embolism 95 | #60 |
| 079 95 | #60 |
| anticoagulants treatment | #60 |
| acute pulmonary embolism | #60 |
| awareness risk factors | #60 |
| fixeddose | #60 |
| constans | #60 |
| pediatric venous thromboembolism | #60 |
| prevalence pulmonary | #60 |
| perfusion ventilation | #61 |
| association protein | #61 |
| amuse | #61 |
| long‐term treatment | #61 |
| rosendaal | #61 |
| benzimidazoles dabigatran | #61 |
| month surgery | #61 |
| dvt 95 | #61 |
| tests prevalence | #61 |
| cdr score | #61 |
| free thyroxine | #61 |
| 3633 | #61 |
| hypocoagulable | #61 |
| ttr patients | #62 |
| 273 patients | #62 |
| human endotoxemia | #62 |
| 250 patients | #62 |
| protein fibrinogen | #62 |
| post thrombotic | #62 |
| combined contraceptives oral | #62 |
| patients administration | #62 |
| informatizado | #62 |
| procoagulant state | #62 |
| activated partial | #62 |
| general practitioners patients | #62 |
| treatment network | #63 |
| vte thromboprophylaxis | #63 |
| 33 women | #63 |
| common odds ratio | #63 |
| venous thromboembolisms | #63 |
| injection endotoxin | #63 |
| rivaroxaban lmwh | #63 |
| factor leiden risk | #63 |
| quantitative test | #63 |
| women mutations | #63 |
| symptoms dvt | #63 |
| physicians predictive | #63 |
| revised geneva score | #63 |
| management anticoagulation | #63 |
| smoking smoking cessation | #63 |
| cvrs | #63 |
| superficial vein | #64 |
| decision rules | #64 |
| heparin fondaparinux | #64 |
| bleeding events patients | #64 |
| postthrombotic | #64 |
| cancer noncancer patients | #64 |
| prior vte | #64 |
| vkas treatment | #64 |
| blinded trial | #64 |
| acute pulmonary | #64 |
| factor inhibitors | #64 |
| thrombophilic risk | #64 |
| dvts | #64 |
| oral thrombin | #64 |
| selfadjustment | #64 |
| patients aortic valve | #64 |
| fvl vte | #65 |
| prothrombin g20210a mutation | #65 |
| accuracy diagnostic tests | #65 |
| ultrasonograms | #65 |
| stroke thromboembolism | #65 |
| prevalence abnormalities | #65 |
| treatment pad | #65 |
| 0 points | #66 |
| newer anticoagulants | #66 |
| female heparin | #66 |
| axa | #66 |
| elfa | #66 |
| death classification | #66 |
| 95 bleeding | #66 |
| risk factor thrombosis | #66 |
| dvt sensitivity | #66 |
| rapid triage | #66 |
| statin therapy risk | #66 |
| standard therapy patients | #67 |
| patients tertiles | #67 |
| atrial fibrillation stroke | #67 |
| apixaban | #67 |
| rate major | #67 |
| patients factor | #67 |
| 1127 | #67 |
| patients benefits | #68 |
| fibrinolytic | #68 |
| 20210g | #68 |
| 1894 | #68 |
| perioperative blood | #68 |
| 05 95 | #68 |
| 3594 | #68 |
| patients bnp levels | #68 |
| ranging study | #68 |
| academic medical centre | #68 |
| coagulation fibrinolysis | #68 |
| thrombosis blood | #69 |
| postphlebitic | #69 |
| certoparin | #69 |
| ionis | #69 |
| recurrent thrombosis patients | #69 |
| heparin ufh | #69 |
| enfermedad tromboembólica | #69 |
| justify | #69 |
| suspected | #69 |
| plasma interleukin | #69 |
| vwfrco | #70 |
| withhold | #70 |
| 8190 | #70 |
| α2ap | #70 |
| aged predictive | #70 |
| gramnegative sepsis | #70 |
| cutoff levels | #70 |
| rivaroxaban treatment | #70 |
| ischemic events patients | #70 |
| mantelhaenszel | #70 |
| major bleeding complications | #70 |
| thrombosis recurrence | #70 |
| patients protein | #70 |
| fixed dose | #70 |
| test patients | #70 |
| elevated cardiac | #70 |
| levels vwf | #71 |
| thromboprophylaxis | #71 |
| clopidogrel placebo | #71 |
| vte vka | #71 |
| unfractionated | #71 |
| plasminogen plg | #71 |
| tests prospective | #71 |
| diagnostic sensitivity specificity | #71 |
| asymptomatic atherosclerosis | #71 |
| topic costs | #71 |
| versus vitamin | #72 |
| overt hypothyroidism | #72 |
| hf studies | #72 |
| new anticoagulant | #72 |
| antithrombin iii iii | #72 |
| ddimer values | #72 |
| elevated factor | #72 |
| pooled rate | #72 |
| patients lmwh | #72 |
| trifurcation | #72 |
| complications hematologic | #72 |
| viia factor | #72 |
| activation prothrombin | #72 |
| ddimer measurement | #73 |
| tomography spiral | #73 |
| reversal agent | #73 |
| soluble fibrin | #73 |
| prolongations | #73 |
| analysis diagnostic | #73 |
| noacs | #73 |
| 12 months 95 | #73 |
| ingelheim | #73 |
| carriers | #74 |
| 2124 | #74 |
| suspected dvt | #74 |
| 5395 | #74 |
| 1732 | #74 |
| study selection | #74 |
| experimental metastasis | #74 |
| prethrombotic state | #74 |
| female hemorrhage | #74 |
| soluble thrombomodulin | #74 |
| 2550 | #74 |
| proteins patients | #74 |
| longterm risk | #74 |
| dvt study | #74 |
| 1334 | #75 |
| selective factor | #75 |
| carotid femoral arteries | #75 |
| retrospective follow | #75 |
| 8492 | #75 |
| 2904 | #75 |
| incidence bleeding events | #75 |
| postoperative dvt | #75 |
| thrombolytic therapy patients | #75 |
| risk thrombosis | #76 |
| angiography ctpa | #76 |
| factor xii deficiency | #76 |
| combined contraceptives | #76 |
| extended anticoagulation | #76 |
| early time | #76 |
| tests primary | #76 |
| oral combined contraceptives | #76 |
| duration thromboprophylaxis | #76 |
| p023 | #77 |
| thrombosis pregnancy | #77 |
| social aspects | #77 |
| individual patient | #77 |
| patients secondary | #77 |
| boehringer | #77 |
| women thrombophilia | #78 |
| ipg | #78 |
| elevated dimer | #78 |
| unprovoked | #78 |
| female fibrinolysis | #78 |
| arterial wall thickness | #78 |
| 20 daily | #78 |
| arterial thromboembolism | #78 |
| limulus test | #79 |
| topic heparin | #79 |
| efficacy agents | #79 |
| vte fvl | #79 |
| vkas | #79 |
| factor adult | #79 |
| time therapeutic | #79 |
| 2486 | #79 |
| suspected acute | #79 |
| humans pulmonary | #79 |
| subhazard ratio | #80 |
| alife | #80 |
| patient data | #80 |
| sspe patients | #80 |
| daily bid | #80 |
| thromboembolism incidence | #80 |
| suspected cancer | #80 |
| bleeding mortality | #80 |
| validation models | #80 |
| 95 05 | #80 |
| vte rate | #80 |
| heterozygous deficiency | #80 |
| test evaluation | #81 |
| systemic inflammatory | #81 |
| walking distance | #81 |
| outpatient basis | #81 |
| weitz | #81 |
| knee arthroplasty patients | #81 |
| lmwh vte | #81 |
| vascular events | #81 |
| topic risk | #81 |
| prothrombin complex concentrate | #81 |
| heparin prevention | #82 |
| crnmb | #82 |
| thrombosis incidence | #82 |
| prospective validation | #82 |
| mammography patients | #82 |
| clinical sign | #82 |
| 50 micrograms | #82 |
| posthoc analysis | #82 |
| timeperiods | #82 |
| 3month followup | #82 |
| thrombolytic drugs | #82 |
| placebo women | #82 |
| common practice | #82 |
| thrombosis thrombophilia | #82 |
| symptomatic carriers | #82 |
| bleeding women | #83 |
| dimer patients | #83 |
| 2213 | #83 |
| elective coronary | #83 |
| patients thrombi | #83 |
| inhibitor dabigatran | #83 |
| 287 | #83 |
| bistro | #83 |
| healthcare setting | #84 |
| inherited thrombophilia | #84 |
| inhibitor rivaroxaban | #84 |
| screening humans | #84 |
| duration therapy | #84 |
| diagnostic outcome | #84 |
| heparin treatment | #84 |
| normotensive patients | #84 |
| prophylactic dose | #84 |
| venous thrombosis patients | #85 |
| anticoagulants antiphospholipid | #85 |
| thrombosis svt | #85 |
| antithrombin iii protein | #85 |
| endotoxins | #85 |
| peripheral vascular diseases | #85 |
| asymptomatic dvt | #85 |
| normal levels | #85 |
| 4576 | #86 |
| major bleeding warfarin | #86 |
| dabigatran vka | #86 |
| elevated ddimer levels | #86 |
| rhapc | #86 |
| venovenous hemofiltration | #86 |
| 75 microg | #86 |
| 10⁶ | #86 |
| contact activation | #87 |
| acute venous | #87 |
| 95 100 | #87 |
| clinical impact | #87 |
| ≤50 | #87 |
| patients 28 | #87 |
| avws | #87 |
| vidas | #87 |
| post‐hoc analysis | #87 |
| obstetric patients | #87 |
| cdr | #88 |
| 3319 | #88 |
| internist | #88 |
| venographic | #88 |
| washout period | #88 |
| activation factor | #88 |
| treatment statins | #88 |
| treatment incidence | #88 |
| lmwhs | #88 |
| 4 points | #88 |
| aged multicenter | #88 |
| reversal strategies | #89 |
| anticoagulants dabigatran | #89 |
| unexplained recurrent | #89 |
| costs patient | #89 |
| beta blockers | #89 |
| stroke bleeding | #89 |
| safety noacs | #89 |
| ventilation lung | #89 |
| tests test | #89 |
| vte venous thromboembolism | #89 |
| matisse | #89 |
| smoking incidence | #89 |
| severe hf | #89 |
| rates major bleeding | #89 |
| adequate treatment | #89 |
| ddimer | #89 |
| cytokine release | #89 |
| fibrinolytic factors | #90 |
| primary thromboprophylaxis | #90 |
| pediatric venous | #90 |
| vka dabigatran | #90 |
| 2293 | #90 |
| thrombophilic risk factors | #90 |
| outweighs | #90 |
| venous thrombosis risk | #90 |
| new patients | #90 |
| popliteal vein | #90 |
| thromboembolism pregnancy | #91 |
| anticoagulants doacs | #91 |
| inconvenience | #91 |
| cdrs | #91 |
| pyridines pyridones | #91 |
| thrombosis women | #91 |
| agents hemorrhage | #91 |
| perfusion ratio | #91 |
| 20210 | #91 |
| 60 95 | #91 |
| single intravenous | #92 |
| combined clinical | #92 |
| thrombotic disease | #92 |
| prophylaxis incidence | #92 |
| direct thrombin inhibitors | #93 |
| scenario analyses | #93 |
| 95 years | #93 |
| compression patients | #93 |
| rivaroxaban edoxaban | #93 |
| incidence knee | #93 |
| anticoagulation reversal | #93 |
| vte surgery | #94 |
| 1027 | #94 |
| atherogenic lipid | #94 |
| 125 patients | #94 |
| patients symptomatic | #94 |
| test result | #94 |
| heparins | #94 |
| hf severity | #94 |
| children vte | #94 |
| direct oral anticoagulant | #95 |
| european consensus statement | #95 |
| viia rfviia | #95 |
| 2 levels | #95 |
| 6 12 months | #96 |
| efficacy rivaroxaban | #96 |
| risk symptomatic | #96 |
| ddimer level | #96 |
| randomised crossover study | #96 |
| symptomatic vte | #96 |
| xii deficiency | #96 |
| fondaparinux treatment | #96 |
| invasive testing | #97 |
| tpa release | #97 |
| difference rates | #97 |
| abnormal perfusion | #97 |
| pyrazoles pyridones | #97 |
| studies evaluated | #97 |
| symptomatic pulmonary embolism | #97 |
| haemophilia patients | #97 |
| fibrin generation | #97 |
| doacs risk | #97 |
| essential thrombocythaemia | #98 |
| supervised exercise therapy | #98 |
| pregnancy postpartum period | #98 |
| simplify | #98 |
| 2875 | #98 |
| activated protein apc | #98 |
| 16slice | #98 |
| hypercoagulable | #98 |
| major bleed | #98 |
| acute dvt | #99 |
| perfusion scintigraphy | #99 |
| 2·0 | #99 |
| probast | #99 |
| risk arterial | #99 |
| hirudin | #99 |
| unselected | #99 |
| lmwh warfarin | #99 |
| increasing levels | #100 |
| fatty foods | #100 |
| patient groups | #100 |
| doubleblind trial | #100 |
| gbd 2010 | #100 |
| prevention recurrent | #100 |
| warfarin patients | #100 |
| 1116 | #100 |
| 3 trials | #100 |
| previews | #100 |
| factor vii factor | #101 |
| aptts | #101 |
| morpholines | #101 |
| factor viia | #101 |
| pts patients | #102 |
| enoxaparin fondaparinux | #102 |
| low pretest probability | #102 |
| 265 patients | #102 |
| 40 microg | #102 |
| alternative diagnosis | #102 |
| venous thromboembolism women | #102 |
| pregnancy puerperium | #103 |
| 338 | #103 |
| therapeutic consequences | #103 |
| cteph patients | #103 |
| adjudicated | #103 |
| doppler method | #103 |
| endogenous thrombin | #103 |
| arthroscopic anterior | #103 |
| term treatment | #104 |
| separate analyses | #104 |
| fibrin degradation products | #104 |
| diagnostic imaging humans | #104 |
| antithrombin iii | #104 |
| partial restoration | #104 |
| recurrence women | #104 |
| absolute increase | #104 |
| assay variation | #104 |
| heparin pregnancy | #104 |
| oral factor | #104 |
| apparent increase | #104 |
| 7 children | #105 |
| 1089 | #105 |
| conventional therapy patients | #105 |
| embryo loss | #105 |
| thrombosis age | #106 |
| study total | #106 |
| thrombophilia | #106 |
| 314 | #106 |
| elevated levels | #106 |
| hospitalized patients hf | #106 |
| thromboprophylaxis patients | #106 |
| blind double | #106 |
| essentials | #106 |
| 2479 | #106 |
| fibrinolytic systems | #106 |
| chest ray | #106 |
| thromboembolic | #107 |
| ddimer levels | #107 |
| topic recurrence | #107 |
| vte risk | #107 |
| definition classification | #107 |
| survival cancer patients | #107 |
| simplified version | #107 |
| grade 1c | #108 |
| specific subgroups | #108 |
| patients cancer | #108 |
| noncancer patients | #108 |
| cardiovascular death stroke | #108 |
| post thrombotic syndrome | #108 |
| human volunteers | #108 |
| 1235 | #109 |
| factor mutation | #109 |
| embolism treatment | #109 |
| 500μg | #109 |
| viia | #109 |
| synthetic pentasaccharide | #109 |
| anticoagulants cohort | #109 |
| thrombin antithrombin | #109 |
| 039 | #109 |
| evaluation studies | #109 |
| routine coagulation | #109 |
| subsequent pregnancy | #110 |
| thrombosis treated | #110 |
| vka doac | #110 |
| embolism quality | #110 |
| inferiority trial | #110 |
| primary safety | #110 |
| antiplasmin | #110 |
| cancer activity | #110 |
| treatment risk factors | #111 |
| siset | #111 |
| obstetric complications | #111 |
| comparison control | #111 |
| predefined | #111 |
| anticoagulants biomarkers | #111 |
| negative predictive 100 | #111 |
| humans intermittent | #111 |
| efficacy prevention | #112 |
| publication anticoagulants | #112 |
| patients ventricular dysfunction | #112 |
| chromogenic | #112 |
| recurrence treatment | #112 |
| topic guidelines | #112 |
| rivaroxaban enoxaparin | #112 |
| patients 70 | #112 |
| risk rivaroxaban | #112 |
| epidemiology risk factors | #112 |
| emergency situations | #112 |
| thromboembolic diseases | #112 |
| metabolic response | #113 |
| patients nephrotoxicity | #113 |
| lmwh risk | #113 |
| nonionic contrast | #113 |
| heterozygous carriers | #113 |
| inappropriate treatment | #113 |
| dialysers | #114 |
| study centre | #114 |
| 0·0 | #114 |
| cancerassociated vte | #114 |
| patients intermediate | #114 |
| total knee replacement | #114 |
| postphlebitic syndrome | #114 |
| patients recurrent | #115 |
| fibrinogen vwf | #115 |
| global public | #115 |
| positive predictive values | #115 |
| hyperhomocysteinaemia | #115 |
| 393 | #115 |
| computed tomography patients | #116 |
| women severe preeclampsia | #116 |
| anticoagulants arthroplasty | #116 |
| major bleeding 95 | #116 |
| vte data | #116 |
| topic dabigatran | #116 |
| reference standard | #116 |
| life treatment | #116 |
| agents heparin | #116 |
| heparin warfarin | #116 |
| effects tnf | #116 |
| protein resistance | #117 |
| arthroscopies | #117 |
| women caesarean | #117 |
| vte children | #117 |
| protein inhibitor pci | #117 |
| 2460 | #117 |
| vte complications | #117 |
| fibrinolytic parameters | #117 |
| 4118 | #118 |
| autopsyconfirmed | #118 |
| 2744 | #118 |
| patients extensive | #118 |
| proximal dvt | #118 |
| arterial thrombosis patients | #118 |
| compared warfarin | #119 |
| incidence pulmonary embolism | #119 |
| humans leg | #119 |
| patients doac | #119 |
| compression stockings | #119 |
| risk thromboembolism | #120 |
| previous vte | #120 |
| lactoferrin leukocyte | #120 |
| thrombosis study | #120 |
| healthy humans | #120 |
| dabigatran factor | #120 |
| rivaroxaban patients | #120 |
| months follow | #120 |
| mortality diseases | #120 |
| acquired deficiency | #120 |
| patients prostatic cancer | #121 |
| thrombocytopenia thrombosis | #121 |
| studies venous | #122 |
| oral hormonal | #122 |
| patients 6 | #122 |
| fatal pulmonary embolism | #122 |
| anti factor | #122 |
| placebo standard | #123 |
| factor xia | #123 |
| acute infection | #123 |
| venous thromboembolism pregnancy | #123 |
| heparin hirudin | #123 |
| early dynamics | #123 |
| minor bleeding | #123 |
| 100 patients | #123 |
| heparin | #123 |
| vte lmwh | #124 |
| atherogenic lipid profile | #124 |
| ft4 levels | #124 |
| statin risk | #124 |
| treatment data | #124 |
| thrombophilia pregnancy | #124 |
| association level | #124 |
| elevated liver enzymes | #125 |
| incidence thrombosis | #125 |
| diseases mortality | #125 |
| intravenous heparin | #125 |
| peripheral arterial disease | #125 |
| puerperal disorders | #125 |
| treatment indication | #125 |
| skin perfusion | #125 |
| fibrinolysis inhibitor | #125 |
| nonsignificantly | #125 |
| thromboembolism recurrence | #125 |
| bayer | #125 |
| doacs treatment | #126 |
| distal dvt | #126 |
| upper extremity | #126 |
| patients permanent | #127 |
| marder | #127 |
| performance scores | #127 |
| unacceptably | #127 |
| thromboprophylaxis lmwh | #127 |
| patients ventilation | #127 |
| occurrence vte | #127 |
| venous thromboembolism risk | #128 |
| direct factor | #128 |
| patients conventional therapy | #128 |
| development vte | #128 |
| prevention | #128 |
| resistance apc | #128 |
| treatment months | #128 |
| 50 age | #128 |
| ctrough | #129 |
| mortality cancer patients | #129 |
| 060 | #129 |
| riete registry | #129 |
| 1041 | #129 |
| elevated biomarkers | #129 |
| patients episode | #130 |
| hospital discharge records | #130 |
| anticoagulants antithrombins | #130 |
| internists | #130 |
| plaster cast | #130 |
| 220 | #130 |
| day 10 | #130 |
| 194 patients | #130 |
| 05 patients | #131 |
| pooled incidence | #131 |
| long‐term clinical outcomes | #131 |
| obviating | #131 |
| tests specificity | #131 |
| linear interpolation | #131 |
| postpartum period women | #132 |
| rivaroxaban versus | #132 |
| hypocoagulability | #132 |
| hoc analysis | #132 |
| started | #133 |
| 80 anticoagulants | #133 |
| fxa inhibitors | #133 |
| direct inhibitors | #133 |
| enoxaparin treatment | #133 |
| avidin | #133 |
| cha2ds2vasc | #133 |
| rco vwf | #134 |
| instituted | #134 |
| risk pad | #134 |
| embolism acute | #134 |
| selectin levels | #134 |
| pulmonary angiography patients | #134 |
| bnp concentration | #135 |
| activator plasminogen | #135 |
| prevalence dvt | #135 |
| anticoagulant prophylaxis | #135 |
| followup patients | #136 |
| 0056 | #136 |
| clinical prediction | #136 |
| apixaban edoxaban | #136 |
| months anticoagulation | #136 |
| severe pph | #136 |
| east asian patients | #136 |
| thrombotic syndrome | #136 |
| 2283 | #137 |
| factor prothrombin | #137 |
| 99 patients | #137 |
| phase 3 trials | #137 |
| point‐of‐care | #137 |
| acquired thrombophilia | #137 |
| diagnostic work | #137 |
| sequential application | #137 |
| antidote | #138 |
| national guidelines | #138 |
| complete inhibition | #138 |
| studies mortality | #138 |
| bleeding warfarin | #138 |
| enhanced factor | #138 |
| intravascular coagulation dic | #138 |
| patients comparison | #139 |
| reproducibility risk | #139 |
| oral anticoagulant treatment | #139 |
| 95 major bleeding | #139 |
| 2465 | #139 |
| 3 weeks | #139 |
| factor viii factor | #139 |
| risk fatal | #139 |
| direct inhibitor | #139 |
| ottawa | #140 |
| dvt incidence | #140 |
| distal deep | #140 |
| vwf rco | #140 |
| 20 iu | #140 |
| 80 cohort | #140 |
| human activated | #140 |
| 12 95 | #140 |
| 0114 | #140 |
| antidotes | #141 |
| thromboembolic disorders | #141 |
| pharmacy records | #141 |
| carriership | #142 |
| thrombin potential | #142 |
| active malignancy | #143 |
| jugular veins | #143 |
| ischaemic events | #143 |
| escherichia humans | #143 |
| treatment pulmonary | #143 |
| geneva | #143 |
| points 95 | #143 |
| warfarin administration | #143 |
| pregnancy female humans | #144 |
| fatal pulmonary | #144 |
| compared treatment | #144 |
| doac treatment | #144 |
| postoperative venous | #144 |
| management vte | #144 |
| topic practice patterns | #144 |
| dose rivaroxaban | #145 |
| filters venous | #145 |
| referred patients | #145 |
| thrombosis model | #145 |
| hyperthyroxinemia | #145 |
| serial testing | #145 |
| patient populations | #145 |
| death cancer patients | #146 |
| months treatment | #146 |
| protein factor | #146 |
| derived microvesicles | #146 |
| tissue factor pathway | #147 |
| personal fees | #147 |
| 2076 | #148 |
| 10 years patients | #148 |
| antithrombotic drugs | #148 |
| long‐acting | #148 |
| rebuttal | #148 |
| acute medical illness | #148 |
| embolism diagnosis | #148 |
| partial thromboplastin | #148 |
| intention treat | #148 |
| individual patient data | #149 |
| vte hospitalization | #149 |
| procoagulant | #149 |
| risk subgroups | #149 |
| thrombocyte | #149 |
| diagnostic score | #149 |
| 0·45 | #149 |
| relevant publications | #149 |
| dimer level | #150 |
| coagulation dic | #151 |
| additional imaging | #151 |
| humans injections | #151 |
| enoxaparin unfractionated heparin | #151 |
| longterm treatment | #152 |
| patient eligibility | #152 |
| bleeding patients | #152 |
| continuous venovenous | #152 |
| patients primary outcome | #152 |
| point systems | #153 |
| thrombosis prevention | #153 |
| cardiopulmonary bypass surgery | #153 |
| extracorporeal circuit | #153 |
| hypercoagulable state | #153 |
| bleeding scores | #154 |
| angioplasty patients | #154 |
| thrombosis factor | #154 |
| activity mortality | #154 |
| direct thrombin | #154 |
| dimer levels | #154 |
| active cancer | #154 |
| drug factor | #155 |
| tomography patients | #155 |
| thromboembolic event | #155 |
| curve sensitivity | #155 |
| states venous | #155 |
| warfarin apixaban | #155 |
| fiia | #155 |
| stockings | #156 |
| daily oral | #156 |
| vte treatment | #156 |
| patients gastrointestinal | #156 |
| 09 | #156 |
| enoxaparin dose | #156 |
| recurrent symptoms | #156 |
| fvl | #156 |
| coagulant activity | #156 |
| cross‐sectional survey | #157 |
| increased thrombin | #157 |
| prophylaxis patients | #157 |
| hemodynamically | #157 |
| duration anticoagulation | #158 |
| underlying malignancy | #158 |
| months chemotherapy | #158 |
| 2126 | #158 |
| dfl | #158 |
| 97 | #158 |
| adjusted relative risk | #159 |
| increased risk thrombosis | #159 |
| thrombotic disorders | #160 |
| schering | #160 |
| guidelines prevention | #160 |
| 120 minutes | #160 |
| 145 patients | #160 |
| children fh | #160 |
| antithrombotic efficacy | #160 |
| plasma dimer | #160 |
| pvo | #161 |
| prophylactics | #161 |
| antagonists patients | #161 |
| 2206 | #162 |
| incidence vte | #162 |
| patients imaging | #162 |
| women time | #162 |
| lysine analogues | #162 |
| venous thrombus | #163 |
| rates vte | #163 |
| increased plasma levels | #163 |
| strain gauge | #163 |
| factors bleeding | #163 |
| coagulation blood | #163 |
| lmwh therapy | #163 |
| 198 patients | #163 |
| imaging test | #163 |
| 028 | #164 |
| observer variability | #164 |
| age comorbidity | #164 |
| inborn humans | #164 |
| justified | #164 |
| mutation factor | #165 |
| relatives patients | #165 |
| subhazard | #165 |
| patients enoxaparin | #165 |
| phlebography | #166 |
| strategies patients | #166 |
| microvascular thrombosis | #166 |
| viii factor | #166 |
| stockings compression | #166 |
| pravastatin therapy | #166 |
| management venous thromboembolism | #166 |
| recurrent thrombosis | #167 |
| thrombin venous | #167 |
| ankle brachial abi | #167 |
| 3658 | #167 |
| cstatistics | #168 |
| current clinical practice | #168 |
| warfarin | #168 |
| cvcs | #168 |
| syndrome pts | #168 |
| recurrent acute | #168 |
| double heterozygosity | #168 |
| treatment 3 months | #168 |
| 3 12 | #169 |
| risk profile | #169 |
| patients infections | #169 |
| fold increased | #169 |
| therapeutic range | #169 |
| postthrombotic syndrome pts | #169 |
| preexistent | #169 |
| heavy menstrual bleeding | #170 |
| cart patients | #170 |
| thrombosis cancer | #170 |
| interobserver agreement | #170 |
| postoperative blood loss | #170 |
| aged algorithms | #171 |
| adamts‐13 | #171 |
| recombinant factor | #171 |
| 57 years | #171 |
| venous thrombotic events | #171 |
| clinical trials patients | #172 |
| antifibrinolytic | #172 |
| risk factors patients | #172 |
| vaginal bleeding | #172 |
| patients blood transfusion | #172 |
| lmw heparin | #172 |
| pulmonology | #172 |
| hospitalized medical patients | #173 |
| pulmonary | #173 |
| inr | #173 |
| bleeds | #173 |
| bleeding tendency | #174 |
| arterial occlusions | #174 |
| patients initial | #174 |
| laboratory monitoring | #174 |
| clinically bleeding | #174 |
| data control | #175 |
| fragment 1 | #175 |
| vte common | #175 |
| reocclusion | #175 |
| arterial venous | #175 |
| picotamide | #177 |
| mitsubishi | #177 |
| prothrombin | #177 |
| short‐ | #178 |
| 122 | #178 |
| hyperthyroidism hypothyroidism | #178 |
| intention analysis | #178 |
| aspirin ticlopidine | #178 |
| concomitance | #179 |
| noninferior | #179 |
| oral female humans | #179 |
| baseline day | #179 |
| vte event | #179 |
| patients deficiency | #180 |
| thromboplastin time | #180 |
| isth | #180 |
| ventilation perfusion | #180 |
| referral bias | #180 |
| additional risk factors | #180 |
| aged partial | #181 |
| acute episode | #182 |
| antithrombin | #182 |
| testing patients | #182 |
| painkillers | #182 |
| biological variation | #183 |
| patients major | #183 |
| 2–4 | #183 |
| hyperhomocysteinemic | #183 |
| coagulation factors | #184 |
| 4150 | #184 |
| thromboinflammation | #184 |
| n110 | #184 |
| prognosis pulmonary | #184 |
| pregnancy vte | #184 |
| risk bleeding | #184 |
| antithrombin iii atiii | #184 |
| treat analysis | #184 |
| subsequent diagnosis | #184 |
| incidental | #184 |
| vte age | #185 |
| deficient patients | #185 |
| studies heparin | #186 |
| patients thromboprophylaxis | #186 |
| symptomatic | #186 |
| brain natriuretic | #186 |
| patients intensive units | #186 |
| hemostatic effects | #186 |
| anticoagulated | #186 |
| live birth rate | #186 |
| cutoff level | #187 |
| risk composite | #187 |
| patients haemophilia | #187 |
| safety apixaban | #187 |
| antifibrinolytic agents | #187 |
| 926 | #188 |
| absolute rate | #188 |
| humans international | #188 |
| spontaneous rupture | #188 |
| doacs vkas | #188 |
| ratio inr | #188 |
| prevalence cancer | #188 |
| patients netherlands | #189 |
| viia female | #189 |
| 64slice | #189 |
| heparin administration | #189 |
| fibrinolysis | #189 |
| willebrand factor antigen | #189 |
| clinical validity | #189 |
| riete | #189 |
| blood loss patients | #189 |
| anticoagulant drugs | #190 |
| ischemic event | #190 |
| ccus | #190 |
| current views | #190 |
| thrombosis patients | #190 |
| gogh | #191 |
| score patients | #191 |
| 07 | #191 |
| venous outflow | #191 |
| acute thrombosis | #191 |
| attending physicians | #191 |
| stroke systemic | #192 |
| 1495 | #192 |
| 058 | #192 |
| coagulation assays | #193 |
| endothelial cell activation | #193 |
| blood coagulation | #194 |
| heparin patients | #194 |
| 070 | #194 |
| anticoagulation | #194 |
| prothrombin activation | #194 |
| target range | #195 |
| risk major | #195 |
| 65 months | #195 |
| recurrent ischemic events | #195 |
| antagonist treatment | #195 |
| antixa levels | #195 |
| complications cardiovascular | #196 |
| coagulation status | #196 |
| 29 95 | #196 |
| abnormal test | #196 |
| treatment groups patients | #198 |
| difference treatment | #198 |
| ate | #198 |
| vii rfviia | #198 |
| vwf adamts13 | #198 |
| sew2871 | #198 |
| patient diagnosis | #199 |
| cachectin | #199 |
| coagulation monitoring | #199 |
| obese controls | #200 |
| incidence cardiovascular events | #200 |
| patients 12 months | #200 |
| screening patients | #200 |
| thromboembolic disease | #201 |
| vte incidence | #201 |
| patients abnormal | #201 |
| validation sets | #201 |
| thrombin factor | #201 |
| peritoneovenous | #202 |
| johnson | #202 |
| arterial thrombosis | #202 |
| 17 95 | #202 |
| symptomatic pad | #203 |
| invitees | #203 |
| worldwide survey | #203 |
| heparin dose | #203 |
| induced activation | #203 |
| antithrombotic agents | #204 |
| levonorgestrel | #204 |
| period time | #205 |
| extended thromboprophylaxis | #205 |
| stroke systemic embolism | #205 |
| thrombophilia risk | #205 |
| low incidence | #205 |
| 0 95 | #205 |
| fgt | #206 |
| venous ultrasonography | #206 |
| data synthesis | #206 |
| patients anticoagulant therapy | #206 |
| varese | #206 |
| algorithms anticoagulants | #207 |
| fviii | #207 |
| 06 | #207 |
| desogestrel | #207 |
| death female humans | #207 |
| methods consecutive | #207 |
| platelet activation patients | #207 |
| systematic review studies | #207 |
| cardiologist | #207 |
| objectively | #207 |
| imt patients | #207 |
| patients hypothyroidism | #208 |
| thrombocythaemia | #208 |
| bleeding compared | #208 |
| deficiency risk | #209 |
| free protein | #209 |
| women frequency | #210 |
| tgt | #210 |
| hirudins | #210 |
| antixa activity | #210 |
| toxaemia | #211 |
| systemic embolism patients | #211 |
| ioxaglate | #211 |
| stocking | #211 |
| anticoagulation management | #212 |
| atrial fibrillation study | #212 |
| heparitin sulfate | #213 |
| plasminogen activator activity | #213 |
| topic practice | #214 |
| correct interpretation | #214 |
| dabigatran dose | #214 |
| studies rivaroxaban | #215 |
| thrombin inhibition | #215 |
| current developments | #215 |
| standard duration | #215 |
| factors vte | #215 |
| duplex venous | #216 |
| betatg | #216 |
| deamino | #216 |
| warfarin stroke | #216 |
| community hospital | #216 |
| undergoing total | #217 |
| studies difference | #217 |
| mildest | #217 |
| diagnostic algorithm | #217 |
| obviates | #217 |
| g20210a | #218 |
| npv 100 | #218 |
| plasminogen activator inhibitor | #218 |
| conclusive evidence | #218 |
| cstatistic | #218 |
| cancer | #219 |
| patients cart | #219 |
| 077 95 | #219 |
| deamino arginine | #219 |
| data extraction | #220 |
| viii female | #220 |
| vii factor | #220 |
| hip replacement surgery | #220 |
| techniques female | #220 |
| heparin humans | #221 |
| hmvec | #221 |
| postoperative vte | #221 |
| preventive measures | #221 |
| healthy human subjects | #221 |
| vte events | #222 |
| proximally | #222 |
| apc resistance | #222 |
| 1 january | #223 |
| substantial proportion | #223 |
| pulmonologists | #223 |
| 1541 | #223 |
| engl | #223 |
| protein pathway | #224 |
| topic factor | #224 |
| thromboendarterectomy | #224 |
| subsequent cancer | #224 |
| kruskalwallis | #225 |
| org | #225 |
| balloon coronary anticoagulants | #225 |
| neoplasms prospective | #225 |
| thrombosis warfarin | #225 |
| extremity amputation | #226 |
| 16 95 | #226 |
| vascular events patients | #226 |
| 0·67 | #226 |
| inr monitoring | #226 |
| acute medical | #227 |
| tests diagnosis | #227 |
| haemostasis | #227 |
| 35 ± | #227 |
| ipe | #228 |
| mild hyperhomocysteinemia | #228 |
| residual thrombus | #229 |
| dalteparin | #229 |
| scant | #229 |
| cgp | #229 |
| advocated | #230 |
| 037 | #230 |
| ft4 | #231 |
| urosepsis | #231 |
| thiazoles | #231 |
| 6 studies | #231 |
| severe preeclampsia | #231 |
| resource utilisation | #231 |
| patients discontinuation | #231 |
| major orthopaedic surgery | #231 |
| habitual abortion | #231 |
| equinox | #231 |
| aspirin dipyridamole | #232 |
| patients warfarin | #232 |
| surgical embolectomy | #233 |
| cancer prevalence | #233 |
| dimer | #233 |
| endogenous thrombin potential | #233 |
| recurrence risk factors | #233 |
| humans netherlands | #233 |
| anticoagulant effects | #233 |
| effective alternative | #234 |
| prothrombotic state | #235 |
| doac | #235 |
| graduated compression | #235 |
| humans meta | #236 |
| brain natriuretic peptide | #236 |
| venous thromboembolic events | #236 |
| myocardial infarction 95 | #237 |
| treatment continuation | #237 |
| oral anticoagulants | #237 |
| 009 | #238 |
| 6500 | #238 |
| patients vkas | #238 |
| predictive tests | #238 |
| rational approach | #239 |
| factor viii fviii | #239 |
| crossover study | #239 |
| anticoagulants aspirin | #239 |
| factor tnf | #239 |
| arterial venous thrombosis | #240 |
| patients initial treatment | #240 |
| aspirin heparin | #241 |
| hip knee arthroplasty | #241 |
| 045 | #241 |
| time therapeutic range | #242 |
| bleeding incidence | #242 |
| pivotal trials | #243 |
| prothrombin fragment | #243 |
| patients intermittent claudication | #243 |
| iohexol | #244 |
| n89 | #245 |
| vte risk factors | #245 |
| children neonates | #246 |
| thrombogenesis | #246 |
| casecontrol | #246 |
| vte cases | #246 |
| 23 95 | #247 |
| lipoproteina levels | #247 |
| warfarin aged | #247 |
| antithrombotic | #247 |
| coronary anticoagulants | #248 |
| committees | #248 |
| patients solid tumours | #248 |
| treatment compared | #248 |
| anti activity | #248 |
| bleeding rates | #249 |
| score risk | #249 |
| diagnostic models | #249 |
| multiple comorbidities | #249 |
| ischemic strokes | #250 |
| ioxaglic | #250 |
| protein risk | #250 |
| fv leiden | #250 |
| 8595 | #251 |
| microthrombosis | #251 |
| finalized | #251 |
| patients contraindications | #251 |
| vkas doacs | #252 |
| somit | #252 |
| simplification | #252 |
| incidence | #253 |
| thrombin thrombosis | #253 |
| agents anticoagulants | #254 |
| treatment duration | #254 |
| palga | #255 |
| fibrinolytic activity | #255 |
| haul | #256 |
| activation humans | #256 |
| medea | #256 |
| clinical utility | #257 |
| bleeding risk | #257 |
| cost‐effectiveness | #257 |
| continuous intravenous | #257 |
| q24h | #257 |
| activity assay | #257 |
| ctpa | #258 |
| patient subgroups | #258 |
| fibrin degradation | #258 |
| 30 50 | #259 |
| unpublished data | #259 |
| dvt risk | #260 |
| sspe | #260 |
| noncarriers | #261 |
| heparin dosing | #261 |
| toxicosis | #261 |
| thrombus size | #261 |
| patients hospitalization | #262 |
| risk pulmonary | #263 |
| optimal duration | #263 |
| blind study | #264 |
| graft type | #265 |
| 400 patients | #266 |
| pbac | #267 |
| einstein | #267 |
| endotoxaemia | #268 |
| statins risk | #268 |
| randomised cross | #269 |
| relation time | #269 |
| propeptide | #269 |
| lysis time | #269 |
| versus aspirin | #269 |
| malignancy patients | #269 |
| exclusion | #270 |
| discontinuing | #270 |
| protein patients | #270 |
| single test | #270 |
| hormonal replacement therapy | #271 |
| orthopaedic patients | #271 |
| platelet serotonin | #271 |
| thrombosis inflammation | #271 |
| 3·0 | #271 |
| protein apc | #271 |
| bleeding patient | #272 |
| groups levels | #272 |
| patients combination | #272 |
| vte recurrence | #272 |
| clopidogrel ticlopidine | #272 |
| efficacy analysis | #273 |
| ankle brachial | #273 |
| prevalence pad | #274 |
| risk levels | #274 |
| cleavage sites | #274 |
| months 12 | #274 |
| international normalized | #275 |
| performance score | #275 |
| parenteral nutrition patients | #275 |
| fourth quartile | #276 |
| antithrombotic agent | #276 |
| smoking hypertension | #277 |
| time aptt | #277 |
| dose reduction | #278 |
| imaging sensitivity | #278 |
| normalized ratio | #278 |
| blood test | #279 |
| rco | #279 |
| aptt | #279 |
| partial thromboplastin time | #280 |
| hospitalized medical | #280 |
| exclusion criteria | #280 |
| obviate | #280 |
| intracranial hemorrhage patients | #280 |
| propositi | #280 |
| patients presence | #281 |
| thromboplastin | #282 |
| diagnostic test | #282 |
| puerperal | #283 |
| presentation patients | #283 |
| neutrophil degranulation | #283 |
| diagnostic sensitivity | #283 |
| thyroid diseases | #283 |
| favor | #284 |
| outpatient treatment | #284 |
| animals anticoagulants | #284 |
| departments | #284 |
| noninferiority margin | #284 |
| test characteristics | #284 |
| major orthopaedic | #285 |
| patients apixaban | #286 |
| plasma bnp | #286 |
| 2630 | #286 |
| gentamicin treatment | #286 |
| clinically | #287 |
| subdistribution | #287 |
| patients pancreatic cancer | #287 |
| disseminated intravascular | #287 |
| levels measured | #287 |
| md patients | #288 |
| premature atherosclerosis | #288 |
| oral combined | #288 |
| 227 | #288 |
| substantiation | #289 |
| vte women | #289 |
| vte rates | #289 |
| cvt patients | #289 |
| clot lysis | #289 |
| n59 | #290 |
| thrombin time | #290 |
| 0·50 | #290 |
| extracted data | #291 |
| current clinical | #291 |
| carriers mutation | #291 |
| 016 | #291 |
| oral contraceptives | #291 |
| willebrand disease vwd | #292 |
| activator inhibitor | #292 |
| 1603 | #292 |
| 2 studies | #292 |
| adverse outcome patients | #293 |
| patients dabigatran | #293 |
| pentasaccharide | #293 |
| 1000 personyears | #293 |
| plasmin activity | #293 |
| cardiac troponin ctnt | #294 |
| lower extremities | #294 |
| patients rivaroxaban | #294 |
| tissuetype plasminogen activator | #294 |
| scenario analysis | #295 |
| extremity dvt | #295 |
| 1025 | #295 |
| classified | #296 |
| coagulation factor viii | #296 |
| peripheral vascular | #296 |
| routine monitoring | #297 |
| observer agreement | #297 |
| specificity npv | #298 |
| episode patients | #298 |
| recurrent miscarriage | #298 |
| thrombocytes | #298 |
| patients inr | #299 |
| inferiority | #300 |
| heparitin | #301 |
| 041 | #301 |
| toxemia | #302 |
| aged neoplasms | #302 |
| subclinical thyroid dysfunction | #302 |
| 155 patients | #302 |
| thromboglobulin | #302 |
| 1214 | #304 |
| absolute difference | #304 |
| rivaroxaban dabigatran | #305 |
| medline embase | #306 |
| prophylactic administration | #306 |
| chimpanzees | #307 |
| noninvasive testing | #308 |
| complex concentrate | #309 |
| hematologic pregnancy | #310 |
| vte pregnancy | #310 |
| thrombotic | #310 |
| surgery day | #310 |
| clinical presentation | #311 |
| percentage points | #311 |
| 105 patients | #311 |
| patients 100 | #311 |
| antithrombins blood | #311 |
| leg male | #312 |
| 598 | #312 |
| vte 95 | #313 |
| negative reactions | #313 |
| obesity risk factor | #313 |
| hereditary thrombophilia | #313 |
| diagnosis | #314 |
| funding | #315 |
| puerperium | #315 |
| cardiologists | #315 |
| postpartum haemorrhage | #315 |
| heparin aspirin | #315 |
| therapeutic dose | #316 |
| apixaban versus | #316 |
| adjudicators | #317 |
| patients followup | #317 |
| deciding | #318 |
| 0·92 | #318 |
| decision model | #319 |
| failure rates | #319 |
| safety outcomes | #319 |
| 1731 | #320 |
| bnp levels | #320 |
| combined administration | #320 |
| influenza infections | #320 |
| patients pregnancy | #320 |
| catheter thrombosis | #320 |
| ventricular dysfunction patients | #321 |
| difference risk | #322 |
| additional data | #322 |
| intermediate phenotype | #322 |
| patients noacs | #322 |
| glaxosmithkline | #324 |
| peripheral arterial | #324 |
| inrs | #324 |
| mortality odds ratio | #325 |
| convincing evidence | #325 |
| mechanical heart valves | #326 |
| blood coagulation factor | #326 |
| 122 patients | #326 |
| pulmonary embolus | #326 |
| clinical | #327 |
| surgery trauma | #327 |
| association vte | #329 |
| thrombotic event | #331 |
| incidence bleeding | #331 |
| vitamin administration | #331 |
| pregnancy outcome women | #331 |
| new oral | #332 |
| 95 percent | #333 |
| n69 | #333 |
| embase databases | #333 |
| analysis trials | #333 |
| 95 confidence limits | #334 |
| incidences | #334 |
| complicate | #334 |
| minor effects | #334 |
| rationale design | #335 |
| patients healthy volunteers | #335 |
| fibrillation benzimidazoles | #335 |
| pulmonary perfusion | #336 |
| septicaemia | #336 |
| central venous catheter | #336 |
| recurrent | #337 |
| plethysmographic | #337 |
| 2 points | #337 |
| total hip replacement | #337 |
| 065 | #337 |
| 035 | #337 |
| aged netherlands | #338 |
| fatal bleeding | #338 |
| coagulation abnormalities | #338 |
| outpatient management | #338 |
| prospective clinical study | #339 |
| placebo trials | #339 |
| noacs warfarin | #339 |
| 024 | #340 |
| patients 12 | #340 |
| antithrombotic effects | #340 |
| 217 | #341 |
| activatable | #341 |
| coagulation markers | #341 |
| knee arthroscopy | #342 |
| noac patients | #342 |
| patients covid19 infection | #344 |
| pretest | #344 |
| splanchnic vein thrombosis | #345 |
| vte prevention | #345 |
| rfviia | #345 |
| antithrombotic strategies | #345 |
| diagnosis vte | #346 |
| embolisms | #346 |
| patients thrombosis | #347 |
| 073 | #347 |
| activated protein resistance | #347 |
| 044 | #348 |
| cochrane central | #348 |
| bsf | #349 |
| chads2 | #349 |
| 2575 | #349 |
| brain predictive | #350 |
| tafia | #350 |
| randomized studies | #350 |
| trousseau | #350 |
| versus warfarin | #351 |
| 013 | #351 |
| factor viii | #351 |
| selection bias | #352 |
| dermatan sulphate | #352 |
| anticoagulants noacs | #352 |
| factor activation | #352 |
| vein | #353 |
| 5075 | #353 |
| 1590 | #353 |
| oral anticoagulant therapy | #353 |
| relative efficacy | #353 |
| aged pulmonary | #354 |
| international normalized ratio | #354 |
| studies diagnostic accuracy | #355 |
| patients gp | #355 |
| protein deficiency | #356 |
| intestinal microbiome | #357 |
| categorised | #357 |
| tests prospective studies | #357 |
| post hoc | #357 |
| 127 patients | #358 |
| sucra | #360 |
| pilots | #360 |
| intermittent claudication | #361 |
| consensus agreement | #362 |
| treatment risk | #362 |
| anticoagulation patients | #364 |
| conventional therapy | #365 |
| humans risk | #365 |
| bleeding rate | #366 |
| topic female | #366 |
| prediction models | #367 |
| time recurrence | #368 |
| infrainguinal | #368 |
| patients 3 | #368 |
| thrombin inhibitor | #369 |
| influenza infection | #370 |
| patients acl reconstruction | #370 |
| 6week | #370 |
| venous stasis | #371 |
| endotoxin infusion | #371 |
| 803 | #372 |
| 055 | #372 |
| patients svt | #373 |
| clinical suspicion | #373 |
| knee surgery | #373 |
| recombinant activated | #373 |
| aprotinin blood | #373 |
| human cytomegalovirus infection | #374 |
| patients scores | #374 |
| helical computed tomography | #374 |
| hmb | #375 |
| subcutaneous | #375 |
| lyg | #377 |
| subclinical hyperthyroidism | #378 |
| contraceptives oral | #380 |
| stroke venous | #380 |
| tafi | #381 |
| ethinyloestradiol | #381 |
| antitnf | #382 |
| prefilter | #383 |
| reassessed | #384 |
| 0·8 | #384 |
| multivariate regression analysis | #384 |
| standardized questionnaire | #384 |
| thromboembolic complications | #384 |
| systemic activation | #385 |
| alpha2m | #385 |
| bleeding events | #386 |
| conference proceedings | #386 |
| surrogate outcome | #386 |
| sensitivity npv | #387 |
| cumulative incidences | #387 |
| antithrombins | #387 |
| delegates | #388 |
| major orthopedic | #388 |
| referred | #389 |
| safety rivaroxaban | #389 |
| systemic embolism | #389 |
| 880 | #389 |
| apixaban warfarin | #390 |
| tinzaparin | #390 |
| vitt | #390 |
| comparison patients | #391 |
| increased bleeding | #391 |
| biosis | #391 |
| abi | #391 |
| postop | #391 |
| drug prescription | #391 |
| patients chest | #392 |
| time presentation | #392 |
| topic female humans | #392 |
| factors thrombosis | #393 |
| kappa values | #393 |
| pulmonary emboli | #394 |
| injections intravenous | #394 |
| clinical score | #394 |
| background patients | #394 |
| 007 | #395 |
| 95 12 | #396 |
| bleeding event | #396 |
| popliteal | #396 |
| replacement surgery | #397 |
| embolic events | #397 |
| hirudins humans | #397 |
| 665 | #397 |
| factors factor | #397 |
| risk score patients | #399 |
| patients risk | #400 |
| echography | #400 |
| risk factors asthma | #400 |
| heparin induced | #400 |
| hemostatic parameters | #401 |
| fibrinolytic agents | #402 |
| controversy | #403 |
| increased risk vte | #403 |
| dabigatran | #403 |
| massive pulmonary embolism | #405 |
| treatment patient | #406 |
| 075 | #406 |
| 2215 | #406 |
| thrombolytic agents | #406 |
| oral anticoagulant | #408 |
| factor levels | #408 |
| biologic effects | #410 |
| noacs patients | #411 |
| safety combination | #411 |
| fviii levels | #411 |
| patients assigned | #411 |
| transfusion patients | #412 |
| major risk factor | #412 |
| 20 microg | #412 |
| euthyroidism | #414 |
| maastricht | #414 |
| coagulation patients | #414 |
| aged odds | #415 |
| xii | #415 |
| hypocortisolism | #415 |
| dose heparin | #416 |
| pai1 levels | #416 |
| intravascular coagulation | #416 |
| deserve | #416 |
| comparable | #417 |
| 95 10 | #417 |
| data risk | #417 |
| carotid femoral | #418 |
| 95 | #418 |
| pretest probability | #418 |
| 269 | #419 |
| risk factors thrombosis | #419 |
| dermatan | #419 |
| ototoxicity | #420 |
| xia | #420 |
| fibrillation risk | #421 |
| 1989 | #422 |
| fibrillation clinical | #422 |
| 2850 | #422 |
| tests radiography | #422 |
| fibrinolysin | #423 |
| subanalysis | #424 |
| fviia | #424 |
| prevalence patients | #425 |
| randomised double | #426 |
| fii | #426 |
| cancer cohort | #426 |
| adjunct | #426 |
| consecutive | #427 |
| activated factor | #427 |
| excessive bleeding | #428 |
| plg | #428 |
| conferences | #428 |
| daily practice | #428 |
| prolactin levels | #429 |
| undergoing elective | #429 |
| daily clinical practice | #429 |
| idiopathic myelofibrosis | #429 |
| patients testing | #429 |
| 1904 | #430 |
| bleeding complications | #431 |
| rule | #431 |
| heparinoids | #431 |
| 04 | #432 |
| outpatients | #433 |
| incidence length | #433 |
| patients systematic review | #434 |
| ncb | #434 |
| blood cultures | #436 |
| firstdegree relatives patients | #436 |
| bolus injection | #437 |
| 059 | #437 |
| proven | #439 |
| composite point | #439 |
| dose adjustment | #439 |
| women compared | #439 |
| prostatic cancer | #439 |
| highrisk populations | #441 |
| concomitant medications | #441 |
| rate vte | #442 |
| 074 | #442 |
| –control study | #444 |
| standard therapies | #444 |
| prespecified | #445 |
| febrile patients | #446 |
| patients atrial fibrillation | #446 |
| female fibrinolytic | #447 |
| 58 | #449 |
| hellp | #449 |
| utrecht | #449 |
| patients parenteral nutrition | #449 |
| 3 12 months | #450 |
| prevalence distribution | #450 |
| stigmatisation | #451 |
| category | #451 |
| pipecolic | #452 |
| noninvasive tests | #453 |
| aspirin risk | #453 |
| thrombin generation | #453 |
| fatal disease | #453 |
| 30 40 | #454 |
| placebo day | #454 |
| factor xii | #454 |
| portal blood | #454 |
| microthrombi | #455 |
| 12week | #455 |
| 026 | #455 |
| dichotomized | #456 |
| fviii vwf | #456 |
| squibb | #457 |
| dicumarol | #457 |
| onwards | #457 |
| hazard ratio 95 | #458 |
| anti levels | #458 |
| iii complexes | #458 |
| svt | #460 |
| plasma lipoprotein | #460 |
| recommend | #460 |
| factor fxa | #461 |
| gastrointestinal cancer | #461 |
| curve biomarkers | #462 |
| expert consensus document | #462 |
| hip arthroplasty replacement | #462 |
| haemolysis | #463 |
| guidelines patients | #463 |
| studies ultrasonography | #464 |
| patients values | #464 |
| gp iib | #464 |
| month follow | #465 |
| diabetes stroke | #466 |
| cancerassociated thrombosis | #466 |
| thrombin formation | #467 |
| accuracy detection | #467 |
| prophylaxis | #468 |
| patients nsaids | #468 |
| intimamedia thickness | #468 |
| eligible studies | #469 |
| bmi≥30 | #469 |
| teaching hospitals | #469 |
| inr patients | #470 |
| roc analysis | #470 |
| hemihepatectomy | #470 |
| test probability | #470 |
| 077 | #470 |
| placebo recipients | #471 |
| prophylactic anticoagulation | #472 |
| hypercoagulability | #472 |
| case control study | #472 |
| cardiovascular risk assessment | #473 |
| thrombophilia testing | #474 |
| patients heparin | #475 |
| plethysmograph | #475 |
| heterozygote humans | #475 |
| endotoxemia | #475 |
| 15 95 | #475 |
| intermittent pneumatic | #475 |
| atria | #477 |
| 08 | #479 |
| haemophiliacs | #479 |
| patients score | #479 |
| versus standard | #480 |
| acutely | #481 |
| thrombosis cvt | #481 |
| hit patients | #481 |
| advisory | #482 |
| postoperative blood | #482 |
| 1162 | #482 |
| transportability | #482 |
| thrombin inhibitors | #483 |
| events mortality | #484 |
| patients hematologic malignancies | #485 |
| diagnostic efficacy | #485 |
| awaited | #486 |
| secondary prophylaxis | #487 |
| composite scores | #487 |
| silent | #488 |
| travel | #488 |
| activity patients | #489 |
| 98 | #490 |
| blinded | #491 |
| hemophilic | #493 |
| residual risk | #493 |
| treatment period | #493 |
| new therapy | #493 |
| pan troglodytes | #493 |
| p00007 | #493 |
| vcf | #494 |
| activated protein | #495 |
| dose oral | #496 |
| replacement hip arthroplasty | #496 |
| favour | #496 |
| heterozygote | #496 |
| 271 | #497 |
| topic risk factors | #497 |
| risk factors stroke | #498 |
| willebrand disease | #498 |
| discriminative ability | #498 |
| blockages | #498 |
| hip knee | #501 |
| nri | #502 |
| ptp | #502 |
| ft4 tsh | #503 |
| subcategories | #503 |
| deficiencies | #503 |
| rapid decrease | #504 |
| nondiagnostic | #505 |
| 1107 | #505 |
| patients referred | #505 |
| complications pulmonary | #505 |
| net clinical | #506 |
| 310 | #506 |
| day surgery | #507 |
| oftentimes | #507 |
| nonionic | #507 |
| inhibitors rivaroxaban | #508 |
| aminocaproates | #509 |
| coagulation tests | #509 |
| 13 95 | #509 |
| guidelines diagnosis | #509 |
| contraceptives | #509 |
| thrombosis animals | #510 |
| angiography patients | #510 |
| new oral anticoagulants | #510 |
| degradation products | #510 |
| viii fviii | #511 |
| epiphenomenon | #512 |
| 019 | #512 |
| serial | #513 |
| 056 | #514 |
| interim analysis | #514 |
| highintensity | #514 |
| daycare | #515 |
| safety | #516 |
| crcl | #517 |
| sensitivity diagnosis | #518 |
| thrombotic diseases | #518 |
| bleeding outcomes | #518 |
| thrombophilia thrombosis | #518 |
| protein antithrombin | #518 |
| treatment cancer patients | #519 |
| groups treatment | #519 |
| study sensitivity | #520 |
| 8090 | #521 |
| 1599 | #521 |
| duration intensity | #521 |
| warfarin therapy | #524 |
| fixed doses | #525 |
| general practitioner | #525 |
| 062 | #527 |
| cindices | #528 |
| cancer age | #528 |
| convincing | #529 |
| 051 | #529 |
| 923 | #529 |
| 378 | #529 |
| health female | #530 |
| fatal | #530 |
| thrombosis hemostasis | #531 |
| betaalanine | #531 |
| medically patients | #531 |
| humans postoperative | #531 |
| intensive units icu | #532 |
| thrombosis risk | #532 |
| 068 | #532 |
| ≥50 years | #532 |
| factor thrombin | #534 |
| therapy cancer | #534 |
| 730 | #536 |
| factor pathway | #537 |
| 449 | #538 |
| patients idiopathic | #538 |
| humans neoplasms | #538 |
| cbo | #539 |
| ddavp | #539 |
| comprehensive search | #539 |
| concise | #539 |
| diagnostic accuracy studies | #540 |
| clinical review | #540 |
| diagnosis acute | #540 |
| 234 | #543 |
| patients eligible | #543 |
| conventional treatment | #543 |
| vascular obstruction | #543 |
| bleeding episodes | #543 |
| thrombotic risk | #543 |
| jak2 mutation | #544 |
| coagulative | #544 |
| pad abi | #544 |
| 00 | #544 |
| v617f | #545 |
| prospective cohort study | #545 |
| hellp syndrome | #545 |
| perc | #545 |
| association statin | #546 |
| screening strategies | #546 |
| bureau | #547 |
| prothrombin complex | #547 |
| primary | #548 |
| adequate | #549 |
| 95 difference | #549 |
| overt | #549 |
| cancer type | #550 |
| percent patients | #550 |
| reviewers | #550 |
| conduction anesthesia | #550 |
| platelet inhibitors | #550 |
| 1103 | #550 |
| day patients | #552 |
| studies sensitivity | #552 |
| amsterdam | #552 |
| management bleeding | #552 |
| careful | #552 |
| 500 patients | #552 |
| femoral arteries | #553 |
| general population patients | #554 |
| ttr | #556 |
| humans infusions | #557 |
| 66 patients | #558 |
| factor vii | #558 |
| vivo treatment | #558 |
| orthopedic surgery | #559 |
| bleeding time | #559 |
| limulus | #561 |
| female humans tests | #563 |
| board directors | #563 |
| patients transfusion | #563 |
| risk development | #563 |
| anamnesis | #564 |
| appears | #564 |
| hip replacement | #564 |
| increasing risk | #565 |
| hyperfibrinolysis | #565 |
| cardiac troponins | #566 |
| withholding | #566 |
| solid tumours | #566 |
| roc curves | #568 |
| patients 2 years | #568 |
| n46 | #568 |
| levothyroxine | #571 |
| alpha1antitrypsin | #571 |
| aggravation | #572 |
| ctnt | #573 |
| cutoff point | #574 |
| revascularization procedures | #574 |
| menstrual bleeding | #574 |
| subcutaneously | #575 |
| women proportion | #575 |
| major bleedings | #575 |
| progression cancer | #577 |
| endothelial barrier | #578 |
| patients vka | #578 |
| thiophenes | #579 |
| pharma | #579 |
| endotoxin | #579 |
| diagnostic tools | #580 |
| notice | #580 |
| 99 | #580 |
| cancer thrombosis | #581 |
| subgroups patients | #583 |
| dummy | #584 |
| unselected patients | #584 |
| coagulation disorders | #585 |
| 094 | #585 |
| chondroitin sulfates | #586 |
| major orthopedic surgery | #588 |
| feasibility safety | #588 |
| helminth proteins | #589 |
| healthy human | #590 |
| malignancy | #590 |
| beta alanine | #590 |
| reversal agents | #590 |
| thrombophilias | #590 |
| doppler ultrasound | #592 |
| massive pulmonary | #592 |
| conventional management | #592 |
| bmi30 | #594 |
| factor fv | #595 |
| severe bleeding | #597 |
| ldf | #597 |
| patency rates | #597 |
| replacement knee | #597 |
| major hemorrhage | #597 |
| infusions intravenous | #598 |
| analysis topic | #599 |
| tests sensitivity | #600 |
| loss surgical | #600 |
| 046 | #601 |
| association patients | #602 |
| vwd | #603 |
| events occurred | #604 |
| clinical characteristics patients | #604 |
| comorbid conditions | #604 |
| diagnostic studies | #606 |
| 0·3 | #607 |
| initial increase | #607 |
| activated coagulation | #607 |
| patients antibodies | #607 |
| treatment acute | #608 |
| tissue factor | #609 |
| arbitrage | #609 |
| pfizer | #609 |
| benefit risk | #610 |
| patients death | #610 |
| airline | #610 |
| 100 years | #610 |
| clinical evaluation | #611 |
| ultrasonography | #613 |
| coagulation inflammation | #614 |
| reluctant | #615 |
| leg | #615 |
| patients bariatric surgery | #615 |
| complications risk | #616 |
| arterial disease | #617 |
| treatment rivaroxaban | #617 |
| occurred | #618 |
| stroke atrial fibrillation | #618 |
| 467 | #618 |
| fh patients | #620 |
| compared placebo | #620 |
| patients elevated | #621 |
| advisory committees | #621 |
| 1002 | #622 |
| sgs | #623 |
| thyrotoxic | #623 |
| thrombocytopenia hit | #623 |
| cochrane central register | #625 |
| peptide bnp | #625 |
| topic practice guidelines | #626 |
| stopped | #626 |
| stroke warfarin | #627 |
| 66 | #628 |
| 5000 | #628 |
| women risk factors | #628 |
| warfarin risk | #628 |
| human subjects | #629 |
| physical training | #629 |
| referral patients | #629 |
| diagnostic algorithms | #629 |
| sanofi | #630 |
| absolute | #630 |
| atiii | #632 |
| risk treatment | #633 |
| screening strategy | #634 |
| uneventful | #635 |
| outweigh | #635 |
| pentoxifylline | #637 |
| travelling | #638 |
| 14 95 | #640 |
| 95 allcause mortality | #640 |
| proceedings | #641 |
| study quality | #641 |
| predictive performance | #642 |
| 3050 | #642 |
| threatening bleeding | #643 |
| neutrophilia | #643 |
| primary outcome measure | #647 |
| association mortality | #647 |
| necessitating | #648 |
| statin treatment | #648 |
| studies efficacy | #648 |
| thrombolysis patients | #651 |
| 036 | #651 |
| fixed | #651 |
| organisations | #652 |
| troglodytes | #652 |
| fxa | #653 |
| hemorrhagic stroke | #653 |
| 127 | #655 |
| patients review | #657 |
| coronary stent implantation | #659 |
| 69 | #659 |
| bleeding death | #659 |
| haematoma | #660 |
| tertiles | #661 |
| physical examination | #661 |
| coagulation proteins | #661 |
| haemophilia | #662 |
| clinical presentations | #662 |
| 1028 | #663 |
| 95 studies | #663 |
| provoked | #664 |
| long term treatment | #664 |
| sepsis shock | #665 |
| phase iii studies | #666 |
| deep | #666 |
| patients completed | #667 |
| presence patients | #667 |
| onethird | #667 |
| guideline adherence | #667 |
| male medical | #668 |
| 8 wk | #669 |
| 1110 | #671 |
| phenprocoumon | #672 |
| elevated plasma | #673 |
| patients cteph | #673 |
| hospitalization hf | #674 |
| managing | #674 |
| il6 levels | #675 |
| clotting factors | #675 |
| inhibitor 1 | #675 |
| prothrombotic | #676 |
| highincome countries | #676 |
| asymptomatic subjects | #677 |
| favourably | #678 |
| jugular | #679 |
| medicine humans | #681 |
| pulmonary endarterectomy | #681 |
| suspicion | #682 |
| conclude | #687 |
| apolipoproteina | #688 |
| efficacy safety | #690 |
| patients bleeding | #692 |
| ambulatory patients | #692 |
| graduated | #693 |
| activator pa | #693 |
| myocardial infarctions | #693 |
| intracranial bleeding | #694 |
| precise mechanisms | #694 |
| administer | #694 |
| composite outcome | #694 |
| 1718 | #695 |
| stroke prevention patients | #696 |
| moyamoya | #696 |
| combined oral contraceptives | #696 |
| ratio male | #698 |
| participant data | #698 |
| difference 95 | #698 |
| compression devices | #700 |
| episode | #700 |
| prothrombin gene | #702 |
| diagnostic errors | #702 |
| therapeutic management | #702 |
| patients confirmed | #703 |
| veins venous | #703 |
| surgery risk | #703 |
| willebrand | #704 |
| data incidence | #706 |
| subclinical hypothyroidism | #708 |
| clinical expression | #709 |
| directors | #709 |
| starters | #711 |
| 048 | #712 |
| gynaecology | #712 |
| medical patients | #712 |
| gastrointestinal bleeding | #712 |
| radionuclide imaging | #713 |
| rate death | #714 |
| neurosurgical patients | #714 |
| 1098 | #714 |
| intravenous bolus | #715 |
| rivaroxaban stroke | #716 |
| menstrual period | #716 |
| adequately | #717 |
| cancer groups | #717 |
| falsely | #718 |
| 10 30 | #718 |
| solid cancer | #718 |
| plasminogen | #719 |
| reagent kits | #719 |
| pulmonary medicine | #720 |
| clinical judgment | #721 |
| nordisk | #721 |
| accp | #721 |
| pyrazoles pyridines | #721 |
| s1p1 | #722 |
| 95 hazard ratio | #724 |
| abnormal | #726 |
| follow period | #726 |
| 59 patients | #727 |
| gentamicins | #727 |
| orthopaedic surgery | #728 |
| diagnostic therapeutic | #728 |
| diagnostic tests | #730 |
| leeches | #732 |
| gentamicin | #732 |
| tumor necrosis factor | #733 |
| oral contraception | #733 |
| relative risk 95 | #734 |
| disease pad | #735 |
| patients levels | #735 |
| hull | #735 |
| clinical prediction rule | #736 |
| atrial fibrillation risk | #736 |
| tests retrospective studies | #736 |
| post hoc analysis | #739 |
| 6 12 | #739 |
| anti tnf | #740 |
| evaluable patients | #741 |
| 040 | #742 |
| unclear | #742 |
| early pregnancy loss | #742 |
| topic predictive | #743 |
| illness time factors | #744 |
| betathromboglobulin | #744 |
| molecular weight | #744 |
| etp | #746 |
| antithrombin activity | #746 |
| patients 50 years | #746 |
| 285 | #746 |
| leukocyte activation | #748 |
| thrombolytic therapy | #749 |
| hospitalization heart failure | #750 |
| indication | #752 |
| advisable | #754 |
| fibrin formation | #754 |
| primary patients | #755 |
| hf risk | #756 |
| pneumatic compression | #756 |
| 95 risk factors | #756 |
| 95 combination | #756 |
| answer | #756 |
| venovenous | #757 |
| 1·7 | #758 |
| loe | #759 |
| 85 | #759 |
| inflammation coagulation | #760 |
| patients peripheral | #761 |
| proportion women | #763 |
| 435 | #763 |
| cprs | #764 |
| start treatment | #764 |
| hip surgery | #765 |
| aspirin clopidogrel | #767 |
| 689 | #767 |
| risk pregnancy | #767 |
| 732 | #768 |
| method drug | #769 |
| 566 | #770 |
| relevant | #770 |
| groups patients | #770 |
| graft patency | #772 |
| baseline values | #772 |
| patients criteria | #773 |
| subcutaneous injections | #774 |
| bmi patients | #774 |
| 1·5 | #776 |
| 992 | #777 |
| patients 65 years | #778 |
| study groups | #778 |
| dose intravenous | #778 |
| dose warfarin | #778 |
| miscarriage | #779 |
| plasmin generation | #780 |
| 066 | #780 |
| patients hyperthyroidism | #780 |
| thromboembolism prophylaxis | #780 |
| age ≥ | #782 |
| factor ixa | #785 |
| onefifth | #785 |
| abnormalities patients | #786 |
| cteph | #787 |
| polypharmacy | #787 |
| topic disease models | #787 |
| general practitioners | #787 |
| 100 personyears | #787 |
| preferable | #788 |
| secondary outcome | #791 |
| recombinant tissue | #793 |
| mechanical heart | #793 |
| inactivators | #795 |
| risk factors risk | #795 |
| 047 | #795 |
| patency | #796 |
| patient years | #796 |
| netherlands | #797 |
| studies prevalence | #797 |
| eligible | #797 |
| lupus anticoagulant | #798 |
| femoropopliteal | #798 |
| theme | #799 |
| patients lower | #799 |
| estrogen therapy | #799 |
| hemophilia patients | #800 |
| willebrand factor | #802 |
| subclinical | #804 |
| randomized patients | #804 |
| microvesicles | #805 |
| anticoagulant agents | #805 |
| fibrillation blood | #806 |
| adverse outcomes patients | #806 |
| stroke risk factors | #807 |
| ventricular dysfunction | #808 |
| hypertension cteph | #809 |
| efficacy patients | #809 |
| activator inhibitor1 | #810 |
| 069 | #811 |
| model patients | #813 |
| primary aim | #814 |
| flights | #816 |
| factor vwf | #816 |
| 0·4 | #818 |
| vehicle control | #820 |
| irrespective | #820 |
| health predictive | #820 |
| abruptio | #821 |
| neuroradiologist | #822 |
| prevention patients | #823 |
| reduction mortality | #823 |
| coc | #824 |
| single administration | #824 |
| risk benefit | #825 |
| study incidence | #827 |
| cardioembolic stroke | #828 |
| gp | #828 |
| patients anticoagulants | #830 |
| cava filters | #832 |
| antithrombotic treatment | #833 |
| 93 | #833 |
| myers | #833 |
| abortion habitual | #835 |
| oral adult | #836 |
| plough | #836 |
| noac | #837 |
| versus placebo | #837 |
| 87 | #838 |
| 057 | #839 |
| genetic defect | #841 |
| risk scores | #844 |
| 49 | #846 |
| antithrombotic therapy | #846 |
| 072 | #847 |
| multidetector row | #847 |
| advise | #848 |
| recurrence risk | #849 |
| caesarean | #850 |
| patients diagnosis | #850 |
| area roc curve | #852 |
| pre‐eclampsia | #853 |
| reference method | #853 |
| 30 patients | #853 |
| advanced prostate | #854 |
| fibrin | #855 |
| clopidogrel aspirin | #855 |
| patients mutation | #859 |
| ultrafiltrate | #860 |
| dutch population | #861 |
| microg | #862 |
| cardiometabolic disease | #863 |
| 090 | #865 |
| placebo study | #866 |
| diagnostic methods | #868 |
| 1046 | #869 |
| 6 month | #870 |
| pyridones | #870 |
| individual participant | #872 |
| longterm clinical outcomes | #872 |
| favoring | #873 |
| tasman | #873 |
| thromboembolic pulmonary | #874 |
| targeted inhibition | #874 |
| imaging reproducibility | #874 |
| plasminogen activation | #875 |
| titles | #875 |
| n15 | #876 |
| cha2ds2 | #877 |
| risk thromboembolic | #878 |
| dabigatran rivaroxaban | #878 |
| 57 | #879 |
| anticoagulants atrial | #879 |
| oral | #881 |
| angiograms | #882 |
| control trial | #883 |
| 92 | #884 |
| imaging tests | #885 |
| prostate turp | #888 |
| handbook | #890 |
| 084 | #894 |
| male mexico | #894 |
| domiciliary | #894 |
| p011 | #896 |
| loading dose | #896 |
| repeatedly | #897 |
| uln | #901 |
| indefinite | #902 |
| bleedings | #904 |
| vkorc1 | #905 |
| wml | #906 |
| 064 | #908 |
| factor activity | #908 |
| subcutaneous administration | #909 |
| patients clinical trials | #911 |
| documented | #911 |
| initially | #912 |
| haemostatic | #912 |
| impedance | #913 |
| specificity sensitivity | #914 |
| combined approach | #916 |
| haemodialysis patients | #916 |
| 317 | #917 |
| thromboembolic events | #918 |
| 022 | #918 |
| chronic thromboembolic | #919 |
| randomeffects model | #920 |
| standard patients | #920 |
| antagonist oral | #920 |
| ultrasound examination | #921 |
| optimal dose | #921 |
| loss patients | #921 |
| estimate male | #923 |
| practise | #923 |
| multifactorial disease | #925 |
| study medication | #925 |
| total hip | #926 |
| 902 | #928 |
| safer | #928 |
| 004 | #929 |
| recurrent events | #930 |
| fxi | #931 |
| treatment placebo | #934 |
| wording | #934 |
| 84 | #936 |
| publication clinical trials | #937 |
| 60 patients | #938 |
| subgroup patients | #938 |
| rrr | #940 |
| families patients | #941 |
| teaching hospital | #943 |
| echocardiographically | #944 |
| stroke atrial | #944 |
| women preeclampsia | #944 |
| emboli | #945 |
| predictive values | #946 |
| ssc | #946 |
| anticoagulation treatment | #947 |
| knee replacement | #948 |
| diagnostic | #948 |
| extensive disease | #948 |
| previous diagnosis | #951 |
| adjudication | #954 |
| registro | #956 |
| dic | #956 |
| cancer humans | #956 |
| network metaanalysis | #956 |
| reassuring | #957 |
| venous insufficiency | #957 |
| day1 | #958 |
| efficacy | #958 |
| combined oral | #961 |
| retropubic | #961 |
| guidelines recommend | #962 |
| 3 months | #963 |
| blood product | #964 |
| travellers | #965 |
| reference lists | #966 |
| inhibitor1 | #966 |
| peaking | #969 |
| greater risk | #970 |
| allogeneic blood | #971 |
| prevalence characteristics | #973 |
| hoc | #973 |
| antiplatelet | #973 |
| risk allcause mortality | #973 |
| segmental | #974 |
| patients anticoagulation | #975 |
| vascular humans | #976 |
| female fibrinogen | #976 |
| fvii | #978 |
| false negative | #979 |
| onset aged aged | #980 |
| 50 100 | #980 |
| 071 | #980 |
| early gestation | #984 |
| 426 | #986 |
| randomised trials | #987 |
| prophylactic treatment | #987 |
| patients safety | #988 |
| vascular patency | #989 |
| study treatment | #990 |
| missed | #991 |
| rises | #991 |
| academic medical center | #992 |
| seminar | #992 |
| normal lung | #993 |
| counteracted | #993 |
| treatment bleeding | #994 |
| aged | #999 |
| 226 | #999 |
| thromboembolic risk | #1000 |
| justification | #1000 |
| lower extremity | #1000 |
| tissue type | #1001 |
| rivaroxaban apixaban | #1002 |
| parenteral administration | #1002 |
| eclamptic | #1003 |
| hyperprolactinaemia | #1005 |
| extended | #1005 |
| interleukin 6 | #1005 |
| pyridines | #1006 |
| orthosis | #1007 |
| easier | #1007 |
| 50 patients | #1007 |
| valsalva maneuver | #1009 |
| venous catheter | #1011 |
| individual participant data | #1012 |
| weighing | #1014 |
| pounds | #1018 |
| ticlopidine | #1018 |
| clotting time | #1019 |
| prostatic carcinoma | #1020 |
| 200 patients | #1022 |
| cha2ds2 vasc | #1023 |
| years risk | #1023 |
| international prospective | #1024 |
| humans randomized | #1024 |
| 076 | #1025 |
| diagnostic challenge | #1026 |
| prothrombin time | #1027 |
| firstdegree relatives | #1030 |
| decision analysis | #1030 |
| ixa | #1031 |
| prolactin | #1032 |
| cardiovascular event | #1033 |
| relatives | #1033 |
| risk hemorrhage | #1033 |
| 052 | #1035 |
| graft occlusion | #1037 |
| male netherlands | #1037 |
| 2 hours | #1039 |
| detect | #1040 |
| 025 | #1041 |
| 3 6 months | #1046 |
| vwf levels | #1047 |
| patients severe asthma | #1047 |
| patients massive | #1050 |
| examiner | #1050 |
| continuation | #1052 |
| patients analysis | #1053 |
| mean±sd | #1054 |
| 221 | #1054 |
| free triiodothyronine | #1056 |
| diseases liver | #1057 |
| coagulant | #1060 |
| birth rate | #1060 |
| 179 | #1060 |
| 610 | #1061 |
| pad | #1061 |
| primary data | #1062 |
| published literature | #1062 |
| false | #1064 |
| 150 | #1065 |
| prekallikrein | #1065 |
| live birth | #1066 |
| 00008 | #1066 |
| 101 | #1066 |
| lysosphingolipid | #1067 |
| cut | #1067 |
| pmol | #1068 |
| register controlled | #1070 |
| 95 increased risk | #1070 |
| observer variation | #1071 |
| specialties | #1072 |
| continued | #1073 |
| thorax | #1074 |
| laboratory diagnosis | #1074 |
| systematic search | #1078 |
| advocate | #1080 |
| 063 | #1080 |
| drawbacks | #1082 |
| longterm therapy | #1087 |
| f1 | #1087 |
| bandages | #1089 |
| clarifications | #1095 |
| stopping | #1095 |
| idarucizumab | #1096 |
| diagnostic utility | #1096 |
| mandated | #1096 |
| 083 | #1099 |
| 1223 | #1099 |
| 62 | #1102 |
| 96 | #1104 |
| fourfold | #1105 |
| blueprint | #1105 |
| clinical protocols | #1107 |
| peptide brain | #1107 |
| pending | #1111 |
| incidence pulmonary | #1112 |
| assigned | #1113 |
| diagnostic approach | #1115 |
| haemodialysis | #1116 |
| bypass grafts | #1116 |
| 252 | #1117 |
| qualified | #1118 |
| sensitivity specificity | #1119 |
| critical appraisal | #1120 |
| randomized controlled trials | #1122 |
| resistance factor | #1123 |
| probands | #1123 |
| new developments | #1124 |
| advised | #1125 |
| new perspectives | #1126 |
| 445 | #1126 |
| cip | #1127 |
| heparininduced thrombocytopenia | #1127 |
| patients pad | #1128 |
| discretion | #1132 |
| judged | #1132 |
| statistic | #1133 |
| ≤10 | #1133 |
| 95 confidence interval | #1134 |
| pulse rate | #1135 |
| gram negative | #1137 |
| 1043 | #1139 |
| disseminated | #1140 |
| 635 | #1141 |
| superior efficacy | #1141 |
| 86 | #1143 |
| 734 | #1145 |
| 844 | #1147 |
| refusal | #1150 |
| roc curve | #1150 |
| medline | #1151 |
| medical records | #1151 |
| embolectomy | #1153 |
| longterm complications | #1154 |
| risk recurrence | #1155 |
| blood loss | #1156 |
| anticoagulation therapy | #1156 |
| patients influenza | #1156 |
| prophylaxis treatment | #1157 |
| 3040 | #1158 |
| patients increased | #1159 |
| extension study | #1161 |
| cvc | #1162 |
| bristol | #1163 |
| published guidelines | #1163 |
| hyperhomocysteinemia | #1164 |
| safety concerns | #1164 |
| stable angina | #1164 |
| intermittent | #1164 |
| viii | #1164 |
| age 65 years | #1165 |
| thromboembolism risk | #1165 |
| angiogram | #1167 |
| glucocorticoid treatment | #1172 |
| crossover design | #1172 |
| atherosclerotic disease | #1172 |
| perioperative bleeding | #1172 |
| occlusive diseases | #1173 |
| practice guideline | #1173 |
| 5 years patients | #1176 |
| macroglobulin | #1176 |
| analysis studies | #1178 |
| findings patients | #1178 |
| 79 | #1179 |
| conceive | #1181 |
| concealed | #1181 |
| patients obesity | #1182 |
| unaware | #1182 |
| hospitalized patients | #1182 |
| conclusive | #1186 |
| combined therapy | #1186 |
| occult | #1189 |
| degree relatives | #1189 |
| adult analysis | #1191 |
| cus | #1194 |
| administration oral | #1195 |
| 21 patients | #1197 |
| mandate | #1199 |
| cardiotonic agents | #1199 |
| international society | #1199 |
| hypercortisolism | #1200 |
| 83 | #1203 |
| 015 | #1204 |
| categorized | #1204 |
| quantitative trait locus | #1204 |
| increase plasma | #1205 |
| 31 | #1207 |
| biomarkers blood | #1210 |
| 56 patients | #1212 |
| pph | #1214 |
| multicenter randomized | #1214 |
| 103 | #1218 |
| patient treatment | #1221 |
| scores patients | #1221 |
| warranted | #1221 |
| ultrasound screening | #1222 |
| 6months | #1223 |
| peak levels | #1224 |
| 64 patients | #1224 |
| vasc | #1225 |
| 16 patients | #1226 |
| sixfold | #1227 |
| blind | #1227 |
| consensus guidelines | #1228 |
| metabolic syndrome patients | #1228 |
| trial background | #1229 |
| radionuclide | #1229 |
| peptide hydrolases | #1229 |
| 65 patients | #1230 |
| rules | #1232 |
| doubles | #1232 |
| aspirin | #1234 |
| milliliter | #1238 |
| postoperative hemorrhage | #1238 |
| coronary angiography patients | #1238 |
| humans length | #1240 |
| clinical criteria | #1241 |
| patients fh | #1242 |
| vte prophylaxis | #1244 |
| neurohormone | #1245 |
| multinational | #1246 |
| thrombolytic | #1247 |
| knee arthroplasty | #1248 |
| intermediate risk | #1250 |
| ml1 | #1252 |
| matter lesions | #1252 |
| subgroups | #1252 |
| artery pulmonary | #1254 |
| extensive | #1257 |
| search strategy | #1257 |
| oral vitamin | #1257 |
| prospective cohort | #1258 |
| symptomatic patients | #1259 |
| major surgery | #1262 |
| entity | #1266 |
| troponins | #1266 |
| visiting | #1266 |
| macroglobulins | #1267 |
| 172 | #1270 |
| amputations | #1273 |
| intensive patients | #1274 |
| equally | #1274 |
| design study | #1276 |
| antiplatelet agents | #1278 |
| proportionally | #1279 |
| routine screening | #1281 |
| statin users | #1281 |
| 75 years | #1281 |
| factors ultrasonography | #1285 |
| thyroxine | #1287 |
| 050 | #1288 |
| blockers | #1290 |
| dermatan sulfate | #1292 |
| janssen | #1295 |
| scan | #1295 |
| perfusion defects | #1295 |
| predictive | #1297 |
| hemofiltration | #1297 |
| insufficiently | #1298 |
| low prevalence | #1299 |
| cardiovascular complications | #1299 |
| dutch | #1300 |
| prolong | #1302 |
| pf4 | #1303 |
| 61 | #1303 |
| pulmonary circulation | #1304 |
| scores | #1305 |
| 95 mortality | #1307 |
| apoa | #1312 |
| 1st | #1312 |
| risk difference | #1312 |
| cyproterone | #1312 |
| adamts13 activity | #1313 |
| tests severity | #1314 |
| 0·7 | #1314 |
| current strategies | #1314 |
| claudication | #1316 |
| atrial fibrillation | #1316 |
| carotid imt | #1317 |
| international guidelines | #1318 |
| replacement hip | #1320 |
| study time | #1321 |
| coagulation factor | #1322 |
| vienna | #1323 |
| increases risk | #1324 |
| lipoproteina | #1325 |
| glycoprotein gpiib | #1325 |
| patients coronavirus disease | #1326 |
| beneficial | #1329 |
| vascular diseases | #1329 |
| antibodies monoclonal antibodies | #1329 |
| low moderate | #1330 |
| plasminogen activators | #1330 |
| thyroid disorders | #1330 |
| 6 months patients | #1331 |
| 77 | #1331 |
| coagulation cascade | #1331 |
| 126 | #1332 |
| frequent complication | #1333 |
| adjusted age | #1335 |
| transurethral resection | #1336 |
| venous catheters | #1342 |
| 91 | #1342 |
| likelihood ratio | #1342 |
| blood sample | #1343 |
| daily patients | #1344 |
| antitrypsin | #1347 |
| surgical trauma | #1347 |
| patients relatives | #1351 |
| neurosurgery | #1355 |
| arthroplasty patients | #1356 |
| patients stable angina | #1357 |
| 15 patients | #1359 |
| allcause mortality 95 | #1359 |
| experimental model | #1359 |
| limb salvage | #1363 |
| arsenal | #1363 |
| vwf | #1363 |
| vtes | #1365 |
| 95 patients | #1366 |
| operatively | #1367 |
| 12 month | #1369 |
| heart valves | #1370 |
| starting | #1372 |
| ethinyl | #1373 |
| acetylsalicylic | #1375 |
| costeffectiveness analysis | #1376 |
| utmost | #1378 |
| consented | #1382 |
| management patients | #1383 |
| gps | #1384 |
| noninferiority | #1385 |
| 224 | #1385 |
| dl1 | #1385 |
| disorders blood | #1386 |
| ivt | #1389 |
| patients cvd | #1392 |
| substitute | #1394 |
| screening tests | #1399 |
| patients control subjects | #1400 |
| record linkage | #1400 |
| antisense oligonucleotide | #1402 |
| 82 | #1402 |
| equipoise | #1402 |
| mandatory | #1403 |
| clinical challenges | #1404 |
| patients advanced cancer | #1405 |
| 1886 | #1405 |
| obese patients | #1406 |
| pregnancy loss | #1406 |
| categories | #1408 |
| 515 | #1408 |
| 994 | #1409 |
| reflected | #1410 |
| inception | #1411 |
| tranexamic | #1413 |
| adamts13 | #1417 |
| 0·1 | #1418 |
| 7 weeks | #1419 |
| 3 6 | #1419 |
| thrombotic complications | #1419 |
| 6 weeks | #1419 |
| total knee | #1420 |
| 95 0 | #1421 |
| university hospitals | #1422 |
| followup data | #1422 |
| daily | #1424 |
| 061 | #1424 |
| ≥55 | #1424 |
| eightfold | #1425 |
| randomised controlled trials | #1427 |
| 080 | #1427 |
| rgs | #1430 |
| casecontrol study | #1430 |
| outcome pregnancy | #1438 |
| 096 | #1439 |
| imaging radiopharmaceuticals | #1439 |
| principal | #1443 |
| 78 | #1443 |
| 1123 | #1445 |
| drug levels | #1446 |
| outcome studies | #1446 |
| weight bmi | #1446 |
| underreporting | #1451 |
| support systems | #1452 |
| population patients | #1454 |
| confusion | #1454 |
| platelet factor | #1455 |
| aged blood | #1455 |
| dip | #1456 |
| mbe | #1457 |
| conclusions patients | #1459 |
| prospectively | #1460 |
| multicenter studies | #1461 |
| humans | #1463 |
| inaccuracy | #1464 |
| funded | #1466 |
| actual | #1466 |
| avoided | #1468 |
| 0·9 | #1468 |
| 26 patients | #1469 |
| heart failure hf | #1469 |
| groin | #1471 |
| risk factors mortality | #1472 |
| prevalences | #1473 |
| 1215 | #1473 |
| centrally | #1474 |
| systemic infection | #1477 |
| probability | #1477 |
| lowest tertile | #1478 |
| remained | #1480 |
| atherothrombotic | #1481 |
| undetermined | #1482 |
| dysfunction patients | #1483 |
| cushing syndrome | #1485 |
| analysis randomized | #1485 |
| methodologic | #1486 |
| phase iii trials | #1486 |
| general practice | #1491 |
| procoagulant activity | #1495 |
| patients control | #1495 |
| randomly | #1496 |
| 64 | #1498 |
| aged natriuretic | #1499 |
| exposing | #1501 |
| imt | #1507 |
| fracture surgery | #1510 |
| specificity 100 | #1512 |
| odds ratio 95 | #1513 |
| growing body | #1514 |
| adverse outcome | #1514 |
| proximal | #1516 |
| pregnancy postpartum | #1520 |
| patients 10 | #1520 |
| ganz | #1520 |
| subgroup | #1521 |
| factor deficiency | #1522 |
| gsk | #1524 |
| chills | #1526 |
| thrombotic events | #1527 |
| contraindicated | #1527 |
| time study | #1529 |
| score | #1529 |
| oral contraceptive | #1534 |
| mechanical compression | #1536 |
| immobilisation | #1539 |
| comparator | #1540 |
| patients life | #1541 |
| humans neoplasm | #1542 |
| hemostatics humans | #1545 |
| 089 | #1548 |
| tsh levels | #1551 |
| patients severe sepsis | #1552 |
| live births | #1552 |
| 23 | #1554 |
| vascular thrombosis | #1555 |
| fees | #1556 |
| neonatal period | #1558 |
| patients year | #1559 |
| discriminatory | #1562 |
| hypothyroidism | #1563 |
| pfa | #1564 |
| enfermedad | #1564 |
| iii topic | #1565 |
| topic | #1566 |
| treatment prevention | #1566 |
| deficient | #1568 |
| 95ci | #1568 |
| hyperlipoproteinemia type | #1568 |
| cushings syndrome | #1568 |
| aged biomarkers | #1571 |
| 36 | #1575 |
| plasminogen activator | #1575 |
| humans platelet | #1576 |
| 012 | #1577 |
| hyperlipoproteinemia | #1580 |
| risk myocardial infarction | #1584 |
| activation markers | #1586 |
| cocs | #1586 |
| study entry | #1586 |
| thyroid dysfunction | #1586 |
| studies association | #1587 |
| adjusted hazard ratio | #1589 |
| volunteers | #1591 |
| 1·1 | #1594 |
| total mortality | #1594 |
| translates | #1597 |
| noncancer | #1598 |
| placebo | #1598 |
| exclude | #1599 |
| lmw | #1601 |
| figures | #1604 |
| paroxetine | #1606 |
| abdominal surgery | #1607 |
| complement pathway | #1609 |
| curability | #1610 |
| general surgery | #1613 |
| 162 | #1613 |
| ethinylestradiol | #1614 |
| recommending | #1615 |
| factors tomography | #1616 |
| prospective cohort studies | #1616 |
| postpartum period | #1616 |
| positive effects | #1616 |
| tests reproducibility | #1616 |
| perinatal outcome | #1618 |
| 155 | #1618 |
| cvd patients | #1619 |
| female hemostasis | #1619 |
| imaging tomography | #1619 |
| proportion | #1620 |
| uncertain | #1621 |
| 12month followup | #1621 |
| 079 | #1623 |
| competing risk | #1628 |
| isis | #1630 |
| major | #1631 |
| venous disease | #1632 |
| incidentally | #1632 |
| pa patients | #1632 |
| clinical patients | #1633 |
| fresh frozen plasma | #1633 |
| double | #1639 |
| study outcomes | #1639 |
| 029 | #1642 |
| 181 | #1643 |
| stroke prevention | #1644 |
| ctni | #1644 |
| patients hospitalized | #1647 |
| mismatched | #1648 |
| 997 | #1651 |
| dorsiflexion | #1651 |
| 35 years | #1652 |
| ≤4 | #1652 |
| studies data | #1653 |
| thrombin activity | #1653 |
| clotting | #1656 |
| remaining | #1660 |
| plasma concentration | #1661 |
| outcome data | #1663 |
| spiral | #1669 |
| homocysteine levels | #1670 |
| disease adult | #1670 |
| thrombi | #1674 |
| inpatient treatment | #1676 |
| daily dosing | #1676 |
| plasma level | #1677 |
| deficiency | #1677 |
| warfarin dose | #1680 |
| arthroscopy | #1684 |
| unreliable | #1686 |
| steroidal anti | #1686 |
| patients acs | #1687 |
| thrombin | #1690 |
| severe renal | #1694 |
| patients brain metastases | #1695 |
| prospective | #1702 |
| necrosis factor | #1705 |
| highest risk | #1707 |
| cancer screening | #1708 |
| awaiting | #1710 |
| yielded | #1712 |
| 033 | #1712 |
| hemorheology | #1715 |
| intravenous | #1715 |
| hematologic malignancies | #1720 |
| bronchospasm | #1720 |
| mb | #1721 |
| female femoral | #1721 |
| diagnostic evaluation | #1721 |
| cardioembolic | #1722 |
| cumulative incidence | #1723 |
| laser doppler | #1724 |
| 107 | #1726 |
| conference | #1726 |
| derived microparticles | #1729 |
| volunteer | #1730 |
| 021 | #1730 |
| 161 | #1733 |
| percentage patients | #1734 |
| east asian | #1735 |
| clinical scores | #1735 |
| patients icu | #1736 |
| rico | #1737 |
| 500 | #1738 |
| minor | #1739 |
| revised | #1744 |
| 691 | #1745 |
| patients ventricular | #1745 |
| table | #1745 |
| profession | #1746 |
| risk cardiovascular events | #1747 |
| hyperinsulinaemia | #1747 |
| turp | #1749 |
| apc | #1749 |
| pselectin | #1750 |
| homozygosity | #1750 |
| replacement | #1750 |
| 128 | #1752 |
| 133 | #1753 |
| intracranial hemorrhages | #1753 |
| 3 studies | #1755 |
| spontaneous | #1756 |
| arterial occlusive | #1758 |
| patients randomized | #1759 |
| audiometry | #1760 |
| assessor | #1760 |
| treatment recommendations | #1760 |
| current treatment | #1761 |
| primary setting | #1762 |
| long‐term | #1763 |
| fx | #1764 |
| human insulin | #1764 |
| duplicate | #1769 |
| initial management | #1770 |
| hemorrhage | #1770 |
| arteriosclerosis | #1770 |
| 2 6 | #1774 |
| allcause death | #1774 |
| 28 weeks | #1781 |
| hemostasis humans | #1782 |
| trough levels | #1785 |
| infusions | #1787 |
| ethinyl estradiol | #1789 |
| clinical consequences | #1790 |
| selfmanagement | #1790 |
| microparticle | #1793 |
| reid | #1793 |
| vascular surgical | #1794 |
| cardiac troponin | #1794 |
| healthy male volunteers | #1799 |
| 042 | #1800 |
| 020 | #1802 |
| aggregation inhibitors | #1802 |
| retrospective analysis | #1805 |
| hemophilia humans | #1808 |
| unpublished | #1810 |
| slc6a4 | #1812 |
| tumor necrosis | #1812 |
| 95 specificity | #1812 |
| overlapped | #1814 |
| 51 | #1815 |
| 078 | #1818 |
| economic evaluation | #1819 |
| conjoint | #1819 |
| interobserver | #1823 |
| awareness | #1824 |
| screening middle | #1825 |
| preference | #1825 |
| 303 | #1828 |
| placebo 95 | #1832 |
| undergoing coronary | #1834 |
| compressibility | #1837 |
| definite | #1837 |
| kaplanmeier estimate | #1838 |
| cushing | #1838 |
| severe sepsis | #1839 |
| central venous | #1842 |
| 1 week | #1842 |
| workup | #1848 |
| orthopaedic | #1849 |
| explanations | #1852 |
| hydroxyethyl starch | #1852 |
| 160 | #1854 |
| fibrinopeptide | #1862 |
| cancer therapies | #1865 |
| alpha 2 | #1867 |
| gramnegative | #1869 |
| serially | #1870 |
| humans pregnancy | #1874 |
| separately | #1876 |
| oral anticoagulation | #1880 |
| diagnostic techniques | #1892 |
| thromboses | #1892 |
| shrs | #1892 |
| lower incidence | #1893 |
| stable patients | #1895 |
| 5 10 | #1897 |
| 067 | #1897 |
| contraindications | #1900 |
| extremity | #1901 |
| tnf | #1901 |
| diagnostic testing | #1901 |
| clt | #1905 |
| hazard ratio | #1906 |
| induced thrombocytopenia | #1906 |
| plaster | #1906 |
| differential effects | #1907 |
| 95 year | #1909 |
| efficacy treatment | #1910 |
| referral | #1910 |
| random | #1911 |
| plato | #1913 |
| experimental mice mice | #1916 |
| 238 | #1918 |
| randomized | #1919 |
| 793 | #1920 |
| 13 patients | #1920 |
| administration | #1921 |
| pregnancy treatment | #1922 |
| stroke 95 | #1923 |
| 868 | #1923 |
| biotin | #1924 |
| 55 years | #1924 |
| venous pressure | #1926 |
| trials patients | #1926 |
| μg | #1927 |
| intracranial hemorrhage | #1927 |
| coronary syndromes | #1928 |
| 272 | #1929 |
| cardiovascular events patients | #1930 |
| chimpanzee | #1931 |
| adjusted | #1932 |
| glucocorticoid | #1934 |
| nonfatal | #1934 |
| relative risks | #1935 |
| 3months | #1935 |
| acute | #1936 |
| 17 | #1936 |
| thrombolytic treatment | #1937 |
| 27 | #1938 |
| randomized placebo | #1947 |
| safety effectiveness | #1950 |
| femoral vein | #1950 |
| 0·5 | #1952 |
| medical illness | #1954 |
| overtreatment | #1955 |
| prolongation | #1958 |
| intravascular | #1959 |
| major risk | #1960 |
| advanced age | #1961 |
| investigators | #1962 |
| observer | #1962 |
| 1050 | #1965 |
| permanent | #1966 |
| 80 female | #1967 |
| hyperglycaemia | #1970 |
| coronary angioplasty | #1971 |
| surgical blood | #1973 |
| 48 hours | #1973 |
| fibrin clot | #1973 |
| potent inhibitor | #1976 |
| renewed | #1976 |
| topic clinical trials | #1978 |
| hyperaldosteronism | #1981 |
| specificity ultrasonography | #1981 |
| 771 | #1981 |
| computerised | #1982 |
| patients pancreatic | #1985 |
| treatment cancer | #1986 |
| 1·0 | #1986 |
| randomized controlled | #1988 |
| coumarins | #1990 |
| 177 | #1991 |
| prospero | #1992 |
| 018 | #1992 |
| cmax | #1994 |
| drug drug therapy | #1994 |
| computerized | #1995 |
| cvt | #1995 |
| hemorrhage patients | #1996 |
| ors | #1998 |
| 602 | #1999 |
| 3 months patients | #2000 |
| clinical severity | #2000 |
| autopsy | #2000 |
| transient increase | #2000 |
| 53 | #2003 |
| 7 patients | #2006 |
| pneumonia patients | #2006 |
| pih | #2011 |
| mantel | #2013 |
| catheterization central | #2014 |
| angina unstable | #2017 |
| mongrel | #2017 |
| poc | #2019 |
| 225 | #2020 |
| type plasminogen | #2023 |
| pathophysiologic | #2024 |
| 35 | #2025 |
| patients statins | #2026 |
| annual | #2028 |
| 15th | #2031 |
| atheroma | #2032 |
| patients lung | #2033 |
| 097 | #2033 |
| pertechnetate | #2036 |
| costs cost | #2041 |
| medical record | #2041 |
| undergoing major | #2042 |
| abstracts | #2042 |
| questioned | #2043 |
| thrice | #2045 |
| prediction rule | #2045 |
| dichotomous | #2046 |
| normal | #2048 |
| superior vena cava | #2051 |
| quartiles | #2051 |
| inadequately | #2052 |
| pregnancy trimester | #2053 |
| 277 | #2053 |
| controversial | #2055 |
| stent implantation | #2056 |
| adherence guidelines | #2056 |
| hospitalized | #2057 |
| randomized comparison | #2060 |
| outpatient | #2061 |
| interobserver variability | #2062 |
| varies | #2063 |
| requested | #2063 |
| clinical indications | #2064 |
| biological neoplasms | #2064 |
| hemostatics | #2070 |
| mcnemar | #2074 |
| national institute | #2074 |
| 188 | #2074 |
| familial hypercholesterolemia | #2077 |
| unavailable | #2079 |
| searched | #2082 |
| disseminate | #2083 |
| ristocetin | #2086 |
| media thickness | #2087 |
| bypasses | #2087 |
| 03 | #2089 |
| versions | #2091 |
| 114 | #2092 |
| square distribution | #2092 |
| tissue plasminogen | #2093 |
| preformed | #2099 |
| reference range | #2099 |
| 038 | #2100 |
| desmopressin | #2101 |
| 59 | #2101 |
| lifetime risk | #2101 |
| placebos | #2102 |
| concealment | #2104 |
| hospital treatment | #2106 |
| fibrin deposition | #2107 |
| argatroban | #2108 |
| 1966 | #2109 |
| 031 | #2109 |
| substantial | #2109 |
| aged 80 | #2111 |
| debated | #2116 |
| jugular vein | #2117 |
| unnecessary | #2118 |
| independently | #2118 |
| exists | #2119 |
| initial | #2119 |
| development validation | #2120 |
| 11 | #2122 |
| clinicaltrialsgov | #2122 |
| coronary stent | #2122 |
| original | #2125 |
| acl reconstruction | #2125 |
| topic surveys | #2127 |
| patients cardiovascular disease | #2127 |
| chose | #2129 |
| controlled | #2129 |
| current recommendations | #2131 |
| odds ratios | #2132 |
| protamines | #2134 |
| congress | #2134 |
| 190 | #2136 |
| 788 | #2137 |
| hip arthroplasty | #2139 |
| heterozygous | #2141 |
| antagonists | #2142 |
| live | #2145 |
| clot | #2145 |
| bodyweight | #2146 |
| professionals | #2146 |
| pancreatic cancer patients | #2157 |
| committee | #2160 |
| oestrogens | #2160 |
| lowdose aspirin | #2163 |
| academic medical | #2167 |
| drains | #2170 |
| embase | #2171 |
| fibrinogen | #2175 |
| 1998 | #2178 |
| trimesters | #2179 |
| reproductive age | #2182 |
| 674 | #2183 |
| advanced cancer | #2183 |
| giant cell arteritis | #2185 |
| fifty | #2185 |
| 2 × | #2185 |
| patients diagnosed | #2187 |
| 631 | #2188 |
| controlled study | #2192 |
| superficial | #2194 |
| difference incidence | #2198 |
| adjust | #2202 |
| diagnostic performance | #2204 |
| increased patients | #2205 |
| pravastatin | #2205 |
| antagonist | #2206 |
| clinical implications | #2208 |
| lower limbs | #2209 |
| diagnosis differential | #2212 |
| neutrophil elastase | #2212 |
| doubled | #2213 |
| pao2 | #2219 |
| 364 | #2219 |
| insufficient | #2221 |
| comparing | #2222 |
| 94 | #2225 |
| differential female | #2225 |
| lung perfusion | #2226 |
| italian society | #2227 |
| 76 | #2233 |
| takeda | #2236 |
| nationwide cohort study | #2245 |
| clot formation | #2247 |
| congenital heart disease | #2252 |
| hemorrhages | #2253 |
| clots | #2257 |
| hivinfected patients | #2257 |
| kilogram | #2259 |
| aprotinin | #2261 |
| 8000 | #2264 |
| hyperthyroidism | #2265 |
| stroke aged | #2265 |
| 12 | #2266 |
| metaanalysis | #2267 |
| 6 months | #2267 |
| patients developed | #2273 |
| reverses | #2273 |
| arterial | #2274 |
| intrinsic pathway | #2275 |
| famine | #2278 |
| 656 | #2279 |
| ultrasonographic | #2281 |
| based case | #2284 |
| setting | #2284 |
| 14 patients | #2286 |
| ft3 | #2288 |
| case control | #2291 |
| patients heart failure | #2293 |
| aged molecular | #2295 |
| daily dose | #2296 |
| sole | #2298 |
| strategy | #2303 |
| 88 | #2308 |
| 0047 | #2310 |
| normalised | #2312 |
| tests | #2314 |
| metaanalysis studies | #2314 |
| initial therapy | #2316 |
| nephelometry | #2316 |
| obstetrics | #2317 |
| adjustments | #2319 |
| method female | #2324 |
| humans myocardial | #2324 |
| methodological | #2325 |
| 60 | #2327 |
| normalized | #2329 |
| brachial | #2332 |
| gradually | #2335 |
| random sample | #2336 |
| positive predictive | #2337 |
| transfusion requirements | #2340 |
| ultrasonography doppler | #2341 |
| 543 | #2343 |
| lacked | #2344 |
| inhibitor | #2344 |
| prescribe | #2347 |
| illness severity | #2350 |
| 20 weeks | #2351 |
| thr | #2353 |
| prefer | #2354 |
| cancer progression | #2364 |
| 053 | #2371 |
| 118 | #2372 |
| receiving | #2374 |
| 099 | #2375 |
| risk bias | #2375 |
| patients active | #2376 |
| hemostasis | #2377 |
| predictable | #2377 |
| enrolling | #2379 |
| acute coronary syndromes | #2379 |
| 187 | #2381 |
| dosing regimen | #2382 |
| anticardiolipin | #2382 |
| 145 | #2387 |
| scintigraphy | #2389 |
| 140 | #2391 |
| 244 | #2393 |
| complication rate | #2400 |
| patients liver cirrhosis | #2401 |
| 757 | #2401 |
| 086 | #2402 |
| letters | #2405 |
| curable | #2406 |
| protein | #2413 |
| periodicals | #2413 |
| postinjection | #2413 |
| risk estimates | #2414 |
| 22 | #2415 |
| sphingosine1 | #2415 |
| study drug | #2424 |
| internal medicine | #2424 |
| 32 | #2425 |
| guidelines | #2426 |
| sensitivity 100 | #2426 |
| coagulants | #2430 |
| legs | #2430 |
| 0048 | #2430 |
| 002 | #2430 |
| patients adult | #2431 |
| ci95 | #2432 |
| normal range | #2433 |
| prolonging | #2434 |
| ptca | #2434 |
| aminoglycoside | #2435 |
| cindex | #2437 |
| 030 | #2438 |
| cumulative | #2439 |
| 166 | #2441 |
| endogenous | #2445 |
| microplate | #2446 |
| 719 | #2448 |
| turbidimetry | #2448 |
| administration schedule | #2449 |
| transmigration | #2453 |
| homocysteine | #2454 |
| anticoagulant activity | #2455 |
| ≥75 | #2459 |
| extensively | #2463 |
| prognostic patients | #2464 |
| watchful | #2464 |
| potential benefits | #2466 |
| nephrotoxic | #2468 |
| therapy acute | #2468 |
| comprised | #2469 |
| 477 | #2469 |
| pharmacologic | #2473 |
| consisted | #2474 |
| current review | #2476 |
| cancer population | #2476 |
| 05 | #2481 |
| 50 | #2482 |
| 648 | #2485 |
| pathway inhibitor | #2485 |
| treatment efficacy | #2489 |
| 829 | #2490 |
| 1015 | #2490 |
| chest | #2493 |
| duration | #2493 |
| 25 | #2495 |
| illness tomography | #2503 |
| 616 | #2503 |
| bnp | #2504 |
| subsequent pregnancies | #2505 |
| 522 | #2507 |
| movie | #2508 |
| recurrence retrospective | #2509 |
| unstable angina | #2510 |
| presentation | #2512 |
| superinfection | #2513 |
| comprising | #2515 |
| drug female humans | #2516 |
| 479 | #2516 |
| sulfates | #2519 |
| 750 | #2520 |
| 463 | #2521 |
| neutrophil extracellular traps | #2521 |
| accurate diagnosis | #2523 |
| 152 | #2523 |
| treatment arms | #2524 |
| scientific | #2529 |
| establish | #2534 |
| 0046 | #2537 |
| 164 | #2537 |
| 874 | #2537 |
| nematode | #2540 |
| 67 | #2542 |
| pyrazoles | #2547 |
| arrive | #2549 |
| decided | #2552 |
| effectiveness analysis | #2553 |
| hydroxyethyl | #2560 |
| haematology | #2560 |
| hours | #2560 |
| 928 | #2565 |
| radiologist | #2566 |
| roc | #2568 |
| biologic | #2569 |
| clinical settings | #2570 |
| infrequent | #2572 |
| kits | #2574 |
| 73 | #2574 |
| humans logistic | #2574 |
| pill | #2575 |
| prevalence | #2575 |
| patients total | #2577 |
| translate | #2577 |
| 973 | #2578 |
| specificity | #2580 |
| cancer chemotherapy | #2581 |
| 374 | #2582 |
| 591 | #2585 |
| efficacious | #2585 |
| pivotal | #2588 |
| analysed | #2589 |
| bolus | #2595 |
| 657 | #2596 |
| multiple organ failure | #2599 |
| hypercholesterolaemia | #2600 |
| doppler duplex | #2602 |
| laboratory investigation | #2603 |
| manifest | #2605 |
| burden disease | #2605 |
| parenteral | #2606 |
| metaregression | #2606 |
| patients 2 | #2608 |
| fatal outcome | #2608 |
| 098 | #2610 |
| p0001 patients | #2613 |
| died | #2615 |
| 886 | #2618 |
| percent | #2619 |
| cost analysis | #2620 |
| aviation | #2620 |
| concentrate | #2621 |
| occlusive | #2622 |
| presenting | #2625 |
| assess | #2626 |
| prescribed | #2631 |
| agents steroidal | #2633 |
| chondroitin | #2635 |
| coincided | #2635 |
| trials rcts | #2635 |
| 10 day | #2637 |
| attractive | #2641 |
| 345 | #2641 |
| mutation patients | #2642 |
| greatest risk | #2643 |
| 23 patients | #2645 |
| decision | #2649 |
| risk cardiovascular disease | #2656 |
| 134 | #2659 |
| recurrence | #2660 |
| hamilton | #2661 |
| c677 | #2662 |
| benzimidazoles | #2662 |
| 679 | #2663 |
| shr | #2667 |
| quartile | #2674 |
| receive | #2675 |
| 439 | #2677 |
| valsalva | #2680 |
| trials | #2682 |
| 516 | #2683 |
| outcome ultrasonography | #2683 |
| initial dose | #2685 |
| iii | #2685 |
| inconclusive | #2686 |
| tmax | #2687 |
| mortality 95 | #2688 |
| tissue plasminogen activator | #2690 |
| 594 | #2691 |
| aso | #2691 |
| bleed | #2692 |
| schedule female | #2694 |
| stillbirth | #2698 |
| patients risk factors | #2702 |
| early discharge | #2703 |
| 14 | #2706 |
| previous stroke | #2720 |
| prematurely | #2725 |
| 897 | #2727 |
| txb2 | #2729 |
| dose low | #2732 |
| management strategies | #2732 |
| cart | #2736 |
| 595 | #2737 |
| classifications | #2739 |
| 427 | #2739 |
| therapeutic options | #2744 |
| risk ratio | #2745 |
| predetermined | #2746 |
| 848 | #2746 |
| patients asthma | #2747 |
| baseline characteristics | #2747 |
| direct comparison | #2752 |
| pan | #2755 |
| nephrotoxicity | #2758 |
| randomised trial | #2764 |
| contusions | #2765 |
| management acute | #2768 |
| 143 | #2768 |
| confounded | #2769 |
| alpha animals | #2772 |
| antithyroid | #2772 |
| expert consensus | #2772 |
| active control | #2775 |
| thrombomodulin | #2776 |
| inpatient | #2776 |
| 563 | #2777 |
| compression | #2778 |
| dosages | #2779 |
| leukocyte count | #2781 |
| mass screening | #2782 |
| 466 | #2783 |
| hemostatic | #2784 |
| primary outcomes | #2785 |
| percentiles | #2788 |
| 90th | #2789 |
| nadph2 | #2791 |
| consecutive series | #2802 |
| 402 | #2802 |
| reaching | #2805 |
| cirrhosis patients | #2805 |
| international | #2809 |
| standardized | #2811 |
| secondary | #2811 |
| embolic | #2812 |
| 406 | #2813 |
| follow studies | #2813 |
| prevalence risk factors | #2814 |
| httlpr | #2816 |
| discriminant analysis | #2817 |
| selectins | #2819 |
| consisting | #2823 |
| equivalency | #2825 |
| bid | #2826 |
| antiplatelet drugs | #2826 |
| genetic variations | #2830 |
| 557 | #2833 |
| male mass | #2834 |
| contacting | #2835 |
| recurrence rate | #2835 |
| helminth | #2836 |
| ketoprostaglandin | #2836 |
| crossover | #2839 |
| kruskal | #2839 |
| 554 | #2843 |
| partum | #2847 |
| anterior cruciate ligament | #2850 |
| carboxypeptidase | #2851 |
| iii trials | #2852 |
| doppler ultrasonography | #2852 |
| ≤2 | #2853 |
| postoperative patients | #2854 |
| new treatment | #2857 |
| post discharge | #2857 |
| specialised | #2858 |
| methods prospective | #2862 |
| 497 | #2870 |
| discontinuation | #2871 |
| 264 | #2876 |
| 628 | #2877 |
| 52 | #2879 |
| excessive | #2880 |
| trimester pregnancy | #2880 |
| hit | #2884 |
| mdct | #2885 |
| balloon angioplasty | #2886 |
| anterior cruciate | #2887 |
| 670 | #2895 |
| eligibility | #2896 |
| systematic review metaanalysis | #2897 |
| 21 | #2897 |
| central venous catheters | #2900 |
| statin | #2902 |
| severe asthma | #2903 |
| feasible | #2903 |
| slight | #2903 |
| 12 patients | #2908 |
| concomitantly | #2910 |
| supposed | #2911 |
| insulin receptors | #2914 |
| leading death | #2917 |
| lowrisk patients | #2917 |
| 39 | #2919 |
| routine clinical practice | #2920 |
| referrals | #2921 |
| older children | #2922 |
| proportions | #2928 |
| 993 | #2928 |
| clear | #2932 |
| 2400 | #2934 |
| risk stratification patients | #2934 |
| aggregation platelet | #2941 |
| control subjects patients | #2945 |
| meier estimate | #2946 |
| addison | #2952 |
| portal | #2954 |
| 100 | #2956 |
| returned | #2957 |
| 270 | #2960 |
| 010 | #2960 |
| 20 | #2961 |
| exercise therapy | #2962 |
| followup | #2962 |
| transabdominal | #2963 |
| 132 | #2974 |
| echocardiography patients | #2975 |
| 123 | #2978 |
| risk myocardial | #2981 |
| lecture | #2984 |
| declare | #2984 |
| eclampsia pregnancy | #2986 |
| glucose levels | #2987 |
| preoperatively | #2988 |
| adult blood | #2990 |
| point | #2991 |
| pneumatic | #2991 |
| n4 | #2992 |
| undefined | #2993 |
| treatable | #2996 |
| cvr | #2997 |
| microvessels | #2998 |
| 499 | #3004 |
| prostacyclin | #3012 |
| dipyridamole | #3013 |
| antigen levels | #3015 |
| factors surveys | #3015 |
| 2 patients | #3016 |
| 081 | #3019 |
| double‐blind | #3022 |
| 35 patients | #3023 |
| nested case | #3025 |
| early recognition | #3025 |
| comorbidity | #3026 |
| contraindication | #3028 |
| intention | #3035 |
| extremities | #3038 |
| 419 | #3040 |
| 50 years | #3040 |
| patients hf | #3041 |
| lymphopenia | #3043 |
| relevant articles | #3044 |
| 095 | #3045 |
| prenatal exposure | #3047 |
| summarize | #3050 |
| respondents | #3052 |
| respects | #3060 |
| subcutaneous injection | #3062 |
| nomogram | #3063 |
| 80 | #3063 |
| fourteen | #3065 |
| 95 p0001 | #3066 |
| patients data | #3067 |
| study prevalence | #3071 |
| subsequently | #3076 |
| 2 4 | #3076 |
| disease aged | #3077 |
| 524 | #3082 |
| 342 | #3083 |
| angioplasty | #3088 |
| chronic renal failure | #3088 |
| independent risk factors | #3089 |
| healthy | #3090 |
| clinical risk factors | #3098 |
| lancet | #3102 |
| reviewer | #3104 |
| practice guidelines | #3109 |
| benchmark | #3110 |
| trimester | #3110 |
| npv | #3115 |
| pregnant woman | #3119 |
| neutrophil activation | #3120 |
| wallis | #3122 |
| oac | #3122 |
| lifelong | #3122 |
| inadequacy | #3123 |
| intravenously | #3129 |
| claimed | #3132 |
| 136 | #3134 |
| 12 months | #3134 |
| meta‐analysis | #3137 |
| 082 | #3142 |
| levels risk | #3142 |
| placentae | #3143 |
| randomized clinical trial | #3145 |
| time interval | #3147 |
| arthroscopic | #3149 |
| 507 | #3153 |
| idiopathic | #3153 |
| marathon | #3155 |
| mega | #3156 |
| avoiding | #3158 |
| radiologists | #3165 |
| initial presentation | #3172 |
| seventh | #3173 |
| cornerstone | #3182 |
| test | #3184 |
| 494 | #3188 |
| revascularisation | #3191 |
| 409 | #3193 |
| diethylstilbestrol | #3194 |
| pregnancy women | #3194 |
| pacientes | #3197 |
| 945 | #3198 |
| plasmin | #3198 |
| therapy risk | #3199 |
| tenth | #3199 |
| gold standard | #3200 |
| vivo model | #3205 |
| res | #3207 |
| patient preference | #3211 |
| catheter | #3212 |
| cancer types | #3219 |
| suggested | #3219 |
| intravenous infusion | #3223 |
| 153 | #3223 |
| 72 hours | #3225 |
| 605 | #3227 |
| methodological quality | #3238 |
| observers | #3239 |
| meetings | #3241 |
| recombinant | #3241 |
| intravenous administration | #3242 |
| risk stroke | #3246 |
| alternative | #3249 |
| bivalirudin | #3251 |
| 198 | #3251 |
| hypothyroid | #3253 |
| 29 | #3253 |
| scoring | #3255 |
| judgement | #3255 |
| normotensive | #3256 |
| 054 | #3257 |
| patient preferences | #3261 |
| glargine | #3265 |
| validated | #3266 |
| patients evidence | #3267 |
| 116 | #3268 |
| immunoassay | #3271 |
| 414 | #3275 |
| 6 | #3277 |
| tranexamic acid | #3279 |
| gbd | #3280 |
| contraceptive | #3281 |
| inclusion | #3284 |
| arthroplasty replacement | #3288 |
| coumarin | #3289 |
| tumor markers | #3289 |
| replace | #3290 |
| 65 years | #3291 |
| swan | #3292 |
| recurrence rates | #3294 |
| efficacy outcomes | #3299 |
| 812 | #3314 |
| rtpa | #3315 |
| reversibility | #3316 |
| anticardiolipin antibodies | #3319 |
| discriminant | #3321 |
| vascular risk | #3322 |
| 104 | #3325 |
| hemophilia | #3328 |
| 972 | #3329 |
| reduces | #3330 |
| 465 | #3330 |
| cruciate ligament | #3331 |
| patients symptoms | #3334 |
| 74 | #3337 |
| meta | #3338 |
| acute coronary syndrome | #3339 |
| cerebrovascular disease | #3344 |
| inpatients | #3344 |
| 362 | #3349 |
| evaluating | #3349 |
| diagnosing | #3354 |
| spontaneous abortion | #3354 |
| 273 | #3355 |
| diagnosis cancer | #3356 |
| common complication | #3356 |
| 15 | #3357 |
| lysate | #3358 |
| 581 | #3359 |
| 092 | #3361 |
| miscarriages | #3365 |
| prevalent | #3371 |
| thrombolysis | #3376 |
| treatment modalities | #3377 |
| 363 | #3378 |
| humans lower | #3379 |
| concluded | #3379 |
| 301 | #3379 |
| intima media | #3380 |
| computed tomography | #3382 |
| hematomas | #3387 |
| function patients | #3389 |
| calf | #3389 |
| contraception | #3390 |
| repeated | #3394 |
| 413 | #3395 |
| p0002 | #3397 |
| cava | #3399 |
| 311 | #3400 |
| tunica | #3403 |
| acute treatment | #3403 |
| 553 | #3403 |
| humans kaplan | #3408 |
| saved | #3415 |
| differs | #3418 |
| randomisation | #3419 |
| preventive | #3419 |
| hypothesised | #3420 |
| surgical patients | #3420 |
| study risk | #3420 |
| thrombocythemia | #3422 |
| odds | #3424 |
| confirm | #3425 |
| testimony | #3430 |
| competing | #3434 |
| natriuretic | #3437 |
| 70 | #3439 |
| ease | #3443 |
| asian patients | #3444 |
| 124 | #3445 |
| 519 | #3447 |
| 487 | #3451 |
| 168 | #3452 |
| prevalence incidence | #3452 |
| evening | #3458 |
| covid19 infection | #3464 |
| differ | #3470 |
| 34 | #3470 |
| intensive chemotherapy | #3471 |
| pregnancy complications | #3472 |
| patients receive | #3472 |
| worsened | #3476 |
| induced platelet | #3479 |
| undiagnosed | #3482 |
| antiphospholipid | #3485 |
| cancer metastasis | #3485 |
| increased morbidity | #3486 |
| asymptomatic | #3487 |
| lower leg | #3487 |
| personyears | #3490 |
| paradox | #3490 |
| pacemaker | #3493 |
| statistical methods | #3494 |
| convergent validity | #3496 |
| failure hf | #3497 |
| 201 | #3504 |
| treat | #3506 |
| hemorrhagic complications | #3506 |
| inhibitors | #3506 |
| 938 | #3513 |
| tomography angiography | #3521 |
| confirmed | #3522 |
| discusses | #3522 |
| 291 | #3527 |
| quintiles | #3529 |
| 95 confidence intervals | #3530 |
| human cytomegalovirus | #3533 |
| lupus | #3533 |
| areas covered | #3537 |
| guidance | #3541 |
| societies | #3541 |
| 113 | #3544 |
| current practice | #3551 |
| gastro | #3551 |
| 10 | #3552 |
| stroke risk | #3559 |
| baboons | #3560 |
| 344 | #3562 |
| benefits risks | #3564 |
| neutralize | #3565 |
| nsaids | #3566 |
| bibliographic | #3567 |
| depends | #3571 |
| patients recurrence | #3573 |
| inconsistent | #3575 |
| safety profiles | #3580 |
| 508 | #3584 |
| evaluates | #3592 |
| prognosis prospective | #3596 |
| necessity | #3596 |
| patient management | #3598 |
| prognostic significance | #3604 |
| vitamin | #3605 |
| risk stratification | #3606 |
| consensus document | #3617 |
| platelet function | #3619 |
| treated | #3619 |
| platelet activation | #3622 |
| interval | #3622 |
| mutation | #3624 |
| lipid profiles | #3626 |
| kappa | #3629 |
| q3 | #3629 |
| organ damage | #3635 |
| analysis performed | #3640 |
| 75 | #3641 |
| homozygote | #3642 |
| undergo | #3642 |
| bypass surgery | #3642 |
| p006 | #3645 |
| externally | #3645 |
| occlusions | #3646 |
| 1960 | #3649 |
| 30 | #3649 |
| interindividual variability | #3651 |
| fibrillation | #3651 |
| coronary events | #3656 |
| atherogenic | #3658 |
| newer | #3662 |
| patients 95 | #3667 |
| outcome administration | #3671 |
| optimal management | #3671 |
| endovascular treatment | #3678 |
| blinding | #3679 |
| treatment complications | #3680 |
| limited data | #3683 |
| 68 | #3684 |
| clopidogrel | #3685 |
| mammography | #3693 |
| myalgia | #3703 |
| 478 | #3706 |
| rationale | #3707 |
| 813 | #3708 |
| rebound | #3720 |
| diagnostic process | #3721 |
| drug monitoring | #3721 |
| pharmacodynamics | #3725 |
| inhibitors humans | #3725 |
| 130 | #3729 |
| unknown | #3731 |
| patient population | #3733 |
| serine proteases | #3736 |
| 349 | #3738 |
| humans intracranial | #3739 |
| effective | #3739 |
| factor 4 | #3741 |
| 585 | #3743 |
| 299 | #3744 |
| network meta | #3746 |
| homozygous | #3747 |
| 495 | #3750 |
| practitioner | #3752 |
| deterioration | #3754 |
| randomised | #3754 |
| objectives | #3759 |
| 8 patients | #3762 |
| subgroup analyses | #3762 |
| 00001 | #3765 |
| host defense | #3769 |
| statin therapy | #3772 |
| scarce | #3773 |
| clinicians patients | #3774 |
| computed ultrasonography | #3774 |
| inherited | #3775 |
| interpretable | #3778 |
| 517 | #3778 |
| 483 | #3782 |
| total knee arthroplasty | #3789 |
| thyroid hormones | #3789 |
| aminoglycosides | #3789 |
| 525 | #3791 |
| 412 | #3795 |
| 441 | #3797 |
| life illness | #3801 |
| 333 | #3802 |
| versus | #3803 |
| vessel wall | #3804 |
| compelling | #3804 |
| preexisting | #3808 |
| outcome measure | #3814 |
| patients lung cancer | #3815 |
| 330 | #3815 |
| valid | #3816 |
| iu | #3818 |
| 55 patients | #3821 |
| fv | #3823 |
| stasis | #3824 |
| lost | #3825 |
| compares | #3830 |
| itching | #3831 |
| proved | #3834 |
| osmolar | #3837 |
| elective | #3838 |
| hydrolases | #3839 |
| patient education | #3843 |
| 197 | #3849 |
| irs | #3856 |
| meeting | #3856 |
| anaesthesia | #3857 |
| 4 patients | #3858 |
| congresses | #3859 |
| review data | #3860 |
| acquired resistance | #3860 |
| male neoplasms | #3862 |
| preferred | #3864 |
| occurring | #3867 |
| death | #3880 |
| cancer survival | #3884 |
| optimisation | #3884 |
| record | #3885 |
| sensitivity | #3885 |
| avoids | #3887 |
| calculated | #3888 |
| 184 | #3890 |
| difference | #3890 |
| 351 | #3890 |
| 10000 | #3902 |
| halflives | #3903 |
| methylamines | #3903 |
| methimazole | #3904 |
| patients time | #3905 |
| incidence prevalence | #3908 |
| specificity tomography | #3915 |
| angiography | #3915 |
| coronary thrombosis | #3918 |
| decide | #3927 |
| 474 | #3931 |
| ankle | #3932 |
| 955 | #3935 |
| 458 | #3938 |
| jak2 | #3939 |
| extravasation | #3945 |
| 405 | #3946 |
| case fatality | #3946 |
| preeclampsia | #3952 |
| neurology | #3953 |
| 56 | #3956 |
| dichotomy | #3961 |
| p004 | #3961 |
| randomized clinical trials | #3963 |
| women | #3964 |
| carboxypeptidases | #3965 |
| postoperatively | #3966 |
| clinical effectiveness | #3968 |
| risk cancer | #3970 |
| uncontrolled | #3970 |
| behalf | #3971 |
| austrian | #3971 |
| cardiovascular events | #3972 |
| 2nd | #3975 |
| data studies | #3975 |
| quality assurance | #3980 |
| pregnancy | #3982 |
| 986 | #3982 |
| continuous infusion | #3983 |
| unstable | #3986 |
| flying | #3986 |
| month | #3987 |
| 488 | #3990 |
| systematic analysis | #3994 |
| sequentially | #4006 |
| calculate | #4010 |
| lower risk | #4011 |
| limited evidence | #4014 |
| patients evaluated | #4016 |
| scored | #4023 |
| secondary prevention | #4026 |
| 538 | #4028 |
| equivalence | #4029 |
| gln | #4031 |
| meyer | #4032 |
| cerebral venous | #4041 |
| 296 | #4045 |
| introduction | #4045 |
| 423 | #4047 |
| 262 | #4051 |
| ended | #4052 |
| validating | #4058 |
| received | #4062 |
| recurrent disease | #4066 |
| cruciate | #4073 |
| elevated | #4074 |
| compare | #4075 |
| pcc | #4077 |
| bariatric | #4077 |
| avoid | #4080 |
| 429 | #4081 |
| 326 | #4083 |
| hour | #4088 |
| natriuretic peptide | #4089 |
| oligosaccharides | #4089 |
| angioplasty balloon | #4091 |
| maneuver | #4092 |
| 3000 | #4093 |
| 16 | #4098 |
| cutoff | #4099 |
| indications | #4099 |
| activation | #4099 |
| contact | #4102 |
| pharmacological | #4106 |
| infusion rate | #4109 |
| 392 | #4113 |
| 335 | #4117 |
| 6 months treatment | #4119 |
| ptm | #4120 |
| completing | #4125 |
| patients low risk | #4133 |
| 008 | #4137 |
| withdrawn | #4137 |
| 41 | #4138 |
| bms | #4146 |
| patients died | #4149 |
| medical students | #4152 |
| haemorrhagic | #4154 |
| continue | #4158 |
| study control | #4161 |
| nulliparous | #4167 |
| 2030 | #4171 |
| patients prostate cancer | #4171 |
| antitumour | #4177 |
| steroidal | #4178 |
| multidisciplinary approach | #4189 |
| direct | #4192 |
| therapy combination | #4198 |
| casts | #4200 |
| 411 | #4212 |
| 485 | #4212 |
| medical center | #4214 |
| 408 | #4215 |
| weighted | #4221 |
| additional | #4222 |
| 452 | #4223 |
| 121 | #4226 |
| 289 | #4226 |
| trough | #4229 |
| crosssectional analysis | #4230 |
| p0005 | #4230 |
| hormonal | #4234 |
| veins | #4235 |
| patients mortality | #4242 |
| cox regression | #4242 |
| 178 | #4246 |
| nsaid | #4261 |
| 263 | #4263 |
| abbreviated | #4267 |
| encountered | #4268 |
| atrial fibrillation patients | #4274 |
| fab | #4279 |
| late pregnancy | #4285 |
| pai1 | #4286 |
| rise | #4287 |
| oral aged | #4294 |
| q4 | #4296 |
| 228 | #4303 |
| share | #4304 |
| 10 patients | #4306 |
| 105 | #4310 |
| rehospitalization | #4314 |
| patients increased risk | #4315 |
| 185 | #4316 |
| tat | #4319 |
| separate | #4322 |
| concentrates | #4328 |
| intima | #4329 |
| devised | #4331 |
| 294 | #4339 |
| 102 | #4340 |
| 455 | #4340 |
| pronounced | #4342 |
| incidental findings | #4345 |
| potential risk factors | #4350 |
| managed | #4350 |
| detrimental | #4356 |
| 253 | #4359 |
| agreed | #4360 |
| young age | #4363 |
| specialist | #4379 |
| minutes | #4383 |
| rapid | #4383 |
| retrospective studies | #4384 |
| 447 | #4385 |
| cd11b | #4387 |
| 288 | #4391 |
| 170 | #4392 |
| concurrently | #4394 |
| slice | #4394 |
| risk cardiovascular | #4396 |
| steadily | #4402 |
| 239 | #4406 |
| negative | #4407 |
| general | #4407 |
| 71 | #4407 |
| bowel diseases | #4407 |
| guideline recommendations | #4408 |
| postoperative day | #4409 |
| ventilation | #4413 |
| splanchnic | #4417 |
| lacking | #4417 |
| immunoassays | #4419 |
| dose aspirin | #4419 |
| recombinant proteins | #4423 |
| 3 patients | #4426 |
| author | #4427 |
| 148 | #4428 |
| 281 | #4429 |
| primary myelofibrosis | #4430 |
| appropriateness | #4433 |
| profoundly | #4436 |
| completed | #4438 |
| platelet | #4440 |
| cellulitis | #4441 |
| sixteen | #4442 |
| concomitant | #4445 |
| assays | #4453 |
| 334 | #4458 |
| 192 | #4459 |
| vascular surgery | #4459 |
| cytomegalovirus infection | #4461 |
| proband | #4461 |
| total costs | #4474 |
| 377 | #4479 |
| 443 | #4482 |
| clinical manifestations | #4486 |
| cd18 | #4486 |
| inadequate | #4487 |
| pancreatic cancer | #4487 |
| coronavirus disease covid19 | #4489 |
| smr | #4492 |
| risk prediction | #4493 |
| bus | #4497 |
| current management | #4498 |
| 476 | #4499 |
| doubling | #4500 |
| infected patients | #4502 |
| activation platelet | #4503 |
| comprises | #4503 |
| 54 | #4513 |
| primary diagnosis | #4515 |
| alpha2 | #4516 |
| therapeutic | #4532 |
| septic | #4534 |
| 3 groups | #4535 |
| male pulmonary | #4541 |
| 526 | #4542 |
| elastase | #4544 |
| hitherto | #4546 |
| fairly | #4552 |
| cardiovascular death | #4559 |
| 985 | #4564 |
| 1250 | #4567 |
| calculating | #4571 |
| cerebrovascular disorders | #4571 |
| multicenter trial | #4574 |
| 2c | #4585 |
| debate | #4586 |
| disadvantage | #4588 |
| plasma concentrations | #4591 |
| 283 | #4592 |
| attenuating | #4594 |
| preserves | #4594 |
| gradual | #4595 |
| eventually | #4595 |
| simplified | #4596 |
| 204 | #4596 |
| 4000 | #4601 |
| 4 | #4601 |
| encouraged | #4603 |
| icer | #4610 |
| frequently | #4611 |
| vii | #4613 |
| acetylsalicylic acid | #4613 |
| vaginal | #4614 |
| 917 | #4619 |
| assay | #4634 |
| subclinical atherosclerosis | #4636 |
| risks benefits | #4640 |
| hospital costs | #4640 |
| 242 | #4642 |
| genetic risk factors | #4644 |
| escalating | #4648 |
| priori | #4654 |
| 003 | #4658 |
| habitual | #4658 |
| survey | #4659 |
| transurethral | #4663 |
| 171 | #4670 |
| myelofibrosis | #4670 |
| thyroid hormone | #4673 |
| 40 | #4675 |
| 407 | #4679 |
| day | #4680 |
| fh | #4680 |
| recurrent stroke | #4681 |
| wheezing | #4693 |
| ranging | #4698 |
| unchanged | #4698 |
| 5 patients | #4701 |
| complicated | #4703 |
| truncated | #4709 |
| therapeutic intervention | #4715 |
| differential humans | #4719 |
| immobilization | #4725 |
| 129 | #4727 |
| orthopedic | #4735 |
| cardiovascular morbidity | #4738 |
| current guidelines | #4739 |
| therapeutic strategies | #4744 |
| ranged | #4769 |
| 027 | #4774 |
| baseline patients | #4775 |
| chronic renal | #4775 |
| acute coronary | #4784 |
| 44 | #4785 |
| scheduled | #4785 |
| molecular | #4792 |
| knee | #4800 |
| insulin glargine | #4801 |
| prophylactic | #4802 |
| arthroplasty | #4803 |
| alternatively | #4810 |
| extracranial | #4813 |
| courses | #4819 |
| diagnostic imaging | #4825 |
| therapy humans | #4836 |
| echocardiography | #4846 |
| 174 | #4848 |
| cholesterol levels | #4853 |
| acl | #4861 |
| definition | #4861 |
| efficiency | #4869 |
| gpiib | #4870 |
| nonvalvular atrial fibrillation | #4870 |
| increased plasma | #4875 |
| unexposed | #4876 |
| gynecological | #4880 |
| antiphospholipid syndrome | #4881 |
| screening tool | #4884 |
| 322 | #4886 |
| antiplatelet therapy | #4891 |
| total | #4891 |
| treating | #4896 |
| abstracted | #4897 |
| doses | #4902 |
| ischemic heart disease | #4905 |
| preparations | #4906 |
| tests prognosis | #4906 |
| served | #4910 |
| chlamydophila | #4913 |
| fmd | #4913 |
| 560 | #4914 |
| recommendation | #4918 |
| geriatrics | #4920 |
| acute ischemic | #4923 |
| renal dysfunction | #4929 |
| 556 | #4932 |
| 154 | #4933 |
| 870 | #4934 |
| cpb | #4939 |
| 325 | #4951 |
| 26 | #4952 |
| satisfied | #4957 |
| appeared | #4959 |
| fund | #4972 |
| dose | #4976 |
| manufacturers | #4976 |
| orthopedics | #4982 |
| albeit | #4982 |
| recommended | #4987 |
| cardiology | #5000 |
| references | #5006 |
| 389 | #5006 |
| epoprostenol | #5009 |
| reminder | #5009 |
| probnp | #5014 |
| point mutation | #5018 |
| risk women | #5023 |
| syndrome patients | #5033 |
| 156 | #5040 |
| screening test | #5040 |
| proposal | #5042 |
| global burden | #5044 |
| primary health | #5045 |
| analytic | #5047 |
| obstetrical | #5048 |
| lasted | #5049 |
| patients sepsis | #5051 |
| limitations | #5055 |
| diagnosis management | #5058 |
| patients myocardial infarction | #5062 |
| spinal surgery | #5065 |
| 255 | #5068 |
| conflicting | #5070 |
| saphenous | #5075 |
| inaccessible | #5078 |
| 1a | #5079 |
| switched | #5084 |
| regarded | #5089 |
| evaluable | #5089 |
| hip fractures | #5090 |
| relation | #5090 |
| transluminal | #5093 |
| menstrual | #5094 |
| fashion | #5098 |
| amputation | #5102 |
| external validation | #5103 |
| arteritis | #5107 |
| inflammatory responses | #5109 |
| oxadiazoles | #5110 |
| dalys | #5112 |
| tailor | #5115 |
| admission patients | #5118 |
| composite | #5120 |
| discriminative | #5123 |
| vivo studies | #5124 |
| bay | #5124 |
| 108 | #5125 |
| 282 | #5129 |
| 0018 | #5130 |
| ischaemic stroke | #5130 |
| 131 | #5131 |
| female | #5131 |
| transfused | #5134 |
| balancing | #5136 |
| contrast media | #5136 |
| fetal death | #5138 |
| activator | #5139 |
| scans | #5143 |
| 341 | #5146 |
| n6 | #5150 |
| kg1 | #5151 |
| shortly | #5157 |
| disagreement | #5157 |
| preclinical studies | #5160 |
| doppler | #5165 |
| 11 patients | #5170 |
| predispose | #5170 |
| hazard | #5171 |
| readers | #5173 |
| prescriptions | #5174 |
| graft failure | #5178 |
| weaknesses | #5185 |
| renal impairment | #5186 |
| 70 patients | #5190 |
| infarctions | #5191 |
| screening | #5193 |
| threefold | #5198 |
| highest | #5202 |
| extracellular vesicles | #5204 |
| acs | #5205 |
| 144 | #5206 |
| hospital patients | #5208 |
| remains | #5209 |
| excess mortality | #5210 |
| doppler color | #5221 |
| polysaccharides | #5223 |
| heparan | #5229 |
| emergencies | #5233 |
| articles | #5233 |
| indwelling | #5241 |
| flowmetry | #5242 |
| gram | #5244 |
| 3 | #5248 |
| platelet aggregation | #5252 |
| considerably | #5253 |
| comparison | #5262 |
| testing | #5264 |
| plasma levels | #5265 |
| estimate | #5288 |
| 365 | #5289 |
| pooling | #5289 |
| aware | #5300 |
| 36 patients | #5301 |
| thrombus | #5301 |
| urokinase | #5302 |
| atherogenesis | #5302 |
| triage | #5303 |
| case reports | #5305 |
| benefit | #5308 |
| reversal | #5310 |
| stroke treatment | #5314 |
| contrasted | #5316 |
| orthomyxoviridae | #5319 |
| openlabel | #5320 |
| 70 years | #5325 |
| aged postoperative | #5330 |
| animal drug evaluation | #5332 |
| dizziness | #5334 |
| absent | #5335 |
| factor humans | #5336 |
| stratify | #5340 |
| reagent | #5341 |
| acute ischemic stroke | #5341 |
| blood vessel | #5343 |
| ultrasound imaging | #5344 |
| fatality | #5347 |
| contrast agents | #5355 |
| arose | #5361 |
| schedule drug | #5363 |
| male | #5363 |
| based guidelines | #5370 |
| hyper | #5372 |
| obstetric | #5376 |
| accepted | #5383 |
| thyrotropin | #5401 |
| informed consent | #5402 |
| blood products | #5405 |
| selected patients | #5406 |
| adult | #5407 |
| heart valve | #5409 |
| intracranial | #5411 |
| questionnaire | #5414 |
| register | #5415 |
| summarized | #5416 |
| 19 | #5417 |
| noninvasive | #5421 |
| clinical risk | #5424 |
| nonsignificant | #5429 |
| protein levels | #5430 |
| concerns | #5439 |
| charts | #5440 |
| hyperprolactinemia | #5441 |
| familiarity | #5442 |
| 37 | #5445 |
| 630 | #5448 |
| retrieved | #5450 |
| cancer growth | #5455 |
| presently | #5456 |
| congenital heart | #5465 |
| registered | #5470 |
| recombinant human | #5474 |
| intermediate | #5475 |
| 340 | #5476 |
| 395 | #5484 |
| allocation | #5488 |
| 247 | #5490 |
| occurrences | #5490 |
| moyamoya disease | #5491 |
| ntprobnp | #5493 |
| kaplan meier | #5496 |
| 260 | #5497 |
| patient risk | #5497 |
| discomfort | #5499 |
| continuing | #5499 |
| 9 patients | #5500 |
| postal | #5503 |
| ssris | #5515 |
| correctly | #5517 |
| weight | #5524 |
| 309 | #5530 |
| period | #5533 |
| erythema | #5539 |
| limitation | #5539 |
| suggestions | #5541 |
| survival benefit | #5542 |
| imputed | #5545 |
| receptor1 | #5563 |
| established | #5563 |
| 175 | #5565 |
| 545 | #5566 |
| management | #5569 |
| reduce risk | #5573 |
| 46 | #5573 |
| 324 | #5595 |
| excludes | #5597 |
| equivalent | #5598 |
| circulating levels | #5598 |
| categorical | #5600 |
| stm | #5607 |
| grounds | #5617 |
| expert | #5620 |
| 02 | #5624 |
| microgram | #5626 |
| minus | #5627 |
| premenopausal women | #5629 |
| retrieve | #5633 |
| food preferences | #5637 |
| drug administration | #5641 |
| platelet count | #5643 |
| 80 years | #5644 |
| reclassification | #5644 |
| 65 | #5651 |
| trial | #5653 |
| 087 | #5667 |
| published data | #5671 |
| 48 | #5676 |
| seventy | #5684 |
| 214 | #5689 |
| latex | #5690 |
| platelet glycoprotein | #5692 |
| reproducible | #5696 |
| 1997 | #5698 |
| meier | #5714 |
| 370 | #5718 |
| return | #5721 |
| 40 years | #5729 |
| atherosclerotic | #5730 |
| 89 | #5732 |
| perform | #5734 |
| 995 | #5748 |
| 091 | #5755 |
| stand | #5756 |
| 0014 | #5761 |
| metabolic effects | #5764 |
| milder | #5771 |
| semiquantitative | #5771 |
| 241 | #5777 |
| recurrence patients | #5781 |
| varied | #5784 |
| creatinine clearance | #5788 |
| 3rd | #5791 |
| mpo | #5804 |
| incidence rates | #5804 |
| 95 women | #5809 |
| orthopedic procedures | #5810 |
| male middle aged | #5811 |
| url | #5812 |
| aircraft | #5819 |
| 1000 | #5819 |
| income countries | #5828 |
| diagnosed | #5840 |
| undergoing surgery | #5843 |
| true | #5852 |
| atrial | #5852 |
| 088 | #5854 |
| attending | #5856 |
| 290 | #5857 |
| women pregnancy | #5857 |
| hip | #5866 |
| advantageous | #5875 |
| complete resolution | #5878 |
| reliable | #5894 |
| occurrence | #5894 |
| excluded | #5899 |
| aged models | #5919 |
| adding | #5923 |
| safety patients | #5927 |
| 22 patients | #5928 |
| aged platelet | #5928 |
| graded | #5934 |
| revision | #5938 |
| premenopause | #5938 |
| 353 | #5945 |
| prodrugs | #5946 |
| rrs | #5949 |
| 141 | #5952 |
| gastrointestinal hemorrhage | #5954 |
| janus kinase | #5959 |
| rcts | #5962 |
| 43 | #5962 |
| families | #5967 |
| 328 | #5971 |
| deemed | #5977 |
| savings | #5980 |
| counseling | #5985 |
| blood platelets | #5987 |
| blood | #5990 |
| receiver operating | #5996 |
| guideline | #5998 |
| cancer incidence | #6006 |
| current standard | #6013 |
| therapeutic interventions | #6028 |
| nadir | #6034 |
| registries risk | #6039 |
| patients experience | #6042 |
| allocated | #6044 |
| ≥3 | #6052 |
| wash | #6059 |
| advance | #6062 |
| quarter | #6065 |
| spect | #6068 |
| glycosaminoglycans | #6069 |
| decompensated | #6074 |
| 24 | #6076 |
| bacteremia | #6090 |
| type iii | #6101 |
| topics | #6101 |
| suggestive | #6105 |
| emerging evidence | #6113 |
| prevent | #6117 |
| safety data | #6120 |
| directly | #6133 |
| 72 | #6135 |
| 267 | #6136 |
| lipid profile | #6140 |
| ≥2 | #6144 |
| normalization | #6151 |
| centuries | #6153 |
| 47 | #6157 |
| generation | #6160 |
| ffa | #6160 |
| lobar | #6161 |
| agents blood | #6164 |
| 292 | #6165 |
| informed | #6173 |
| pharmacodynamic | #6188 |
| lung male | #6190 |
| updating | #6192 |
| advantages disadvantages | #6194 |
| lower | #6195 |
| bilateral | #6198 |
| cyclosporine | #6208 |
| tumour growth | #6212 |
| pathogenetic | #6221 |
| femoral artery | #6224 |
| terminated | #6228 |
| mortality morbidity | #6228 |
| new drugs | #6229 |
| 312 | #6230 |
| evidence base | #6232 |
| vitro studies | #6234 |
| crp | #6235 |
| discontinued | #6236 |
| 111 | #6240 |
| abdomen | #6248 |
| denmark | #6254 |
| proportional | #6268 |
| colleagues | #6273 |
| practitioners | #6273 |
| administered | #6277 |
| 1978 | #6283 |
| screened | #6293 |
| infused | #6297 |
| 840 | #6318 |
| prostatectomy | #6330 |
| 017 | #6334 |
| saphenous vein | #6339 |
| 63 | #6340 |
| 135 | #6340 |
| percentile | #6344 |
| higher doses | #6345 |
| adequacy | #6347 |
| divided | #6348 |
| apache | #6351 |
| screen | #6357 |
| opinions | #6360 |
| opposed | #6362 |
| percentage | #6370 |
| longterm followup | #6372 |
| risk mortality | #6386 |
| dyslipidemias | #6390 |
| kaplan | #6391 |
| consensus | #6392 |
| 208 | #6397 |
| potential mechanisms | #6404 |
| factor gene | #6405 |
| roche | #6405 |
| initiated | #6408 |
| compensated | #6411 |
| investigating | #6427 |
| ultrasound | #6441 |
| restenosis | #6442 |
| bootstrap | #6452 |
| collection | #6457 |
| post operative | #6464 |
| enzyme linked | #6467 |
| bariatric surgery | #6468 |
| coronary syndrome | #6469 |
| decreased risk | #6471 |
| 218 | #6472 |
| perfusion | #6475 |
| imbalance | #6484 |
| angina pectoris | #6493 |
| calendar | #6498 |
| peripheral artery disease | #6501 |
| accuracy | #6501 |
| cancer cell | #6502 |
| incidence risk | #6502 |
| complement activation | #6505 |
| pregnancies | #6519 |
| surgical procedure | #6520 |
| supervised | #6521 |
| models male | #6522 |
| 138 | #6523 |
| washout | #6524 |
| 318 | #6524 |
| triiodothyronine | #6524 |
| peripheral | #6525 |
| vena | #6527 |
| increased incidence | #6532 |
| highrisk patients | #6532 |
| cochrane | #6532 |
| placebo patients | #6536 |
| replaced | #6537 |
| exogenous | #6538 |
| bowel | #6538 |
| aspirin patients | #6540 |
| thirteen | #6540 |
| year | #6546 |
| superior | #6549 |
| clinical assessment | #6550 |
| cohorts | #6555 |
| dilemma | #6560 |
| crt | #6561 |
| dosing | #6576 |
| tertile | #6581 |
| 231 | #6586 |
| limited | #6589 |
| md | #6592 |
| prediction | #6596 |
| treatment choice | #6600 |
| pooled | #6601 |
| occurs | #6610 |
| 510 | #6611 |
| belgium | #6620 |
| crude | #6621 |
| injections | #6638 |
| genetic testing | #6641 |
| pancreatic neoplasms | #6641 |
| individual | #6650 |
| complications | #6650 |
| complaints | #6652 |
| degranulation | #6663 |
| methylenetetrahydrofolate | #6665 |
| liver diseases | #6674 |
| patents | #6680 |
| smoking cessation | #6696 |
| 17 patients | #6704 |
| routinely | #6706 |
| tumour progression | #6708 |
| saline | #6709 |
| 194 | #6713 |
| approval | #6727 |
| recognised | #6729 |
| hazard ratios | #6729 |
| thromboxane | #6734 |
| allcause mortality | #6744 |
| multicenter | #6747 |
| appropriately | #6748 |
| increasing age | #6751 |
| 385 | #6766 |
| body temperature | #6766 |
| q1 | #6768 |
| clinical signs | #6771 |
| age patients | #6774 |
| 2 groups | #6780 |
| defined | #6780 |
| expense | #6781 |
| 42 patients | #6791 |
| train | #6796 |
| hyperglycemia | #6801 |
| reached | #6803 |
| premedication | #6803 |
| response relationship | #6807 |
| plasma proteins | #6807 |
| benefits | #6810 |
| cardiovascular risk | #6821 |
| 256 | #6831 |
| 280 | #6838 |
| iqr | #6839 |
| glucocorticoids | #6840 |
| summary | #6850 |
| 279 | #6854 |
| cancer diagnosis | #6856 |
| systematic | #6870 |
| points | #6877 |
| ambulatory | #6883 |
| weekly | #6884 |
| reviews | #6891 |
| physicians | #6893 |
| fibrillation patients | #6898 |
| adverse event | #6912 |
| disturbances | #6912 |
| sought | #6918 |
| 112 | #6923 |
| 251 | #6940 |
| complications patients | #6948 |
| vasopressin | #6957 |
| failure | #6965 |
| subsequent | #6971 |
| hematologic | #6974 |
| intensity | #6976 |
| 246 | #6976 |
| humans hydroxymethylglutaryl | #6982 |
| papers | #6983 |
| tpa | #6986 |
| intervals | #6987 |
| addressed | #6989 |
| 259 | #6992 |
| 222 | #6995 |
| shock septic | #6995 |
| adapted | #6998 |
| disclosed | #7001 |
| incidence risk factors | #7008 |
| hazards models | #7015 |
| cardiovascular disease | #7019 |
| myeloperoxidase | #7020 |
| lung cancer patients | #7023 |
| stenting | #7024 |
| responded | #7026 |
| cohort | #7037 |
| 1 patient | #7038 |
| unacceptable | #7039 |
| interleukin8 | #7042 |
| reductases | #7045 |
| preventing | #7056 |
| curve | #7058 |
| patients baseline | #7065 |
| animal doseresponse relationship | #7071 |
| reduced risk | #7075 |
| written | #7080 |
| applicability | #7084 |
| asymptomatic patients | #7086 |
| monoclonal antibody | #7098 |
| hospitalization humans | #7101 |
| computed | #7104 |
| betacoronavirus covid19 | #7104 |
| novartis | #7108 |
| complications pregnancy | #7111 |
| infarction stroke | #7114 |
| superiority | #7116 |
| interquartile range | #7120 |
| select | #7122 |
| carotid intima | #7141 |
| internationality | #7146 |
| surveys questionnaires | #7160 |
| 163 | #7166 |
| pharmacy | #7167 |
| patients renal | #7171 |
| physicians patients | #7177 |
| randomization | #7184 |
| liver cirrhosis | #7187 |
| 211 | #7188 |
| brain metastases | #7190 |
| oral animals | #7192 |
| walking | #7195 |
| drawn | #7196 |
| combination | #7197 |
| 5year | #7204 |
| withdrawal | #7204 |
| acting | #7210 |
| cardiovascular disease cvd | #7210 |
| disposition | #7212 |
| paucity | #7218 |
| humans lung | #7221 |
| 20 patients | #7225 |
| sulfate | #7240 |
| operating characteristic | #7244 |
| vldl | #7250 |
| treatment children | #7250 |
| hematocrit | #7255 |
| retrospective cohort study | #7257 |
| 199 | #7257 |
| alongside | #7258 |
| clinical benefit | #7265 |
| controls | #7267 |
| diagnostics | #7270 |
| option | #7273 |
| grouped | #7275 |
| young women | #7278 |
| products | #7282 |
| likelihood | #7284 |
| modest | #7290 |
| sensitivity analysis | #7290 |
| atrium | #7291 |
| 360 | #7303 |
| types | #7304 |
| factors stroke | #7305 |
| undergoing | #7327 |
| partial | #7330 |
| patients isolated | #7332 |
| ischemic stroke | #7338 |
| pectoris | #7338 |
| interleukin6 | #7352 |
| 1c | #7352 |
| myocardial infarction | #7356 |
| p0001 | #7356 |
| standardised | #7356 |
| betacoronavirus | #7357 |
| simple | #7360 |
| radiology | #7379 |
| pap | #7392 |
| patients aspirin | #7400 |
| angiopathies | #7401 |
| regimens | #7405 |
| 109 | #7409 |
| bias | #7411 |
| peptide fragments | #7413 |
| iiia | #7424 |
| intravenous injection | #7429 |
| 420 | #7431 |
| propranolol | #7438 |
| favourable | #7440 |
| hypercholesterolemia | #7441 |
| respective | #7444 |
| dose dependent | #7447 |
| infusion | #7448 |
| clinical setting | #7454 |
| ways | #7465 |
| risk adverse | #7497 |
| il6 | #7510 |
| mortality rates | #7515 |
| 209 | #7516 |
| considerations | #7517 |
| exclusions | #7518 |
| patient safety | #7520 |
| urgently | #7522 |
| angina | #7522 |
| cmv infection | #7541 |
| phase iii | #7555 |
| 257 | #7558 |
| € | #7559 |
| interim | #7561 |
| injection | #7564 |
| 191 | #7578 |
| comorbid | #7578 |
| cinahl | #7578 |
| pheochromocytoma | #7585 |
| ischaemic | #7598 |
| antibodies monoclonal | #7601 |
| reasons | #7602 |
| tended | #7608 |
| pooled analysis | #7609 |
| azathioprine | #7615 |
| 13 | #7616 |
| predictor | #7620 |
| femoral | #7640 |
| random allocation | #7646 |
| 29 patients | #7647 |
| epidemiological studies | #7647 |
| abrupt | #7655 |
| derivation | #7662 |
| interquartile | #7675 |
| manifestation | #7676 |
| temporary | #7679 |
| positive patients | #7687 |
| medical conditions | #7705 |
| 18 | #7705 |
| seventeen | #7710 |
| 304 | #7719 |
| ligament | #7732 |
| consent | #7733 |
| study association | #7735 |
| cytomegalovirus | #7736 |
| severe | #7742 |
| adverse outcomes | #7745 |
| costs | #7753 |
| cardiac surgical | #7760 |
| 189 | #7770 |
| cochrane library | #7771 |
| pregnancy outcome | #7787 |
| 110 | #7802 |
| manufacturer | #7802 |
| ≤ | #7803 |
| 9 | #7811 |
| oxygenases | #7813 |
| male gender | #7815 |
| interleukin | #7816 |
| pts | #7819 |
| 31 patients | #7828 |
| label | #7828 |
| hormone replacement | #7828 |
| cpr | #7829 |
| 5 | #7833 |
| abortion | #7838 |
| influenza | #7845 |
| radiation exposure | #7850 |
| regular | #7877 |
| tramadol | #7878 |
| academic | #7878 |
| septic patients | #7880 |
| 95 confidence | #7884 |
| replacing | #7886 |
| patients chemotherapy | #7888 |
| iib | #7908 |
| journals | #7922 |
| strict | #7927 |
| expertise | #7928 |
| bioavailability | #7930 |
| adoption | #7934 |
| urogenital | #7939 |
| highrisk | #7939 |
| diseased | #7944 |
| increasing evidence | #7947 |
| disadvantages | #7949 |
| 243 | #7965 |
| patients 1 | #7972 |
| human blood | #7973 |
| fragment | #7975 |
| new class | #7976 |
| 28 | #7989 |
| individualized | #7990 |
| aim | #7992 |
| premenopausal | #7995 |
| advice | #8016 |
| qol | #8022 |
| malignant disease | #8026 |
| pulmonary disease | #8031 |
| 99mtc | #8034 |
| oligonucleotides | #8040 |
| vascular disease | #8049 |
| 600 | #8051 |
| medical | #8051 |
| preventable | #8051 |
| list | #8059 |
| selective | #8062 |
| routine clinical | #8068 |
| fact | #8078 |
| lasting | #8080 |
| helpful | #8084 |
| 36 months | #8086 |
| outcome acute | #8092 |
| extracorporeal | #8095 |
| 248 | #8113 |
| 90 | #8114 |
| training | #8120 |
| patients heart | #8120 |
| 2004 | #8122 |
| initiating | #8123 |
| tsh | #8125 |
| cholesterol ldl | #8138 |
| sensorineural | #8140 |
| imaging studies | #8141 |
| investigational | #8141 |
| mild | #8156 |
| nosocomial | #8164 |
| multiple organ | #8175 |
| stroke | #8176 |
| 237 | #8183 |
| 158 | #8184 |
| arteries | #8190 |
| parenteral nutrition | #8204 |
| confidence | #8204 |
| renal dialysis | #8209 |
| 33 | #8223 |
| renal function | #8228 |
| impairment | #8228 |
| 81 | #8233 |
| therapy | #8235 |
| quantitative | #8240 |
| smoking | #8243 |
| lowest | #8250 |
| lists | #8250 |
| version | #8260 |
| 125i | #8264 |
| activated | #8264 |
| minimum | #8270 |
| mortality | #8280 |
| leukopenia | #8281 |
| 0008 | #8284 |
| agents | #8286 |
| 119 | #8290 |
| utilisation | #8298 |
| practice | #8310 |
| suffered | #8316 |
| schedule | #8320 |
| thrombectomy | #8322 |
| postulated | #8338 |
| endothelium vascular | #8338 |
| immunosorbent assay | #8339 |
| elimination | #8341 |
| linked immunosorbent | #8345 |
| hematology | #8351 |
| 2 years | #8382 |
| absence presence | #8382 |
| cell derived | #8384 |
| 229 | #8394 |
| draw | #8405 |
| 28 patients | #8415 |
| occur | #8415 |
| ≥50 | #8416 |
| reports | #8427 |
| 137 | #8433 |
| mentioned | #8436 |
| covid19 coronavirus | #8447 |
| 265 | #8452 |
| glucuronidase | #8458 |
| patient characteristics | #8459 |
| transient ischemic | #8463 |
| procedures operative | #8463 |
| 295 | #8466 |
| exceed | #8486 |
| knowledge | #8493 |
| 27 patients | #8496 |
| evaluate | #8501 |
| covariate | #8501 |
| criterion | #8504 |
| inborn | #8519 |
| validate | #8528 |
| rabbits | #8537 |
| atherosclerosis | #8557 |
| large cohort | #8558 |
| menstrual cycle | #8563 |
| 193 | #8565 |
| 250 | #8568 |
| adjusted life | #8574 |
| leukocytes | #8581 |
| 146 | #8582 |
| adolescent | #8582 |
| row | #8590 |
| thirty | #8596 |
| carotid arteries | #8596 |
| safety profile | #8602 |
| cox | #8604 |
| intensities | #8605 |
| risks | #8606 |
| fish oil | #8624 |
| 15 years | #8624 |
| attenuates | #8625 |
| entry | #8639 |
| thresholds | #8646 |
| presumed | #8652 |
| emissioncomputed | #8654 |
| 223 | #8655 |
| hydroxymethylglutaryl coa | #8656 |
| valves | #8658 |
| syndrome | #8664 |
| factors patients | #8666 |
| evaluations | #8679 |
| certainty | #8687 |
| markers | #8689 |
| renal failure | #8690 |
| biomarkers | #8693 |
| polytetrafluoroethylene | #8698 |
| publication aged aged | #8706 |
| portal vein | #8708 |
| hold | #8723 |
| 1 2 | #8723 |
| additional studies | #8726 |
| cardiotonic | #8729 |
| definitions | #8731 |
| address | #8733 |
| judgment | #8744 |
| platelet counts | #8754 |
| requiring | #8755 |
| endovascular | #8756 |
| practical | #8756 |
| cardiovascular | #8756 |
| vasoactive | #8762 |
| 236 | #8763 |
| interpret | #8766 |
| undetected | #8778 |
| subpopulation | #8789 |
| medical treatment | #8792 |
| illnesses | #8798 |
| cardiovascular mortality | #8802 |
| 249 | #8834 |
| internship | #8836 |
| hydroxymethylglutaryl | #8837 |
| convenient | #8837 |
| resolving | #8863 |
| representative | #8864 |
| 2 | #8872 |
| cesarean | #8876 |
| merits | #8887 |
| endarterectomy | #8896 |
| chronic liver disease | #8902 |
| mimics | #8903 |
| early treatment | #8910 |
| surgical intervention | #8911 |
| micrograms | #8914 |
| planned | #8914 |
| epoxide | #8916 |
| aged myocardial | #8919 |
| influenced | #8934 |
| normal subjects | #8936 |
| proportional hazards | #8945 |
| signs symptoms | #8945 |
| clinicians | #8956 |
| cessation | #8958 |
| experienced | #8960 |
| heparan sulfate | #8962 |
| leads | #8973 |
| 24 hours | #8977 |
| rct | #8980 |
| options | #9002 |
| patients placebo | #9002 |
| comprise | #9005 |
| chemoprevention | #9005 |
| clinical events | #9007 |
| societies medical | #9007 |
| reply | #9017 |
| receiver | #9026 |
| rank | #9043 |
| 7 | #9061 |
| databases factual | #9064 |
| early mortality | #9075 |
| mps | #9080 |
| diagnose | #9080 |
| frequency | #9083 |
| jan | #9088 |
| statins | #9090 |
| alpha1 | #9115 |
| blood proteins | #9116 |
| prone | #9142 |
| time points | #9147 |
| valve prosthesis | #9147 |
| patient patients | #9150 |
| pelvis | #9158 |
| square | #9165 |
| life threatening | #9170 |
| molecular mechanisms | #9179 |
| 75 patients | #9183 |
| advanced stage | #9184 |
| lysis | #9190 |
| editor | #9193 |
| consensus statement | #9209 |
| 361 | #9213 |
| considerable | #9225 |
| platelets | #9226 |
| 1 month | #9227 |
| dyspnea | #9230 |
| pci | #9230 |
| performs | #9233 |
| contrast | #9238 |
| 4 hours | #9259 |
| extrinsic | #9263 |
| hazards | #9264 |
| illness surveys | #9264 |
| experts | #9266 |
| uncomplicated | #9267 |
| mumol | #9278 |
| attenuation | #9283 |
| rabbit | #9286 |
| positive | #9286 |
| trial registration | #9297 |
| corresponded | #9298 |
| dialysis | #9319 |
| feasibility | #9320 |
| earlier | #9339 |
| suboptimal | #9342 |
| p0004 | #9355 |
| patients negative | #9355 |
| preceded | #9376 |
| loss | #9378 |
| 014 | #9380 |
| higher incidence | #9380 |
| purposes | #9383 |
| invited | #9384 |
| single center | #9385 |
| death patients | #9391 |
| radioactivity | #9394 |
| bacterial infections | #9401 |
| fourth | #9402 |
| 2b | #9412 |
| ascending | #9415 |
| haemorrhage | #9425 |
| 167 | #9436 |
| properly | #9442 |
| rheumatic | #9446 |
| hospitalised | #9448 |
| dysfunction | #9460 |
| belonged | #9480 |
| secondary analysis | #9483 |
| respiratory tract | #9486 |
| 169 | #9490 |
| 240 | #9493 |
| ipd | #9502 |
| factual | #9503 |
| valvular | #9505 |
| thyroid function | #9507 |
| selectin | #9509 |
| hrs | #9524 |
| inflammatory agents | #9529 |
| confirms | #9530 |
| designed | #9535 |
| cardiopulmonary bypass | #9540 |
| swelling | #9542 |
| 3 4 | #9544 |
| insight | #9557 |
| cooperation | #9561 |
| requirements | #9566 |
| hemoglobins | #9573 |
| rose | #9592 |
| il10 | #9597 |
| observational cohort | #9598 |
| lpa | #9600 |
| rates | #9617 |
| comparative effectiveness | #9630 |
| kidney failure | #9638 |
| primary point | #9638 |
| successful treatment | #9639 |
| laboratories | #9644 |
| cardiogenic | #9645 |
| optimal treatment | #9650 |
| 2008 | #9656 |
| hf | #9670 |
| published | #9674 |
| congestive | #9695 |
| pathophysiological | #9704 |
| patients hospital | #9713 |
| spontaneously | #9720 |
| modalities | #9721 |
| inappropriate | #9724 |
| reuptake | #9727 |
| acts | #9729 |
| identifier | #9730 |
| 2007 | #9732 |
| lactoferrin | #9734 |
| 42 | #9744 |
| substitutes | #9747 |
| hypothetical | #9754 |
| nested | #9764 |
| nonesterified | #9768 |
| 90 patients | #9777 |
| reproducibility | #9778 |
| sepsis | #9802 |
| 210 | #9803 |
| absence | #9813 |
| straightforward | #9814 |
| precise | #9817 |
| easily | #9817 |
| nmol | #9828 |
| coa reductase | #9828 |
| classification | #9836 |
| craniotomy | #9839 |
| 212 | #9839 |
| 0006 | #9849 |
| utility | #9855 |
| danish | #9857 |
| labile | #9865 |
| nonhuman primates | #9871 |
| heterozygotes | #9871 |
| discordant | #9908 |
| moderately | #9919 |
| cmv | #9930 |
| 60 years | #9933 |
| lower limb | #9936 |
| promise | #9937 |
| 2003 | #9941 |
| degradation | #9941 |
| tomography | #9944 |
| treatment strategy | #9951 |
| 216 | #9958 |
| low dose | #9971 |
| investigator | #9983 |
| detecting | #9992 |
| regimen | #9995 |
| 12 hours | #9997 |
| casecontrol studies | #9997 |
| pancreatic | #9997 |
| 213 | #10000 |
| neoplasm metastasis | #10001 |
| chance | #10008 |
| physician | #10015 |
| extending | #10027 |
| informative | #10028 |
| hereditary | #10041 |
| obstacles | #10045 |
| protective | #10045 |
| addressing | #10051 |
| medication adherence | #10052 |
| mthfr | #10079 |
| presentations | #10082 |
| familial | #10087 |
| higher prevalence | #10089 |
| chart | #10108 |
| recipients | #10113 |
| qualitative | #10117 |
| 1980 | #10134 |
| completely | #10145 |
| tested | #10150 |
| aged obesity | #10170 |
| 182 | #10176 |
| invasive | #10181 |
| abnormalities | #10186 |
| regularly | #10189 |
| cast | #10193 |
| multicentre | #10198 |
| investigations | #10199 |
| cell activation | #10199 |
| cardiovascular risk factors | #10209 |
| clinical data | #10213 |
| medical therapy | #10213 |
| tumor necrosis factoralpha | #10215 |
| replacement therapy | #10225 |
| routine | #10234 |
| syndrome humans | #10253 |
| heart failure | #10265 |
| 183 | #10280 |
| gaps | #10291 |
| hospitalization | #10293 |
| blood transfusion | #10293 |
| postpartum | #10305 |
| measuring | #10314 |
| aetiology | #10315 |
| 8 | #10318 |
| photon emission | #10329 |
| dilution | #10336 |
| 032 | #10336 |
| 667 | #10337 |
| worldwide | #10337 |
| aorta | #10352 |
| greatly | #10352 |
| indirectly | #10377 |
| restoration | #10378 |
| creatinine | #10381 |
| cardiopulmonary | #10385 |
| pneumonia viral | #10397 |
| medical management | #10404 |
| outcome measures | #10408 |
| p0003 | #10408 |
| tissue injury | #10411 |
| bidirectional | #10419 |
| reductase inhibitors | #10432 |
| circulation | #10432 |
| transfusion | #10435 |
| enrolment | #10446 |
| reflux | #10457 |
| patients age | #10461 |
| priority | #10461 |
| quality life | #10471 |
| phase 3 | #10481 |
| activity levels | #10489 |
| increased prevalence | #10489 |
| 1991 | #10491 |
| style | #10491 |
| 147 | #10501 |
| predictive factors | #10514 |
| sex age | #10526 |
| assessing | #10529 |
| necrosis | #10534 |
| matched | #10556 |
| lower rate | #10558 |
| portable | #10563 |
| ray | #10570 |
| patients moderate | #10570 |
| 125 | #10574 |
| p002 | #10576 |
| pulmonary artery | #10578 |
| inform | #10580 |
| antisense | #10583 |
| recurrences | #10583 |
| 293 | #10584 |
| 180 | #10598 |
| manifestations | #10601 |
| closer | #10602 |
| microvascular | #10605 |
| 159 | #10605 |
| vasoconstrictor | #10607 |
| hospitals | #10612 |
| medical oncology | #10615 |
| november | #10628 |
| percutaneous coronary | #10633 |
| persist | #10635 |
| fragments | #10637 |
| ascertained | #10641 |
| 1b | #10647 |
| publication administration | #10653 |
| postoperative | #10659 |
| concerned | #10674 |
| held | #10674 |
| pulmonary vascular | #10690 |
| term | #10697 |
| discriminate | #10697 |
| risk developing | #10704 |
| synergism | #10709 |
| multivariable analysis | #10713 |
| neutrophil | #10729 |
| consultation | #10735 |
| centres | #10751 |
| median duration | #10755 |
| decisions | #10759 |
| entire | #10774 |
| haemoglobin | #10797 |
| perioperative | #10798 |
| patients cirrhosis | #10804 |
| term mortality | #10829 |
| 300 | #10832 |
| 38 | #10849 |
| prospective observational | #10855 |
| sustained | #10865 |
| randomised controlled | #10867 |
| anatomical | #10873 |
| diagnoses | #10903 |
| airways | #10903 |
| neurosurgical | #10905 |
| monoclonal antibodies monoclonal | #10909 |
| coronavirus infections | #10921 |
| maximal | #10924 |
| threatening | #10963 |
| amniotic | #10987 |
| coronary intervention | #10989 |
| relative | #10990 |
| blocker | #10996 |
| needed | #11009 |
| obese | #11037 |
| ischemic | #11057 |
| neutropenia | #11057 |
| attained | #11062 |
| summarizes | #11062 |
| ethical | #11062 |
| treatment option | #11070 |
| balloon | #11071 |
| 12 weeks | #11074 |
| originally | #11083 |
| inability | #11108 |
| location | #11108 |
| catheters | #11143 |
| beta2 | #11159 |
| ischemic attack | #11165 |
| hematoma | #11189 |
| confirmation | #11199 |
| neoplasms risk | #11201 |
| metabolic syndrome | #11202 |
| iia | #11204 |
| strokes | #11217 |
| choice | #11228 |
| eligible patients | #11247 |
| risk groups | #11263 |
| 1992 | #11272 |
| humans kidney | #11281 |
| cerebrovascular | #11281 |
| waiting | #11282 |
| ≥1 | #11291 |
| endothelial function | #11297 |
| troponin | #11304 |
| determine | #11306 |
| 202 | #11308 |
| aged prevalence | #11331 |
| post | #11332 |
| adherent | #11338 |
| acute respiratory | #11345 |
| acute myocardial infarction | #11361 |
| event | #11363 |
| combination therapy | #11380 |
| glycoprotein | #11391 |
| factors smoking | #11395 |
| reconstructive | #11397 |
| apply | #11399 |
| developed | #11405 |
| 2005 | #11415 |
| competent | #11416 |
| medically | #11426 |
| treatment decisions | #11427 |
| prostaglandins | #11434 |
| diuretics | #11439 |
| hematological malignancies | #11443 |
| morbidity | #11445 |
| media | #11464 |
| protocol | #11487 |
| satisfying | #11502 |
| performances | #11525 |
| hospital admission | #11526 |
| placebo treatment | #11533 |
| occlusion | #11533 |
| multicenter study | #11542 |
| outflow | #11542 |
| enrolled | #11545 |
| humans intensive | #11570 |
| 55 | #11577 |
| chronic inflammation | #11600 |
| definitive | #11621 |
| younger patients | #11624 |
| baseline | #11624 |
| sct | #11638 |
| investigate | #11670 |
| normal controls | #11684 |
| contribution | #11687 |
| reference | #11694 |
| life qol | #11697 |
| lipopolysaccharides | #11699 |
| hypotension | #11715 |
| ascites | #11717 |
| myoglobin | #11741 |
| independent risk | #11745 |
| acute myocardial | #11753 |
| radiopharmaceuticals | #11783 |
| extent | #11786 |
| orally | #11790 |
| involving | #11792 |
| 2010 | #11802 |
| nonspecific | #11809 |
| vena cava | #11829 |
| distinction | #11841 |
| episodes | #11865 |
| eclampsia | #11872 |
| release | #11874 |
| woman | #11885 |
| 151 | #11891 |
| 006 | #11906 |
| elicited | #11912 |
| icu patients | #11915 |
| vasculitis | #11937 |
| activating | #11948 |
| age | #11953 |
| sulphate | #11955 |
| began | #11957 |
| lethality | #11967 |
| collectively | #11970 |
| inferior | #11978 |
| serum creatinine | #11979 |
| myocardial injury | #11980 |
| adp | #11981 |
| immunosorbent | #12006 |
| cardiovascular diseases | #12015 |
| mortality rate | #12041 |
| reduced | #12043 |
| thirds | #12057 |
| dietary intake | #12057 |
| minority | #12058 |
| monitored | #12061 |
| differently | #12066 |
| early pregnancy | #12076 |
| humanized | #12077 |
| wounds injuries | #12079 |
| fair | #12096 |
| thoracotomy | #12111 |
| evidenced | #12130 |
| 1995 | #12135 |
| elevated risk | #12140 |
| 085 | #12141 |
| profile | #12143 |
| prostate | #12153 |
| 149 | #12157 |
| 120 | #12170 |
| digoxin | #12177 |
| offset | #12179 |
| uncommon | #12187 |
| healthcare | #12202 |
| causality | #12208 |
| lung | #12208 |
| spent | #12219 |
| takes | #12233 |
| tendency | #12271 |
| pregnancy risk | #12276 |
| expectancy | #12281 |
| resolve | #12300 |
| flaps | #12302 |
| micromol | #12326 |
| mismatch | #12335 |
| favored | #12342 |
| births | #12351 |
| obstructive pulmonary | #12358 |
| epinephrine | #12365 |
| dependently | #12372 |
| prescription | #12394 |
| registration | #12398 |
| incremental | #12399 |
| inflammatory response | #12409 |
| switzerland | #12409 |
| consistent | #12418 |
| potential confounders | #12425 |
| echocardiographic | #12450 |
| fifty patients | #12451 |
| arginine | #12475 |
| patient discharge | #12480 |
| apparent | #12483 |
| prospective randomized | #12486 |
| sensitivity analyses | #12490 |
| 117 | #12494 |
| switch | #12513 |
| 10 years | #12521 |
| standards | #12524 |
| requires | #12540 |
| guide | #12540 |
| statistically | #12548 |
| prognostic | #12579 |
| chronic obstructive | #12584 |
| monoclonal | #12589 |
| rapidly | #12597 |
| tomography ray | #12611 |
| lipoprotein | #12619 |
| literature | #12637 |
| repeat | #12653 |
| single dose | #12673 |
| drug interactions | #12680 |
| hypertension pulmonary | #12684 |
| physiological | #12687 |
| pharmacogenetics | #12706 |
| 45 | #12708 |
| prostatic | #12708 |
| endocrine | #12709 |
| ifngamma | #12722 |
| minute | #12733 |
| dosage | #12736 |
| congestive heart failure | #12747 |
| cardiac surgery | #12756 |
| personal | #12770 |
| estrogens | #12778 |
| animal model | #12796 |
| thyroid | #12808 |
| settings | #12820 |
| malignancies | #12823 |
| infections | #12836 |
| burden | #12849 |
| intraoperative complications | #12862 |
| cancer patient | #12864 |
| reporting | #12866 |
| 196 | #12881 |
| 1999 | #12904 |
| cvd | #12906 |
| raised | #12910 |
| endpoints | #12912 |
| extracted | #12940 |
| confirming | #12947 |
| 18 years | #12976 |
| ray computed | #12983 |
| postoperative complications | #12990 |
| filters | #13009 |
| monotherapy | #13017 |
| transiently | #13024 |
| instance | #13041 |
| oral administration | #13041 |
| located | #13049 |
| tumor angiogenesis | #13067 |
| based cohort | #13094 |
| fold | #13100 |
| severity | #13106 |
| cancer risk | #13107 |
| escalation | #13107 |
| vomiting | #13112 |
| physical | #13112 |
| latin | #13125 |
| sexes | #13143 |
| drug therapy | #13144 |
| 0 | #13145 |
| ratio | #13159 |
| focused | #13189 |
| appearance | #13195 |
| compliance | #13199 |
| pregnant women | #13202 |
| optimal | #13213 |
| expensive | #13226 |
| support | #13231 |
| exist | #13235 |
| 142 | #13236 |
| lack | #13240 |
| narcotic | #13261 |
| formal | #13262 |
| commercially | #13265 |
| participant | #13273 |
| median follow | #13286 |
| indirect | #13288 |
| emission computed | #13352 |
| mediator | #13366 |
| maintain | #13391 |
| electronic databases | #13394 |
| hypothesized | #13395 |
| advantage | #13432 |
| admitted | #13437 |
| p00001 | #13442 |
| anti | #13455 |
| reliably | #13459 |
| surveys | #13463 |
| endothelial dysfunction | #13466 |
| transient | #13478 |
| patients experienced | #13481 |
| provided | #13489 |
| crosssectional study | #13491 |
| patients patient | #13494 |
| surrogate | #13537 |
| vivo | #13545 |
| retrospectively | #13548 |
| maintained | #13555 |
| 195 | #13556 |
| pulmonary hypertension | #13563 |
| accurate | #13563 |
| longterm outcomes | #13585 |
| monitoring | #13620 |
| laboratory | #13629 |
| elucidated | #13643 |
| abdominal | #13652 |
| whilst | #13665 |
| mitral | #13682 |
| north america | #13705 |
| marker | #13707 |
| competence | #13708 |
| vascular | #13708 |
| 45 years | #13716 |
| 2009 | #13734 |
| icu | #13748 |
| drug effects | #13753 |
| medicine | #13755 |
| healthy individuals | #13758 |
| inhibitory effects | #13763 |
| establishing | #13766 |
| explanation | #13773 |
| pelvic | #13773 |
| participating | #13774 |
| phospholipid | #13776 |
| heart diseases | #13789 |
| women risk | #13816 |
| conservative | #13820 |
| circulating | #13824 |
| condition | #13859 |
| kidney diseases | #13860 |
| systematically | #13868 |
| tissue | #13876 |
| coronary angiography | #13889 |
| internal | #13916 |
| techniques | #13923 |
| microparticles | #13927 |
| dissemination | #13928 |
| 1993 | #13939 |
| 176 | #13979 |
| require | #13986 |
| castration | #13998 |
| radioisotopes | #14011 |
| 48 patients | #14013 |
| insufficiency | #14022 |
| algorithms | #14029 |
| members | #14033 |
| risk death | #14033 |
| requirement | #14046 |
| independent predictors | #14058 |
| continuous | #14060 |
| organ failure | #14072 |
| situations | #14084 |
| focus | #14084 |
| vasoconstriction | #14119 |
| offer | #14137 |
| supporting | #14164 |
| activates | #14188 |
| cardiac output | #14194 |
| leukocyte | #14204 |
| mitral valve | #14205 |
| sensitivities | #14216 |
| document | #14242 |
| primary prevention | #14248 |
| newborns | #14256 |
| nausea | #14276 |
| making | #14285 |
| effectiveness | #14304 |
| independent | #14342 |
| inhibition | #14357 |
| 4 years | #14367 |
| meaningful | #14371 |
| pathologic | #14372 |
| female fetal | #14377 |
| acquired | #14378 |
| min1 | #14391 |
| 6 patients | #14391 |
| amniotic fluid | #14403 |
| substances | #14409 |
| pregnant | #14423 |
| disease chronic | #14460 |
| interleukin1 | #14489 |
| infarction | #14491 |
| influence | #14509 |
| interventions | #14510 |
| costeffectiveness | #14535 |
| locations | #14586 |
| participated | #14592 |
| similarities | #14608 |
| 205 | #14632 |
| statistics | #14637 |
| renal insufficiency | #14637 |
| reasonable | #14646 |
| comparative | #14648 |
| natural | #14667 |
| blood samples | #14672 |
| surgery patients | #14696 |
| entered | #14698 |
| pandemics | #14707 |
| classify | #14715 |
| institutes | #14736 |
| surveyed | #14741 |
| 39 patients | #14742 |
| sampled | #14749 |
| 2017 | #14783 |
| arms | #14785 |
| independent predictor | #14787 |
| validity | #14787 |
| databases | #14808 |
| heart association | #14814 |
| white matter | #14816 |
| complete | #14819 |
| stable | #14828 |
| cox proportional | #14835 |
| pge2 | #14844 |
| duplex | #14845 |
| population | #14872 |
| contribute | #14928 |
| retest | #14931 |
| criteria | #14938 |
| premature | #14952 |
| critical illness | #15004 |
| phospholipids | #15030 |
| european society | #15041 |
| cardiac catheterization | #15042 |
| prostheses | #15059 |
| questionnaires | #15082 |
| treatment failure | #15087 |
| sf36 | #15089 |
| elective surgical | #15107 |
| controlled clinical | #15109 |
| flight | #15110 |
| ldl | #15120 |
| relate | #15127 |
| health costs | #15128 |
| initiation | #15140 |
| obstruction | #15142 |
| obstructive | #15146 |
| stratification | #15164 |
| proper | #15177 |
| selection | #15187 |
| registries | #15197 |
| decrease | #15201 |
| copd | #15201 |
| randomized controlled trial | #15210 |
| unilateral | #15223 |
| ongoing | #15230 |
| induces | #15231 |
| individuals | #15239 |
| young patients | #15247 |
| previous | #15250 |
| methods retrospective | #15255 |
| disorders | #15278 |
| drug | #15278 |
| myocardial | #15279 |
| 4 weeks | #15296 |
| quantitation | #15298 |
| fewer | #15300 |
| hospital discharge | #15328 |
| quantify | #15340 |
| activators | #15356 |
| neonates | #15370 |
| consequence | #15405 |
| locally | #15441 |
| impaired | #15446 |
| pedigree | #15471 |
| randomised controlled trial | #15474 |
| women age | #15474 |
| grafts | #15484 |
| zealand | #15509 |
| asthma | #15511 |
| undetectable | #15512 |
| current literature | #15513 |
| records | #15520 |
| 1994 | #15522 |
| aggregation | #15535 |
| thrombocytopenia | #15537 |
| implementation | #15538 |
| pa | #15540 |
| intended | #15567 |
| reviewed | #15577 |
| surgery | #15590 |
| updated | #15592 |
| discharged | #15616 |
| immunoenzyme | #15617 |
| purpose | #15634 |
| heterozygosity | #15660 |
| centre | #15666 |
| standard | #15679 |
| patients admitted | #15702 |
| perinatal | #15711 |
| explain | #15726 |
| view | #15729 |
| unexpected | #15737 |
| detection | #15766 |
| start | #15808 |
| examination | #15813 |
| effectively | #15813 |
| prescribing | #15823 |
| vary | #15829 |
| febrile | #15847 |
| confer | #15849 |
| serologic | #15853 |
| reach | #15876 |
| interpretation | #15881 |
| janus | #15892 |
| numerous | #15899 |
| inter | #15907 |
| quality adjusted | #15919 |
| dyslipidemia | #15942 |
| prominent | #15961 |
| blocked | #15985 |
| severely | #15997 |
| discuss | #15997 |
| alanine | #15998 |
| external | #16007 |
| causal | #16021 |
| hepatectomy | #16025 |
| complication | #16054 |
| compared controls | #16057 |
| rarely | #16076 |
| systemic inflammation | #16077 |
| fever | #16082 |
| metabolic | #16112 |
| demonstrates | #16117 |
| insensitive | #16125 |
| affect | #16135 |
| conditional | #16136 |
| basis | #16144 |
| carotid | #16168 |
| bypass | #16221 |
| early | #16262 |
| antiretroviral | #16271 |
| neoplasms | #16294 |
| hospital | #16314 |
| special | #16336 |
| signs | #16384 |
| cost | #16418 |
| recommendations | #16420 |
| aimed | #16432 |
| area | #16442 |
| syndromes | #16485 |
| unable | #16508 |
| prevented | #16513 |
| develop | #16513 |
| cancer treatment | #16516 |
| 106 | #16543 |
| radiography | #16545 |
| calibrated | #16568 |
| multivariable | #16576 |
| 2021 | #16583 |
| descriptive | #16618 |
| alternatives | #16629 |
| integrins | #16641 |
| creactive protein | #16645 |
| gained | #16652 |
| consists | #16666 |
| weeks | #16674 |
| downregulation | #16681 |
| residual | #16708 |
| prior | #16725 |
| explained | #16763 |
| fat | #16775 |
| electrocardiography | #16807 |
| epidemiology | #16821 |
| potent | #16848 |
| thought | #16868 |
| genetic risk | #16876 |
| survival | #16892 |
| 093 | #16911 |
| humans liver | #16932 |
| constitute | #16939 |
| gestational age | #16946 |
| vasodilator | #16950 |
| driven | #16958 |
| critically patients | #16965 |
| enable | #16976 |
| verify | #16984 |
| smokers | #16998 |
| inherent | #17023 |
| carotid artery | #17040 |
| apolipoproteins | #17063 |
| individual patients | #17078 |
| markedly | #17097 |
| units | #17139 |
| estimates | #17144 |
| assayed | #17145 |
| elderly patients | #17150 |
| regard | #17197 |
| critically | #17220 |
| adjustment | #17237 |
| cooperative | #17262 |
| lung neoplasms | #17262 |
| estimated | #17274 |
| largest | #17288 |
| acute phase | #17288 |
| 400 | #17295 |
| clinician | #17339 |
| desirable | #17347 |
| 2019 | #17393 |
| limb | #17439 |
| dilated | #17443 |
| disease cvd | #17451 |
| synthetic | #17459 |
| increasingly | #17488 |
| kinds | #17510 |
| antibodies | #17538 |
| prompt | #17565 |
| demographics | #17584 |
| cirrhosis | #17586 |
| 0002 | #17604 |
| finding | #17620 |
| applicable | #17636 |
| obtaining | #17637 |
| coronary | #17653 |
| sex factors | #17688 |
| prosthesis | #17710 |
| independent risk factor | #17712 |
| distal | #17714 |
| multivariate analysis | #17792 |
| gastrointestinal | #17804 |
| selecting | #17815 |
| 3 years | #17833 |
| 2006 | #17840 |
| illustrated | #17852 |
| 1 | #17853 |
| hemorrhagic | #17855 |
| drugs | #17878 |
| current evidence | #17881 |
| undergone | #17883 |
| marked | #17903 |
| epidemiologic | #17920 |
| hospitalizations | #17922 |
| nationwide | #17924 |
| global | #17933 |
| percutaneous | #17942 |
| essential | #17964 |
| corticosteroids | #17975 |
| distant | #18007 |
| intensive | #18031 |
| reductase | #18047 |
| verified | #18052 |
| peptide | #18060 |
| defects | #18070 |
| 000 | #18092 |
| operated | #18111 |
| trend | #18115 |
| centers | #18134 |
| protein crp | #18152 |
| clinical significance | #18164 |
| consistently | #18169 |
| quality | #18175 |
| chemotherapy | #18203 |
| prenatal | #18250 |
| participate | #18252 |
| deaths | #18263 |
| year follow | #18286 |
| ventricular function | #18296 |
| metastases | #18296 |
| inflammatory bowel | #18314 |
| gestation | #18344 |
| tolerated | #18425 |
| attributable | #18434 |
| and or | #18480 |
| coa | #18497 |
| larger | #18513 |
| mutations | #18533 |
| humans hypertension | #18543 |
| stratified | #18569 |
| heart disease | #18579 |
| commercial | #18589 |
| bayes | #18675 |
| ≥ | #18700 |
| extra | #18726 |
| mechanisms | #18742 |
| questions | #18760 |
| plasma | #18797 |
| conventional | #18799 |
| monoclonal antibodies | #18844 |
| increases | #18850 |
| life | #18851 |
| vessel | #18855 |
| oligopeptides | #18887 |
| clearance | #18903 |
| validation | #18907 |
| classical | #18919 |
| hormone | #18938 |
| molecular basis | #19034 |
| single | #19069 |
| worse | #19094 |
| statistical | #19103 |
| soluble | #19124 |
| simultaneously | #19131 |
| tailored | #19134 |
| real | #19158 |
| 5 years | #19189 |
| variable | #19205 |
| moderate | #19239 |
| contributes | #19241 |
| decade | #19291 |
| infarct | #19308 |
| ages | #19312 |
| pubmed | #19345 |
| 0005 | #19412 |
| essentially | #19469 |
| ventricular | #19481 |
| investigates | #19493 |
| 2 3 | #19507 |
| therapies | #19511 |
| called | #19515 |
| partially | #19535 |
| explore | #19544 |
| endothelium | #19553 |
| systemic | #19561 |
| january | #19567 |
| uterine | #19582 |
| reversed | #19601 |
| procedures | #19611 |
| tka | #19675 |
| etiology | #19677 |
| operating | #19692 |
| guided | #19709 |
| histology | #19727 |
| characterised | #19753 |
| inflammation | #19779 |
| median followup | #19863 |
| exclusively | #19881 |
| autologous | #19886 |
| graft | #19904 |
| endothelial cell | #19986 |
| controlled trial | #20019 |
| comorbidities | #20045 |
| gestational | #20050 |
| 2002 | #20050 |
| additionally | #20057 |
| cytokines | #20058 |
| salvage | #20102 |
| inversely | #20149 |
| concentration | #20153 |
| predisposition disease | #20162 |
| diastolic | #20170 |
| small | #20201 |
| alterations | #20228 |
| body | #20230 |
| alpha | #20261 |
| polymorphism genetic | #20264 |
| variables | #20277 |
| subjects | #20283 |
| combine | #20369 |
| adjusting | #20377 |
| catheterization | #20391 |
| introduced | #20458 |
| 1 3 | #20492 |
| younger | #20499 |
| hormones | #20508 |
| length | #20512 |
| theoretically | #20515 |
| ability | #20536 |
| analyses | #20553 |
| clarify | #20561 |
| persistent | #20562 |
| elisa | #20562 |
| improves | #20570 |
| september | #20598 |
| persons | #20696 |
| humans models | #20753 |
| active | #20756 |
| observational | #20823 |
| incorporated | #20843 |
| prognosis | #20934 |
| fetal | #20955 |
| reduce | #21005 |
| measure | #21033 |
| auc | #21046 |
| report | #21048 |
| intrinsic | #21055 |
| responsible | #21081 |
| constructed | #21098 |
| innate | #21135 |
| attenuated | #21137 |
| operative | #21137 |
| 1 year | #21144 |
| designated | #21167 |
| october | #21177 |
| performing | #21185 |
| × | #21191 |
| upper | #21226 |
| reflecting | #21230 |
| selected | #21264 |
| depending | #21267 |
| preschool female | #21270 |
| 005 | #21324 |
| hemodynamics humans | #21403 |
| symptoms | #21425 |
| center | #21469 |
| differed | #21501 |
| 1990 | #21507 |
| 0004 | #21546 |
| logistic | #21639 |
| explored | #21757 |
| animals antibodies | #21767 |
| young | #21860 |
| 139 | #21894 |
| majority | #21894 |
| observe | #21969 |
| facilitate | #21994 |
| decreased | #22047 |
| progression | #22078 |
| genotype | #22116 |
| imaging | #22125 |
| coronary disease | #22178 |
| tract | #22180 |
| neoadjuvant | #22207 |
| generally | #22291 |
| regression | #22321 |
| surgical procedures | #22327 |
| authors | #22330 |
| demonstrated | #22352 |
| inhibiting | #22426 |
| newborn male | #22473 |
| varying | #22556 |
| significance | #22586 |
| represented | #22593 |
| slower | #22607 |
| allogeneic | #22614 |
| grade | #22615 |
| phase | #22698 |
| older | #22831 |
| differential | #22835 |
| july | #22843 |
| modified | #22851 |
| march | #22907 |
| application | #22920 |
| combining | #22961 |
| ratios | #22986 |
| 2012 | #23037 |
| anti inflammatory | #23123 |
| offered | #23214 |
| protocols | #23283 |
| 2016 | #23284 |
| challenging | #23285 |
| yielding | #23334 |
| prevents | #23432 |
| resting | #23488 |
| includes | #23496 |
| renal | #23566 |
| median | #23599 |
| inhibits | #23686 |
| inbred c57bl mice | #23705 |
| increasing | #23723 |
| endopeptidases | #23727 |
| advanced | #23745 |
| adverse | #23767 |
| naive | #23767 |
| reactive protein | #23807 |
| minimal | #23827 |
| interestingly | #23831 |
| showing | #23885 |
| longer | #23967 |
| surgical | #24020 |
| vascular endothelial | #24085 |
| prolonged | #24478 |
| generate | #24487 |
| count | #24514 |
| december | #24569 |
| unrelated | #24572 |
| determining | #24577 |
| activity | #24581 |
| changed | #24651 |
| implies | #24682 |
| underlying | #24749 |
| suggests | #24813 |
| august | #24821 |
| linearly | #24940 |
| february | #24945 |
| frequent | #25109 |
| june | #25175 |
| representing | #25214 |
| acceptable | #25300 |
| carried | #25310 |
| illness | #25373 |
| suitable | #25501 |
| enhance | #25503 |
| 0003 | #25598 |
| linked | #25616 |
| local | #25663 |
| mm | #25732 |
| fully | #25888 |
| reducing | #25912 |
| describes | #25923 |
| difficult | #26054 |
| supported | #26091 |
| scanning | #26181 |
| differentiate | #26212 |
| respect | #26378 |
| promising | #26384 |
| asked | #26410 |
| define | #26421 |
| defective | #26510 |
| female heart | #26685 |
| dependent | #26722 |
| leading | #26774 |
| improving | #27057 |
| contained | #27059 |
| national | #27215 |
| strongest | #27229 |
| quantitatively | #27333 |
| recognized | #27386 |
| commonly | #27411 |
| mass bmi | #27411 |
| implicated | #27484 |
| caused | #27495 |
| remain | #27689 |
| correlate | #27710 |
| artery | #27999 |
| cross | #28142 |
| recorded | #28182 |
| detected | #28405 |
| inflammatory | #28439 |
| multivariate | #28454 |
| examine | #28475 |
| beta | #28655 |
| allowed | #28793 |
| hypothesis | #28801 |
| improved | #28920 |
| required | #29047 |
| large | #29116 |
| chemically | #29137 |
| short | #29272 |
| patients chronic | #29316 |
| genetic predisposition | #29434 |
| bmi | #29470 |
| female health | #29531 |
| achieved | #29589 |
| 001 | #29634 |
| underwent | #29797 |
| 2011 | #30149 |
| indicating | #30233 |
| approved | #30511 |
| declined | #30756 |
| participants | #30828 |
| predisposition | #30981 |
| genotype humans | #31051 |
| aims | #31216 |
| measured | #31265 |
| antineoplastic agents | #31706 |
| expected | #31791 |
| specific | #31901 |
| endothelial | #32294 |
| modality | #32386 |
| inhibit | #32629 |
| conducted | #32675 |
| predicted | #32889 |
| inhibited | #33631 |
| agreement | #33673 |
| sensitive | #34362 |
| antineoplastic | #34560 |
| correlated | #34744 |
| greater | #34856 |
| poor | #35078 |
| neoplasms male | #35230 |
| humans magnetic | #35433 |
| 0001 | #35646 |
| free | #35793 |
| sectional | #35852 |
| include | #39773 |
| collected | #40746 |
| examined | #41010 |
| mediated | #41310 |
| neoplasm | #47468 |
Jalankan laporan | |
Prominent publications by Harry Roger Büller
International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer
[ PUBLICATION ]
BACKGROUND: Guidelines addressing the management of venous thromboembolism (VTE) in cancer patients are heterogeneous and their implementation has been suboptimal worldwide.
OBJECTIVES: To establish a common international consensus addressing practical, clinically relevant questions in this setting.
METHODS: An international consensus working group of experts was set up to develop guidelines according to an evidence-based medicine approach, using the GRADE system.
RESULTS: For the ...
| Dikenal sebagai Vte Patients | Venous Thromboembolism | Prophylaxis Lmwh | 3 Months | Practice Guidelines |
KOL-Index: 20177
OBJECTIVES: The objective of this study was to compare the predictive performance of bleeding risk-estimation tools in a cohort of patients with atrial fibrillation (AF) undergoing anticoagulation.
BACKGROUND: Three bleeding risk-prediction schemes have been derived for and validated in patients with AF: HEMORR(2)HAGES (Hepatic or Renal Disease, Ethanol Abuse, Malignancy, Older Age, Reduced Platelet Count or Function, Re-Bleeding, Hypertension, Anemia, Genetic Factors, Excessive Fall ...
| Dikenal sebagai Atrial Fibrillation | Bled Bleeding | Hemorr2hages Atria | Intracranial Hemorrhage | Topic Risk |
Antithrombotic Therapy for Venous Thromboembolic Disease The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
[ PUBLICATION ]
This chapter about antithrombotic therapy for venous thromboembolic disease is part of the seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence Based Guidelines. Grade 1 recommendations are strong and indicate that the benefits do, or do not, outweigh risks, burden, and costs. Grade 2 suggests that individual patients' values may lead to different choices (for a full understanding of the grading see Guyatt et al, CHEST 2004; 126:179S-187S). Among the key ...
| Dikenal sebagai Antithrombotic Therapy | Grade 1a | Venous Thromboembolic Disease | Vka Lmwh | Inr Range |
KOL-Index: 16684
PURPOSE: Initial heparinization followed by vitamin K antagonists is the treatment of choice for patients with venous thromboembolism. There is controversy whether known malignancy is a risk factor for recurrences and bleeding complications during this treatment. Furthermore, the incidence of such events in these patients is dependent on the achieved International Normalized Ratio (INR). The aim of this study was to assess the incidence of venous thromboembolic recurrence and major ...
| Dikenal sebagai Venous Thromboembolism | Bleeding Complications | Patients Malignancy | Retrospective Analysis | International Normalized |
KOL-Index: 16378
BACKGROUND: Venous thromboembolism occurs commonly in patients with cancer. Direct oral anticoagulants are non-inferior to conventional anticoagulants for the treatment of venous thromboembolism. We hypothesised that edoxaban, a direct oral inhibitor of activated clotting factor Xa, might be more suitable than conventional anticoagulants in the management of cancer-associated venous thromboembolism. The aim of this study was to assess the efficacy and safety of edoxaban compared with ...
| Dikenal sebagai Venous Thromboembolism | Patients Cancer | Hazard Ratio | Clinically Relevant Bleeding | Factor Inhibitors |
KOL-Index: 15975
BACKGROUND: Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous thromboembolism is unclear.
METHODS: In a randomized, double-blind, noninferiority study, we randomly assigned patients with acute venous thromboembolism, who had initially received heparin, to receive edoxaban at a dose of 60 mg once daily, or 30 mg once daily (e.g., in the case of patients with creatinine clearance of 30 to 50 ml per minute or a body weight below 60 kg), ...
| Dikenal sebagai Warfarin Patients | Hazard Ratio | Venous Thromboembolism | Pulmonary Embolism | Primary Efficacy Outcome |
ADAMTS‐13 and von Willebrand factor predict venous thromboembolism in patients with cancer
[ PUBLICATION ]
ESSENTIALS: Cancer patients are at high risk of venous thromboembolism (VTE). In this study, cases and controls were cancer patients who did or did not develop VTE. von Willebrand factor (VWF) levels were higher if compared with controls and correlated with cancer stage. VWF and ADAMTS-13 are associated with the occurrence of VTE in cancer.
BACKGROUND: Patients with cancer are at high risk of venous thromboembolism (VTE). ADAMTS-13 regulates von Willebrand factor (VWF) activity, which ...
| Dikenal sebagai Willebrand Factor | Venous Thromboembolism | Vte Cancer | Vwf Adamts13 | Khorana Score |
KOL-Index: 15571
BACKGROUND: Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without the need for laboratory monitoring.
METHODS: We conducted an open-label, randomized, event-driven, noninferiority study that compared oral rivaroxaban alone (15 mg twice daily for 3 weeks, followed by 20 mg once daily) with subcutaneous enoxaparin followed by a vitamin K antagonist (either warfarin or ...
| Dikenal sebagai Oral Rivaroxaban | Venous Thromboembolism | Vitamin Antagonist | Continued Treatment | Hazard Ratio |
KOL-Index: 15512
BACKGROUND: After hip replacement surgery, prophylaxis following discharge from hospital is recommended to reduce the risk of venous thromboembolism. Our aim was to assess the oral, direct thrombin inhibitor dabigatran etexilate for such prophylaxis.
METHODS: In this double-blind study, we randomised 3494 patients undergoing total hip replacement to treatment for 28-35 days with dabigatran etexilate 220 mg (n=1157) or 150 mg (1174) once daily, starting with a half-dose 1-4 h after ...
| Dikenal sebagai Hip Replacement | Dabigatran Enoxaparin | Venous Thromboembolism | Etexilate Versus | Primary Efficacy Outcome |
KOL-Index: 15505
CONTEXT: Previous studies have evaluated the safety of relatively complex combinations of clinical decision rules and diagnostic tests in patients with suspected pulmonary embolism.
OBJECTIVE: To assess the clinical effectiveness of a simplified algorithm using a dichotomized clinical decision rule, D-dimer testing, and computed tomography (CT) in patients with suspected pulmonary embolism.
DESIGN, SETTING, AND PATIENTS: Prospective cohort study of consecutive patients with clinically ...
| Dikenal sebagai Pulmonary Embolism | Computed Tomography | Dimer Testing | Patients Suspected | 3 Months |
KOL-Index: 15415
BACKGROUND: Dabigatran etexilate is an oral direct thrombin inhibitor undergoing evaluation for the prevention of venous thromboembolism (VTE) following orthopedic surgery.
METHODS: In a multicenter, parallel-group, double-blind study, 1973 patients undergoing total hip or knee replacement were randomized to 6-10 days of oral dabigatran etexilate (50, 150 mg twice daily, 300 mg once daily, 225 mg twice daily), starting 1-4 h after surgery, or subcutaneous enoxaparin (40 mg once daily) ...
| Dikenal sebagai Total Hip | Dabigatran Etexilate | Thromboembolic Events | Knee Replacement | Vte Patients |
KOL-Index: 14849
BACKGROUND: Oral anticoagulants, such as dabigatran etexilate, an oral, direct thrombin inhibitor, that do not require monitoring or dose adjustment offer potential for prophylaxis against venous thromboembolism (VTE) after total knee replacement surgery.
METHODS: In this randomized, double-blind study, 2076 patients undergoing total knee replacement received dabigatran etexilate, 150 mg or 220 mg once-daily, starting with a half-dose 1-4 hours after surgery, or subcutaneous enoxaparin ...
| Dikenal sebagai Subcutaneous Enoxaparin | Oral Dabigatran | Total Knee Replacement | Venous Thromboembolism | Prevention Vte |
Subcutaneous Fondaparinux versus Intravenous Unfractionated Heparin in the Initial Treatment of Pulmonary Embolism
[ PUBLICATION ]
BACKGROUND: The standard initial treatment of hemodynamically stable patients with pulmonary embolism is intravenous unfractionated heparin, requiring laboratory monitoring and hospitalization.
METHODS: We conducted a randomized, open-label trial involving 2213 patients with acute symptomatic pulmonary embolism to compare the efficacy and safety of the synthetic antithrombotic agent fondaparinux with those of unfractionated heparin and to document noninferiority in terms of efficacy. ...
| Dikenal sebagai Unfractionated Heparin | Pulmonary Embolism | Initial Treatment | Subcutaneous Fondaparinux | Intravenous Injections |
KOL-Index: 14727
OBJECTIVES: To determine the rate of a first recurrent venous thromboembolism (VTE) event after discontinuation of anticoagulant treatment in patients with a first episode of unprovoked VTE, and the cumulative incidence for recurrent VTE up to 10 years.
DESIGN: Systematic review and meta-analysis.
DATA SOURCES: Medline, Embase, and the Cochrane Central Register of Controlled Trials (from inception to 15 March 2019).
STUDY SELECTION: Randomised controlled trials and prospective cohort ...
| Dikenal sebagai Anticoagulant Treatment | Recurrent Vte | Unprovoked Venous | 10 Years | 95 Confidence Interval |
Orang -orang kunci untuk Pulmonary Embolism
Top Kols di dunia
Pilih frasa pencarian pulmonary embolism , pulmonary embolism patients , pulmonary embolism 95 , pulmonary embolism diagnosis , pulmonary embolism treatment
Harry Roger Büller:Dampak ahli
Konsep yang manaHarry Roger Büllermemiliki pengaruh langsung:Pulmonary embolism, Venous thromboembolism, Venous thrombosis, Major bleeding, Deep vein thrombosis, Atrial fibrillation, Vein thrombosis.
Harry Roger Büller:Dampak Kol
Konsep yang terkait dengan karya penulis lain yang manafor which Harry Roger Büller memiliki pengaruh:Venous thromboembolism, Pulmonary embolism, Atrial fibrillation, Deep vein thrombosis, Oral anticoagulants, Major bleeding, Vte patients.
Tools
Apakah ini profil Anda? Klaim profil Anda Salin URL Sematkan tautan ke profil Anda |